{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T10:52:15Z","timestamp":1792234335360,"version":"4.4.0"},"reference-count":687,"publisher":"Japanese Circulation Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2021,8,25]]},"DOI":"10.1253\/circj.cj-20-0910","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T22:07:31Z","timestamp":1626905251000},"page":"1590-1689","source":"Crossref","is-referenced-by-count":115,"title":["JCS\/JHFS 2018 Guideline on the Diagnosis and Treatment of Cardiomyopathies"],"prefix":"10.1253","volume":"85","author":[{"given":"Hiroaki","family":"Kitaoka","sequence":"first","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Tsutsui","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kubo","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Geriatrics, Kochi Medical School, Kochi University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Ide","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishiro","family":"Chikamori","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noboru","family":"Fujino","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular and Internal Medicine, Kanazawa University, Graduate School of Medical Science"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiki","family":"Higo","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University Graduate School of Medical Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Isobe","sequence":"additional","affiliation":[{"name":"Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizuko","family":"Kamiya","sequence":"additional","affiliation":[{"name":"Department of Perinatology and Gynecology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Kato","sequence":"additional","affiliation":[{"name":"Division of Pathology, Saiseikai Fukuoka General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Kihara","sequence":"additional","affiliation":[{"name":"Kobe City Medical Center General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigetoyo","family":"Kogaki","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Osaka General Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Issei","family":"Komuro","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhisa","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Women\u2019s Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Ono","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, The University of Tokyo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Internal Medicine III, Hamamatsu University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Cardiac Rehabilitation, Saitama International Medical Center, Saitama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiro","family":"Matsui","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Hanaoka Seishu Memorial Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouji","family":"Matsushima","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyushu University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Sawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Teraoka","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miyuki","family":"Tsuchihashi-Makaya","sequence":"additional","affiliation":[{"name":"School of Nursing, Kitasato University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatsue","family":"Ishibashi-Ueda","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Cerebral and Cardiovascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arata","family":"Fukusima","sequence":"additional","affiliation":[{"name":"Asabu Heart & Gastrointestinal Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Tokyo Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shungo","family":"Hikoso","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhiko","family":"Imamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Ishida","sequence":"additional","affiliation":[{"name":"Nippon Medical School, Musashikosugi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Kawai","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kohno","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyorin University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kurisu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Hiroshima University Graduate School of Biomedical and Health Sciences"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Nagata","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Fukui CardioVascular Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Morita","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Takano","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shiga","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyoshi","family":"Takei","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tokyo Medical University Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Yuasa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Keio University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teppei","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsu","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Pulmonology, and Nephrology, Yamagata University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Akasaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Wakayama Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Doi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Chikamori Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masafumi","family":"Kitakaze","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Hanwa Daini Senboku Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masami","family":"Kosuge","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Yokohama City University Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morimasa","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitonobu","family":"Tomoike","sequence":"additional","affiliation":[{"name":"Sakakibara Heart Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Japanese Circulation Society Joint Working Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. \u3000Goodwin JF, Gordon H, Hollman A, Bishop MB. Clinical aspects of cardiomyopathy. <i>BMJ<\/i> 1961; 1: 69\u201379.","DOI":"10.1136\/bmj.1.5219.69"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. \u3000Report of the WHO\/ISFC task force on the definition and classification of cardiomyopathies. <i>Br Heart J<\/i> 1980; 44: 672\u2013673.","DOI":"10.1136\/hrt.44.6.672"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. \u3000Richardson P, McKenna W, Bristow M, Maisch B, Mautner B, O\u2019Connell J, et al. Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the De\ufb01nition and Classi\ufb01cation of cardio-myopathies. <i>Circulation<\/i> 1996; 93: 841\u2013842.","DOI":"10.1161\/01.CIR.93.5.841"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. \u3000Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, et al. Contemporary de\ufb01nitions and classi\ufb01cation of the cardiomyopathies: An American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. <i>Circulation<\/i> 2006; 113: 1807\u20131816.","DOI":"10.1161\/CIRCULATIONAHA.106.174287"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. \u3000Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classi\ufb01cation of the cardiomyopathies: A position statement from the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2008; 29: 270\u2013276.","DOI":"10.1093\/eurheartj\/ehm342"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. \u3000Burke MA, Day SM, Deswal A, Elliott P, Evanovich LL, Hung J, et al. 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. <i>JACC<\/i> 2020; 76: e159\u2013e240.","DOI":"10.1016\/j.jacc.2020.08.045"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. \u3000Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2014; 35: 2733\u20132779.","DOI":"10.1093\/eurheartj\/ehu284"},{"key":"8","unstructured":"8. \u3000\u539a\u751f\u52b4\u50cd\u7701\u96e3\u6cbb\u6027\u75be\u60a3\u514b\u670d\u7814\u7a76\u4e8b\u696d\u7279\u767a\u6027\u5fc3\u7b4b\u75c7\u8abf\u67fb\u7814\u7a76\u73ed: \u5317\u7560\u9855, \u53cb\u6c60\u4ec1\u66a2\u7de8. \u5fc3\u7b4b\u75c7: \u8a3a\u65ad\u306e\u624b\u5f15\u304d\u3068\u305d\u306e\u89e3\u8aac. \u304b\u308a\u3093\u820e 2005."},{"key":"9","unstructured":"9. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2011\u5e74\u5ea6\u5408\u540c\u7814\u7a76\u73ed\u5831\u544a): \u80a5\u5927\u578b\u5fc3\u7b4b\u75c7\u306e\u8a3a\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2012\u5e74\u6539\u8a02\u7248). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2012_doi_h.pdf"},{"key":"10","unstructured":"10. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2009\u20132010\u5e74\u5ea6\u5408\u540c\u7814\u7a76\u73ed\u5831\u544a): \u62e1\u5f35\u578b\u5fc3\u7b4b\u75c7\u306a\u3089\u3073\u306b\u95a2\u9023\u3059\u308b\u4e8c\u6b21\u6027\u5fc3\u7b4b\u75c7\u306e\u8a3a\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 2011. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2011_tomoike_h.pdf"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. \u3000Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"12","unstructured":"12. \u3000Minds \u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u9078\u5b9a\u90e8\u4f1a\u76e3\u4fee, \u798f\u4e95\u6b21\u77e2, \u5409\u7530\u96c5\u535a, \u5c71\u53e3\u76f4\u4eba\u7de8\u96c6. Minds \u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u4f5c\u6210\u306e\u624b\u5f15\u304d 2007. \u533b\u5b66\u66f8\u9662 2007: 15\u201316."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. \u3000Arbustini E, Narula N, Dec GW, Reddy KS, Greenberg B, Kushwaha S, et al. The MOGE(S) classi\ufb01cation for a phenotype-genotype nomenclature of cardiomyopathy: Endorsed by the World Heart Federation. <i>J Am Coll Cardiol<\/i> 2013; 62: 2046\u20132072.","DOI":"10.1016\/j.jacc.2013.08.1644"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. \u3000Maron BJ. Clinical course and management of hypertrophic cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 655\u2013668.","DOI":"10.1056\/NEJMra1710575"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. \u3000Marian AJ, Braunwald E. Hypertrophic cardiomyopathy: Genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. <i>Circ Res<\/i> 2017; 121: 749\u2013770.","DOI":"10.1161\/CIRCRESAHA.117.311059"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. \u3000Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. <i>Mol Genet Metab<\/i> 2018; 123: 416\u2013427.","DOI":"10.1016\/j.ymgme.2018.02.014"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. \u3000Maurer MS, Schwartz JH, Gundapaneni B, Elliot PM, Merlini G, Waddington-Cruz M, et al; ATTR-ACT Study Investigators. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016.","DOI":"10.1056\/NEJMoa1805689"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. \u3000Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. <i>Circulation<\/i> 2006; 114: 2232\u20132239.","DOI":"10.1161\/CIRCULATIONAHA.106.644682"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. \u3000Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. <i>Heart<\/i> 2008; 94: 1288\u20131294.","DOI":"10.1136\/hrt.2007.126003"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. \u3000Rowin EJ, Maron BJ, Olivotto I, Maron MS. Role of exercise testing in hypertrophic cardiomyopathy. <i>JACC Cardiovasc Imaging<\/i> 2017; 10: 1374\u20131386.","DOI":"10.1016\/j.jcmg.2017.07.016"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. \u3000Maron MS, Rowin EJ, Olivotto I, Casey SA, Arretini A, Tomberli B, et al. Contemporary natural history and management of nonobstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2016; 67: 1399\u20131409.","DOI":"10.1016\/j.jacc.2016.01.023"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. \u3000Maron BJ, Rowin EJ, Udelson JE, Maron MS. Clinical spectrum and management of heart failure in hypertrophic cardiomyopathy. <i>JACC Heart Fail<\/i> 2018; 6: 353\u2013363.","DOI":"10.1016\/j.jchf.2017.09.011"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. \u3000Geske JB, Ommen SR, Gersh BJ. Hypertrophic cardiomyopathy: Clinical update. <i>JACC Heart Fail<\/i> 2018; 6: 364\u2013375.","DOI":"10.1016\/j.jchf.2018.02.010"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. \u3000Minami Y, Kajimoto K, Terajima Y, Yashiro B, Okayama D, Haruki S, et al. Clinical implications of midventricular obstruction in patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2011; 57: 2346\u20132355.","DOI":"10.1016\/j.jacc.2011.02.033"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. \u3000Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS, et al. Prevalence, clinical signi\ufb01cance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2008; 118: 1541\u20131549.","DOI":"10.1161\/CIRCULATIONAHA.108.781401"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. \u3000Efthimiadis GK, Pagourelias ED, Parcharidou D, Gossios T, Kamperidis V, Theofilogiannakos EK, et al. Clinical characteristics and natural history of hypertrophic cardiomyopathy with midventricular obstruction. <i>Circ J<\/i> 2013; 77: 2366\u20132374.","DOI":"10.1253\/circj.CJ-12-1561"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. \u3000Sakamoto T, Tei C, Murayama M, Ichiyasu H, Hada Y. Giant T wave inversion as a manifestation of asymmetrical apical hypertrophy (AAH) of the left ventricle: Echocardiographic and ultrasono-cardiotomographic study. <i>Jpn Heart J<\/i> 1976; 17: 611\u2013629.","DOI":"10.1536\/ihj.17.611"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. \u3000Yamaguchi H, Ishimura T, Nishiyama S, Nagasaki F, Nakanishi S, Takatsu F, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): Ventriculographic and echocardiographic features in 30 patients. <i>Am J Cardiol<\/i> 1979; 44: 401\u2013412.","DOI":"10.1016\/0002-9149(79)90388-6"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. \u3000Kubo T, Kitaoka H, Okawa M, Hirota T, Hoshikawa E, Hayato K, et al. Clinical pro\ufb01les of hypertrophic cardiomyopathy with apical phenotype: Comparison of pure-apical form and distal-dominant form. <i>Circ J<\/i> 2009; 73: 2330\u20132336.","DOI":"10.1253\/circj.CJ-09-0438"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. \u3000Jan MF, Todaro MC, Oreto L, Tajik AJ. Apical hypertrophic cardiomyopathy: Present status. <i>Int J Cardiol<\/i> 2016; 222: 745\u2013759.","DOI":"10.1016\/j.ijcard.2016.07.154"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. \u3000Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. <i>Am J Cardiol<\/i> 2003; 92: 1183\u20131186.","DOI":"10.1016\/j.amjcard.2003.07.027"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. \u3000Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR, et al. Prevalence, clinical pro\ufb01le, and signi\ufb01cance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2006; 114: 216\u2013225.","DOI":"10.1161\/CIRCULATIONAHA.105.583500"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. \u3000Thaman R, Gimeno JR, Murphy RT, Kubo T, Sachdev B, Mogensen J, et al. Prevalence and clinical signi\ufb01cance of systolic impairment in hypertrophic cardiomyopathy. <i>Heart<\/i> 2005; 91: 920\u2013925.","DOI":"10.1136\/hrt.2003.031161"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. \u3000Olivotto I, Cecchi F, Poggesi C, Yacoub MH. Patterns of disease progression in hypertrophic cardiomyopathy: An individualized approach to clinical staging. <i>Circ Heart Fail<\/i> 2012; 5: 535\u2013546.","DOI":"10.1161\/CIRCHEARTFAILURE.112.967026"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. \u3000Kitaoka H, Kubo T, Doi YL. Hypertrophic cardiomyopathy: A heterogeneous and lifelong disease in the real world. <i>Circ J<\/i> 2020; 84: 1218\u20131226.","DOI":"10.1253\/circj.CJ-20-0524"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. \u3000Coats CJ, Elliott PM. Genetic biomarkers in hypertrophic cardiomyopathy. <i>Biomark Med<\/i> 2013; 7: 505\u2013516.","DOI":"10.2217\/bmm.13.79"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. \u3000Teekakirikul P, Eminaga S, Toka O, Alcalai R, Wang L, Wakimoto H, et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires TGF-\u03b2. <i>J Clin Invest<\/i> 2010; 120: 3520\u20133529.","DOI":"10.1172\/JCI42028"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. \u3000Burke MA, Cook SA, Seidman JG, Seidman CE. Clinical and mechanistic insights into the genetics of cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2016; 68: 2871\u20132886.","DOI":"10.1016\/j.jacc.2016.08.079"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. \u3000Kaufman BD, Auerbach S, Reddy S, Manlhiot C, Deng L, Prakash A, et al. RAAS gene polymorphisms in\ufb02uence progression of pediatric hypertrophic cardiomyopathy. <i>Hum Genet<\/i> 2007; 122: 515\u2013523.","DOI":"10.1007\/s00439-007-0429-9"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. \u3000Olivotto I, Girolami F, Sciagr\u00e0 R, Ackerman MJ, Sotgia B, et al. Microvascular function is selectively impaired in patients with hypertrophic cardiomyopathy and sarcomere myo\ufb01lament gene mutations. <i>J Am Coll Cardiol<\/i> 2011; 58: 839\u2013848.","DOI":"10.1016\/j.jacc.2011.05.018"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. \u3000Girolami F, Ho CY, Semsarian C, Ackerman MJ, Sotgia B, Bos JM, et al. Clinical features and outcome of hypertrophic cardiomyopathy associated with triple sarcomere protein gene mutations. <i>J Am Coll Cardiol<\/i> 2010; 55: 1444\u20131453.","DOI":"10.1016\/j.jacc.2009.11.062"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. \u3000Fujita T, Fujino N, Anan R, Tei C, Kubo T, Doi Y, et al. Sarcomere gene mutations are associated with increased cardiovascular events in left ventricular hypertrophy: Results from multicenter registration in Japan. <i>JACC Heart Fail<\/i> 2013; 1: 459\u2013466.","DOI":"10.1016\/j.jchf.2013.08.007"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. \u3000Elliott P, Baker R, Pasquale F, Quarta G, Ebrahim H, Mehta AB, et al; ACES study group. Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: The European Anderson-Fabry Disease survey. <i>Heart<\/i> 2011; 97: 1957\u20131960.","DOI":"10.1136\/heartjnl-2011-300364"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. \u3000Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry\u2019s disease in men with left ventricular hypertrophy. <i>N Engl J Med<\/i> 1995; 333: 288\u2013293.","DOI":"10.1056\/NEJM199508033330504"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. \u3000Kubo T, Ochi Y, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. <i>J Cardiol<\/i> 2017; 69: 302\u2013307.","DOI":"10.1016\/j.jjcc.2016.05.014"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. \u3000MacRae CA, Ghaisas N, Kass S, Donnelly, Basson CY, Watkins HC, et al. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome maps to a locus on chromosome 7q3. <i>J Clin Invest<\/i> 1995; 96: 1216\u20131220.","DOI":"10.1172\/JCI118154"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. \u3000Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Ali Hassan AS, et al. Identi\ufb01cation of a gene responsible for familial Wolff-Parkinson-White syndrome. <i>N Engl J Med<\/i> 2001; 344: 1823\u20131831.","DOI":"10.1056\/NEJM200106143442403"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. \u3000Arad M, Benson DW, Perez-Atayde AR, McKenna WJ, Sparks EA, Kanter RJ, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. <i>J Clin Invest<\/i> 2002; 109: 357\u2013362.","DOI":"10.1172\/JCI0214571"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. \u3000Arad M, Maron BJ, Gorham JM, Johnson WH Jr, Saul JP, Perez-Atayde AR, et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. <i>N Engl J Med<\/i> 2005; 352: 362\u2013372.","DOI":"10.1056\/NEJMoa033349"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. \u3000Cheng Z, Cui Q, Tian Z, Xie H, Chen L, Fang L, et al. Danon disease as a cause of concentric left ventricular hypertrophy in patients who underwent endomyocardial biopsy. <i>Eur Heart J<\/i> 2012; 33: 649\u2013656.","DOI":"10.1093\/eurheartj\/ehr420"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. \u3000Limongelli G, Pacileo G, Marino B, Digilio MC, Sarkozy A, Elliott P, et al. Prevalence and clinical signi\ufb01cance of cardiovascular abnormalities in patients with the LEOPARD syndrome. <i>Am J Cardiol<\/i> 2007; 100: 736\u2013741.","DOI":"10.1016\/j.amjcard.2007.03.093"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. \u3000Sarkozy A, Digilio MC, Dallapiccola B. Leopard syndrome. <i>Orphanet J Rare Dis<\/i> 2008; 3: 13.","DOI":"10.1186\/1750-1172-3-13"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. \u3000Lin AE, Grossfeld PD, Hamilton RM, Smoot L, Gripp KW, Proud V, et al. Further delineation of cardiac abnormalities in Costello syndrome. <i>Am J Med Genet<\/i> 2002; 111: 115\u2013129.","DOI":"10.1002\/ajmg.10558"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. \u3000Falk RH. Diagnosis and management of the cardiac amyloidoses. <i>Circulation<\/i> 2005; 112: 2047\u20132060.","DOI":"10.1161\/CIRCULATIONAHA.104.489187"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. \u3000Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C. Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis. <i>Circulation<\/i> 2017; 135: 1357\u20131377.","DOI":"10.1161\/CIRCULATIONAHA.116.024438"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. \u3000Izumiya Y, Takashio S, Oda S, Yamashita Y, Tsujita K. Recent advances in diagnosis and treatment of cardiac amyloidosis. <i>J Cardiol<\/i> 2018; 71: 135\u2013143.","DOI":"10.1016\/j.jjcc.2017.10.003"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57. \u3000JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 1610\u20131671.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58. \u3000Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2013; 34: 2636\u20132648.","DOI":"10.1093\/eurheartj\/eht210"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59. \u3000Ullmo S, Vial Y, Di Bernardo S, Roth-Kleiner M, Mivelaz Y, Sekarski N, et al. Pathologic ventricular hypertrophy in the offspring of diabetic mothers: A retrospective study. <i>Eur Heart J<\/i> 2007; 28: 1319\u20131325.","DOI":"10.1093\/eurheartj\/ehl416"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60. \u3000Huddle KR, Kalliatakis B, Skoularigis J. Pheochromocytoma associated with clinical and echocardiographic features simulating hypertrophic obstructive cardiomyopathy. <i>Chest<\/i> 1996; 109: 1394\u20131397.","DOI":"10.1378\/chest.109.5.1394"},{"key":"61","unstructured":"61. \u3000Hradec J, Marek J, Petr\u00e1sek J. The nature of cardiac hypertrophy in acromegaly: An echocardiographic study. <i>Cor Vasa<\/i> 1988; 30: 186\u2013199."},{"key":"62","doi-asserted-by":"crossref","unstructured":"62. \u3000Sachtleben TR, Berg KE, Elias BA, Cheatham JP, Felix GL, Hofschire PJ. The effects of anabolic steroids on myocardial structure and cardiovascular \ufb01tness. <i>Med Sci Sports Exerc<\/i> 1993; 25: 1240\u20131245.","DOI":"10.1249\/00005768-199311000-00006"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63. \u3000Rapezzi C, Arbustini E, Caforio AL, Charron P, Gimeno-Blanes J, Heli\u00f6 T, et al. Diagnostic work-up in cardiomyopathies: Bridging the gap between clinical phenotypes and \ufb01nal diagnosis. A position statement from the ESC Working Group on Myocardial and Pericardial Diseases. <i>Eur Heart J<\/i> 2013; 34: 1448\u20131458.","DOI":"10.1093\/eurheartj\/ehs397"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64. \u3000Miura K, Nakagawa H, Morikawa Y, Sasayama S, Matsumori A, Hasegawa K, et al. Epidemiology of idiopathic cardiomyopathy in Japan: Results from a nationwide survey. <i>Heart<\/i> 2002; 87: 126\u2013130.","DOI":"10.1136\/heart.87.2.126"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65. \u3000Matsumori A, Furukawa Y, Hasegawa K, Sato Y, Nakagawa H, Morikawa Y, et al. Epidemiologic and clinical characteristics of cardiomyopathies in Japan: Results from nationwide surveys. <i>Circ J<\/i> 2002; 66: 323\u2013336.","DOI":"10.1253\/circj.66.323"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66. \u3000Hada Y, Sakamoto T, Amano K, Yamaguchi T, Takenaka K, Takahashi H, et al. Prevalence of hypertrophic cardiomyopathy in a population of adult Japanese workers as detected by echocardiographic screening. <i>Am J Cardiol<\/i> 1987; 59: 183\u2013184.","DOI":"10.1016\/S0002-9149(87)80107-8"},{"key":"67","doi-asserted-by":"crossref","unstructured":"67. \u3000Maron BJ, Gardin JM, Flack JM, Gidding SS, Kurosaki TT, Bild DE. Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults. <i>Circulation<\/i> 1995; 92: 785\u2013789.","DOI":"10.1161\/01.CIR.92.4.785"},{"key":"68","doi-asserted-by":"crossref","unstructured":"68. \u3000Maron BJ, Mathenge R, Casey SA, Poliac LC, Longe TF. Clinical pro\ufb01le of hypertrophic cardiomyopathy identi\ufb01ed de novo in rural communities. <i>J Am Coll Cardiol<\/i> 1999; 33: 1590\u20131595.","DOI":"10.1016\/S0735-1097(99)00039-X"},{"key":"69","doi-asserted-by":"crossref","unstructured":"69. \u3000Maron BJ, Spirito P, Roman MJ, Paranicas M, Okin PM, Best LG, et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). <i>Am J Cardiol<\/i> 2004; 93: 1510\u20131514.","DOI":"10.1016\/j.amjcard.2004.03.007"},{"key":"70","doi-asserted-by":"crossref","unstructured":"70. \u3000Zou Y, Song L, Wang Z, Ma A, Liu T, Gu H, et al. Prevalence of idiopathic hypertrophic cardiomyopathy in China: A population-based echocardiographic analysis of 8080 adults. <i>Am J Med<\/i> 2004; 116: 14\u201318.","DOI":"10.1016\/j.amjmed.2003.05.009"},{"key":"71","doi-asserted-by":"crossref","unstructured":"71. \u3000Maro EE, Janabi M, Kaushik R. Clinical and echocardiographic study of hypertrophic cardiomyopathy in Tanzania. <i>Trop Doct<\/i> 2006; 36: 225\u2013227.","DOI":"10.1258\/004947506778604904"},{"key":"72","doi-asserted-by":"crossref","unstructured":"72. \u3000Maron BJ, Rowin EJ, Maron MS. Global burden of hypertrophic cardiomyopathy. <i>JACC Heart Fail<\/i> 2018; 6: 376\u2013378.","DOI":"10.1016\/j.jchf.2018.03.004"},{"key":"73","doi-asserted-by":"crossref","unstructured":"73. \u3000Semsarian C, Ingles J, Maron MS, Maron BJ. New perspectives on the prevalence of hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2015; 65: 1249\u20131254.","DOI":"10.1016\/j.jacc.2015.01.019"},{"key":"74","doi-asserted-by":"crossref","unstructured":"74. \u3000\u6cb3\u5408\u5fe0\u4e00. \u7279\u767a\u6027\u5fc3\u7b4b\u75c7\u306e\u4e88\u5f8c\u8abf\u67fb. \u539a\u751f\u7701\u7279\u767a\u6027\u5fc3\u7b4b\u75c7\u8abf\u67fb\u7814\u7a76\u73ed\u662d\u548c57\u5e74\u5ea6\u5831\u544a\u96c6 1983: 63\u201366.","DOI":"10.1051\/lait:1983623-6246"},{"key":"75","doi-asserted-by":"crossref","unstructured":"75. \u3000Hardarson T, De la Calzada CS, Curiel R, Goodwin JF. Prognosis and mortality of hypertrophic obstructive cardiomyopathy. <i>Lancet<\/i> 1973; 302: 1462\u20131467.","DOI":"10.1016\/S0140-6736(73)92730-X"},{"key":"76","doi-asserted-by":"crossref","unstructured":"76. \u3000McKenna WJ, Dean\ufb01eld JE. Hypertrophic cardiomyopathy: An important cause of sudden death. <i>Arch Dis Child<\/i> 1984; 59: 971\u2013975.","DOI":"10.1136\/adc.59.10.971"},{"key":"77","doi-asserted-by":"crossref","unstructured":"77. \u3000Olivotto I, Maron MS, Adabag AS, Casey SA, Vargui D, Link MS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2005; 46: 480\u2013487.","DOI":"10.1016\/j.jacc.2005.04.043"},{"key":"78","doi-asserted-by":"crossref","unstructured":"78. \u3000Maron BJ, Casey SA, Poliac LC, Gohman TE, Almquist AK, Aeppli DM. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. <i>JAMA<\/i> 1999; 281: 650\u2013655.","DOI":"10.1001\/jama.281.7.650"},{"key":"79","doi-asserted-by":"crossref","unstructured":"79. \u3000Kubo T, Hirota T, Baba Y, Ochi Y, Takahashi A, Yamasaki N, et al. Patients\u2019 characteristics and clinical course of hypertrophic cardiomyopathy in a regional Japanese cohort: Results from Kochi RYOMA study. <i>Circ J<\/i> 2018; 82: 824\u2013830.","DOI":"10.1253\/circj.CJ-17-0845"},{"key":"80","doi-asserted-by":"crossref","unstructured":"80. \u3000Kodama K, Hamada M, Kazatani Y, Matsuzaki K, Murakami E, Shigematsu Y, et al. Clinical characteristics in Japanese patients with coexistent hypertrophic cardiomyopathy and coronary vasospasm. <i>Angiology<\/i> 1998; 49: 849\u2013855.","DOI":"10.1177\/000331979804900909"},{"key":"81","doi-asserted-by":"crossref","unstructured":"81. \u3000Shigematsu Y, Hamada M, Mukai M, Matsuoka H, Sumimoto T, Hiwada K. Mechanism of atrial \ufb01brillation and increased incidence of thromboembolism in patients with hypertrophic cardiomyopathy. <i>Jpn Circ J<\/i> 1995; 59: 329\u2013336.","DOI":"10.1253\/jcj.59.329"},{"key":"82","doi-asserted-by":"crossref","unstructured":"82. \u3000McKenna W, Dean\ufb01eld J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis in hypertrophic cardiomyopathy: Role of age and clinical, electrocardiographic and hemodynamic features. <i>Am J Cardiol<\/i> 1981; 47: 532\u2013538.","DOI":"10.1016\/0002-9149(81)90535-X"},{"key":"83","doi-asserted-by":"crossref","unstructured":"83. \u3000Nienaber CA, Hiller S, Spielmann RP, Geiger M, Kuck KH. Syncope in hypertrophic cardiomyopathy: Multivariate analysis of prognostic determinants. <i>J Am Coll Cardiol<\/i> 1990; 15: 948\u2013955.","DOI":"10.1016\/0735-1097(90)90222-B"},{"key":"84","doi-asserted-by":"crossref","unstructured":"84. \u3000Maron BJ, Roberts WC, Epstein SE. Sudden death in hypertrophic cardiomyopathy: A pro\ufb01le of 78 patients. <i>Circulation<\/i> 1982; 65: 1388\u20131394.","DOI":"10.1161\/01.CIR.65.7.1388"},{"key":"85","doi-asserted-by":"crossref","unstructured":"85. \u3000Fighali S, Krajcer Z, Edelman S, Leachman RD. Progression of hypertrophic cardiomyopathy into a hypokinetic left ventricle: Higher incidence in patients with midventricular obstruction. <i>J Am Coll Cardiol<\/i> 1987; 9: 288\u2013294.","DOI":"10.1016\/S0735-1097(87)80377-7"},{"key":"86","unstructured":"86. \u3000Wynne J, Braunwald E. The cardiomyopathies. <i>In<\/i>: Zipes DP, Libby P, Bonow RO, editors. Braunwald\u2019s heart disease: A textbook of cardiovascular medicine, 7th edn. Philadelphia: Elsevier Saunders, 2005; 1673."},{"key":"87","doi-asserted-by":"crossref","unstructured":"87. \u3000Ryan MP, Cleland JG, French JA, Joshi J, Choudhury L, Chojnowska L, et al. The standard electrocardiogram as a screening test for hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1995; 76: 689\u2013694.","DOI":"10.1016\/S0002-9149(99)80198-2"},{"key":"88","doi-asserted-by":"crossref","unstructured":"88. \u3000Chen CH, Nobuyoshi M, Kawai C. ECG pattern of left ventricular hypertrophy in nonobstructive hypertrophic cardiomyopathy: The signi\ufb01cance of the mid-precordial changes. <i>Am Heart J<\/i> 1979; 97: 687\u2013695.","DOI":"10.1016\/0002-8703(79)90002-4"},{"key":"89","doi-asserted-by":"crossref","unstructured":"89. \u3000Maron BJ, Wolfson JK, Cir\u00f3 E, Spirito P. Relation of electrocardiographic abnormalities and patterns of left ventricular hypertrophy identi\ufb01ed by 2-dimensional echocardiography in patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1983; 51: 189\u2013194.","DOI":"10.1016\/S0002-9149(83)80034-4"},{"key":"90","doi-asserted-by":"crossref","unstructured":"90. \u3000McKenna WJ, Borggrefe M, England D, Deanfield J, Oakley CM, Goodwin JF. The natural history of left ventricular hypertrophy in hypertrophic cardiomyopathy: An electrocardiographic study. <i>Circulation<\/i> 1982; 66: 1233\u20131240.","DOI":"10.1161\/01.CIR.66.6.1233"},{"key":"91","doi-asserted-by":"crossref","unstructured":"91. \u3000Suwa M, Yoneda Y, Nakayama A, Hanada H, Nakayama Y, Hirota Y, et al. Prognostic significance of conduction disturbance and reduction of left precordial voltage of electrocardiogram in hypertrophic cardiomyopathy. <i>Jpn Circ J<\/i> 1989; 53: 1045\u20131054.","DOI":"10.1253\/jcj.53.1045"},{"key":"92","doi-asserted-by":"crossref","unstructured":"92. \u3000Lemery R, Kleinebenne A, Nihoyannopoulos P, Aber V, Alfonso F, McKenna WJ. Q waves in hypertrophic cardiomyopathy in relation to the distribution and severity of right and left ventricular hypertrophy. <i>J Am Coll Cardiol<\/i> 1990; 16: 368\u2013374.","DOI":"10.1016\/0735-1097(90)90587-F"},{"key":"93","doi-asserted-by":"crossref","unstructured":"93. \u3000Shibata M, Yamakado T, Imanaka-Yoshida K, Isaka N, Nakano T. Familial hypertrophic cardiomyopathy with Wolff-Parkinson-White syndrome progressing to ventricular dilation. <i>Am Heart J<\/i> 1996; 131: 1223\u20131225.","DOI":"10.1016\/S0002-8703(96)90102-7"},{"key":"94","doi-asserted-by":"crossref","unstructured":"94. \u3000Krikler DM, Davies MJ, Rowland E, Goodwin JF, Evans RC, Shaw DB. Sudden death in hypertrophic cardiomyopathy: Associated accessory atrioventricular pathways. <i>Br Heart J<\/i> 1980; 43: 245\u2013251.","DOI":"10.1136\/hrt.43.3.245"},{"key":"95","doi-asserted-by":"crossref","unstructured":"95. \u3000Koga Y, Katoh A, Matsuyama K, Ikeda H, Hiyamuta K, Toshima H, et al. Disappearance of giant negative T waves in patients with the Japanese form of apical hypertrophy. <i>J Am Coll Cardiol<\/i> 1995; 26: 1672\u20131678.","DOI":"10.1016\/0735-1097(95)00377-0"},{"key":"96","doi-asserted-by":"crossref","unstructured":"96. \u3000Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. <i>Am J Cardiol<\/i> 1993; 72: 973\u2013976.","DOI":"10.1016\/0002-9149(93)91118-2"},{"key":"97","doi-asserted-by":"crossref","unstructured":"97. \u3000Yi G, Elliott P, McKenna WJ, Prasad K, Sharma S, Guo XH, et al. QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1998; 82: 1514\u20131519.","DOI":"10.1016\/S0002-9149(98)00696-1"},{"key":"98","doi-asserted-by":"crossref","unstructured":"98. \u3000Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: A prospective study. <i>Am J Cardiol<\/i> 1981; 48: 252\u2013257.","DOI":"10.1016\/0002-9149(81)90604-4"},{"key":"99","doi-asserted-by":"crossref","unstructured":"99. \u3000McKenna WJ, England D, Doi YL, Deanfield J, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. I: In\ufb02uence on prognosis. <i>Br Heart J<\/i> 1981; 46: 168\u2013172.","DOI":"10.1136\/hrt.46.2.168"},{"key":"100","doi-asserted-by":"crossref","unstructured":"100. \u3000Alfonso F, Frenneaux MP, McKenna WJ. Clinical sustained uniform ventricular tachycardia in hypertrophic cardiomyopathy: Association with left ventricular apical aneurysm. <i>Br Heart J<\/i> 1989; 61: 178\u2013181.","DOI":"10.1136\/hrt.61.2.178"},{"key":"101","doi-asserted-by":"crossref","unstructured":"101. \u3000Stewart JT, McKenna WJ. Arrhythmias in hypertrophic cardiomyopathy. <i>J Cardiovasc Electrophysiol<\/i> 1991; 2: 516\u2013524.","DOI":"10.1111\/j.1540-8167.1991.tb01354.x"},{"key":"102","doi-asserted-by":"crossref","unstructured":"102. \u3000Fauchier JP, Cosnay P, Moquet B, Balleh H, Rouesnel P. Late ventricular potentials and spontaneous and induced ventricular arrhythmias in dilated or hypertrophic cardiomyopathies: A prospective study about 83 patients. <i>Pacing Clin Electrophysiol<\/i> 1988; 11: 1974\u20131983.","DOI":"10.1111\/j.1540-8159.1988.tb06337.x"},{"key":"103","doi-asserted-by":"crossref","unstructured":"103. \u3000Kulakowski P, Counihan PJ, Camm AJ, McKenna WJ. The value of time and frequency domain, and spectral temporal mapping analysis of the signal-averaged electrocardiogram in identi\ufb01cation of patients with hypertrophic cardiomyopathy at increased risk of sudden death. <i>Eur Heart J<\/i> 1993; 14: 941\u2013950.","DOI":"10.1093\/eurheartj\/14.7.941"},{"key":"104","doi-asserted-by":"crossref","unstructured":"104. \u3000Elliott PM, Poloniecki J, Dickie S, Sharma S, Monserrat L, Varnava A, et al. Sudden death in hypertrophic cardiomyopathy: Identi\ufb01cation of high risk patients. <i>J Am Coll Cardiol<\/i> 2000; 36: 2212\u20132218.","DOI":"10.1016\/S0735-1097(00)01003-2"},{"key":"105","doi-asserted-by":"crossref","unstructured":"105. \u3000Ciampi Q, Betocchi S, Lombardi R, Manganelli F, Storto G, Losi MA, et al. Hemodynamic determinants of exercise-induced abnormal blood pressure response in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 40: 278\u2013284.","DOI":"10.1016\/S0735-1097(02)01950-2"},{"key":"106","doi-asserted-by":"crossref","unstructured":"106. \u3000Coats CJ, Rantell K, Bartnik A, Patel A, Mist B, McKenna WJ, et al. Cardiopulmonary exercise testing and prognosis in hypertrophic cardiomyopathy. <i>Circ Heart Fail<\/i> 2015; 8: 1022\u20131031.","DOI":"10.1161\/CIRCHEARTFAILURE.114.002248"},{"key":"107","doi-asserted-by":"crossref","unstructured":"107. \u3000Masri A, Pierson LM, Smedira NG, Agarwal S, Lytle BW, Naji P, et al. Predictors of long-term outcomes in patients with hypertrophic cardiomyopathy undergoing cardiopulmonary stress testing and echocardiography. <i>Am Heart J<\/i> 2015; 169: 684\u2013692.e1.","DOI":"10.1016\/j.ahj.2015.02.006"},{"key":"108","doi-asserted-by":"crossref","unstructured":"108. \u3000Sorajja P, Allison T, Hayes C, Nishimura RA, Lam CSP, Ommen SR. Prognostic utility of metabolic exercise testing in minimally symptomatic patients with obstructive hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2012; 109: 1494\u20131498.","DOI":"10.1016\/j.amjcard.2012.01.363"},{"key":"109","doi-asserted-by":"crossref","unstructured":"109. \u3000Magr\u00ec D, Limongelli G, Re F, Agostoni P, Zachara E, Correale M, et al. Cardiopulmonary exercise test and sudden cardiac death risk in hypertrophic cardiomyopathy. <i>Heart<\/i> 2016; 102: 602\u2013609.","DOI":"10.1136\/heartjnl-2015-308453"},{"key":"110","doi-asserted-by":"crossref","unstructured":"110. \u3000Fananapazir L, Tracy CM, Leon MB, Winkler JB, Cannon RO 3rd, Bonow RO, et al. Electrophysiologic abnormalities in patients with hypertrophic cardiomyopathy: A consecutive analysis in 155 patients. <i>Circulation<\/i> 1989; 80: 1259\u20131268.","DOI":"10.1161\/01.CIR.80.5.1259"},{"key":"111","doi-asserted-by":"crossref","unstructured":"111. \u3000Watson RM, Schwartz JL, Maron BJ, Tucker E, Rosing DR, Josephson ME. Inducible polymorphic ventricular tachycardia and ventricular \ufb01brillation in a subgroup of patients with hypertrophic cardiomyopathy at high risk for sudden death. <i>J Am Coll Cardiol<\/i> 1987; 10: 761\u2013774.","DOI":"10.1016\/S0735-1097(87)80268-1"},{"key":"112","doi-asserted-by":"crossref","unstructured":"112. \u3000Fananapazir L, Chang AC, Epstein SE, McAreavey D. Prognostic determinants in hypertrophic cardiomyopathy: Prospective evaluation of a therapeutic strategy based on clinical, Holter, hemodynamic, and electrophysiological \ufb01ndings. <i>Circulation<\/i> 1992; 86: 730\u2013740.","DOI":"10.1161\/01.CIR.86.3.730"},{"key":"113","unstructured":"113. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. 2021\u5e74\u6539\u8a02\u7248. \u5faa\u74b0\u5668\u8d85\u97f3\u6ce2\u691c\u67fb\u306e\u9069\u5fdc\u3068\u5224\u8aad\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2021\/03\/JCS2021_Ohte.pdf"},{"key":"114","doi-asserted-by":"crossref","unstructured":"114. \u3000Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A wide angle, two dimensional echocardiographic study of 125 patients. <i>Am J Cardiol<\/i> 1981; 48: 418\u2013428.","DOI":"10.1016\/0002-9149(81)90068-0"},{"key":"115","doi-asserted-by":"crossref","unstructured":"115. \u3000Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: A two-dimensional echocardiographic study. <i>J Am Coll Cardiol<\/i> 1983; 2: 437\u2013444.","DOI":"10.1016\/S0735-1097(83)80269-1"},{"key":"116","doi-asserted-by":"crossref","unstructured":"116. \u3000Kawano M, Takenaka T, Otsuji Y, Teraguchi H, Yoshifuku S, Yuasa T, et al. Signi\ufb01cance of asymmetric basal posterior wall thinning in patients with cardiac Fabry\u2019s disease. <i>Am J Cardiol<\/i> 2007; 99: 261\u2013263.","DOI":"10.1016\/j.amjcard.2006.07.088"},{"key":"117","doi-asserted-by":"crossref","unstructured":"117. \u3000Pieroni M, Chimenti C, De Cobelli F, Del Maschio A, Gaudio C, Russo MA, et al. Fabry\u2019s disease cardiomyopathy: Echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. <i>J Am Coll Cardiol<\/i> 2006; 47: 1663\u20131671.","DOI":"10.1016\/j.jacc.2005.11.070"},{"key":"118","doi-asserted-by":"crossref","unstructured":"118. \u3000Liu H, Pozios I, Haileselassie B, Nowbar A, Sorensen LL, Phillip S, et al. Role of global longitudinal strain in predicting outcomes in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2017; 120: 670\u2013675.","DOI":"10.1016\/j.amjcard.2017.05.039"},{"key":"119","unstructured":"119. \u3000Maron BJ, Spirito P. Implications of left ventricular remodeling in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1998; 81: 1339\u20131344."},{"key":"120","doi-asserted-by":"crossref","unstructured":"120. \u3000Maron BJ, Spirito P, Green KJ, Wesley YE, Bonow RO, J Arce. Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1987; 10: 733\u2013742.","DOI":"10.1016\/S0735-1097(87)80264-4"},{"key":"121","doi-asserted-by":"crossref","unstructured":"121. \u3000Nishimura RA, Appleton CP, Red\ufb01eld MM, Ilstrup DM, Holmes DR Jr, Tajik AJ. Noninvasive doppler echocardiographic evaluation of left ventricular \ufb01lling pressures in patients with cardiomyopathies: A simultaneous Doppler echocardiographic and cardiac catheterization study. <i>J Am Coll Cardiol<\/i> 1996; 28: 1226\u20131233.","DOI":"10.1016\/S0735-1097(96)00315-4"},{"key":"122","doi-asserted-by":"crossref","unstructured":"122. \u3000Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>Eur Heart J Cardiovasc Imaging<\/i> 2016; 17: 1321\u20131360.","DOI":"10.1093\/ehjci\/jew082"},{"key":"123","doi-asserted-by":"crossref","unstructured":"123. \u3000Ro R, Halpern D, Sahn DJ, Homel P, Arabadjian M, Lopresto C, et al. Vector flow mapping in obstructive hypertrophic cardiomyopathy to assess the relationship of early systolic left ventricular \ufb02ow and the mitral valve. <i>J Am Coll Cardiol<\/i> 2014; 64: 1984\u20131995.","DOI":"10.1016\/j.jacc.2014.04.090"},{"key":"124","doi-asserted-by":"crossref","unstructured":"124. \u3000Sherrid MV, Balaram S, Kim B, Axel L, Swistel DG. The mitral valve in obstructive hypertrophic cardiomyopathy: A test in context. <i>J Am Coll Cardiol<\/i> 2016; 67: 1846\u20131858.","DOI":"10.1016\/j.jacc.2016.01.071"},{"key":"125","doi-asserted-by":"crossref","unstructured":"125. \u3000Silbiger JJ. Abnormalities of the mitral apparatus in hypertrophic cardiomyopathy: Echocardiographic, pathophysiologic, and surgical insights. <i>J Am Soc Echocardiogr<\/i> 2016; 29: 622\u2013639.","DOI":"10.1016\/j.echo.2016.03.003"},{"key":"126","doi-asserted-by":"crossref","unstructured":"126. \u3000Shah PM, Taylor RD, Wong M. Abnormal mitral valve coaptation in hypertrophic obstructive cardiomyopathy: Proposed role in systolic anterior motion of mitral valve. <i>Am J Cardiol<\/i> 1981; 48: 258\u2013262.","DOI":"10.1016\/0002-9149(81)90605-6"},{"key":"127","doi-asserted-by":"crossref","unstructured":"127. \u3000Sherrid MV, Chu CK, Delia E, Mogtader A, Dwyer EM Jr. An echocardiographic study of the \ufb02uid mechanics of obstruction in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1993; 22: 816\u2013825.","DOI":"10.1016\/0735-1097(93)90196-8"},{"key":"128","doi-asserted-by":"crossref","unstructured":"128. \u3000Sherrid MV, Gunsburg DZ, Moldenhauer S, Pearle G. Systolic anterior motion begins at low left ventricular out\ufb02ow tract velocity in obstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2000; 36: 1344\u20131354.","DOI":"10.1016\/S0735-1097(00)00830-5"},{"key":"129","unstructured":"129. \u3000Braunwald E. Heart disease: A textbook of cardiovascular medicine, 5th edn. Philadelphia: WB Saunders, 1997; 1420."},{"key":"130","doi-asserted-by":"crossref","unstructured":"130. \u3000Suzuki K, Akashi YJ. Exercise stress echocardiography in hypertrophic cardiomyopathy. <i>J Echocardiogr<\/i> 2017; 15: 110\u2013117.","DOI":"10.1007\/s12574-017-0338-4"},{"key":"131","doi-asserted-by":"crossref","unstructured":"131. \u3000Oki T, Fukuda N, Iuchi A, Tabata T, Tanimoto M, Manabe K, et al. Transesophageal echocardiographic evaluation of mitral regurgitation in hypertrophic cardiomyopathy: Contributions of eccentric left ventricular hypertrophy and related abnormalities of the mitral complex. <i>J Am Soc Echocardiogr<\/i> 1995; 8: 503\u2013510.","DOI":"10.1016\/S0894-7317(05)80338-4"},{"key":"132","doi-asserted-by":"crossref","unstructured":"132. \u3000Yu EH, Omran AS, Wigle ED, Williams WG, Siu SC, Rakowski H. Mitral regurgitation in hypertrophic obstructive cardiomyopathy: Relationship to obstruction and relief with myectomy. <i>J Am Coll Cardiol<\/i> 2000; 36: 2219\u20132225.","DOI":"10.1016\/S0735-1097(00)01019-6"},{"key":"133","unstructured":"133. \u3000Budoff MJ, Cohen MC, Garcia MJ, Hodgson JM, Hundley WG, Lima JA, et al. ACCF\/AHA clinical competence statement on cardiac imaging with computed tomography and magnetic resonance. A report of the American College of Cardiology Foundation\/American Heart Association\/American College of Physicians Task Force on Clinical Competence and Training. <i>Circulation<\/i> 2005; 112: 598\u2013617."},{"key":"134","doi-asserted-by":"crossref","unstructured":"134. \u30002016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Eur Heart J<\/i> 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"135","doi-asserted-by":"crossref","unstructured":"135. \u3000Bogaert J, Olivotto I. MR imaging in hypertrophic cardiomyopathy: From magnet to bedside. <i>Radiology<\/i> 2014; 273: 329\u2013348.","DOI":"10.1148\/radiol.14131626"},{"key":"136","doi-asserted-by":"crossref","unstructured":"136. \u3000Maron MS, Maron BJ. Clinical impact of contemporary cardiovascular magnetic resonance imaging in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2015; 132: 292\u2013298.","DOI":"10.1161\/CIRCULATIONAHA.114.014283"},{"key":"137","doi-asserted-by":"crossref","unstructured":"137. \u3000Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N, et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2005; 112: 855\u2013861.","DOI":"10.1161\/CIRCULATIONAHA.104.507723"},{"key":"138","doi-asserted-by":"crossref","unstructured":"138. \u3000Posma JL, Blanksma PK, van der Wall EE, Hamer HP, Mooyaart EL, Lie KI. Assessment of quantitative hypertrophy scores in hypertrophic cardiomyopathy: Magnetic resonance imaging versus echocardiography. <i>Am Heart J<\/i> 1996; 132: 1020\u20131027.","DOI":"10.1016\/S0002-8703(96)90016-2"},{"key":"139","doi-asserted-by":"crossref","unstructured":"139. \u3000Maron MS, Lesser JR, Maron BJ. Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance. <i>Am J Cardiol<\/i> 2010; 105: 1842\u20131843.","DOI":"10.1016\/j.amjcard.2010.01.367"},{"key":"140","doi-asserted-by":"crossref","unstructured":"140. \u3000Maron MS, Olivotto I, Harrigan C, Appelbaum E, Gibson CM, Lesser JR, et al. Mitral valve abnormalities identi\ufb01ed by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2011; 124: 40\u201347.","DOI":"10.1161\/CIRCULATIONAHA.110.985812"},{"key":"141","doi-asserted-by":"crossref","unstructured":"141. \u3000Harrigan CJ, Appelbaum E, Maron BJ, Buros JL, Gibson CM, Lesser JR, et al. Signi\ufb01cance of papillary muscle abnormalities identi\ufb01ed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2008; 101: 668\u2013673.","DOI":"10.1016\/j.amjcard.2007.10.032"},{"key":"142","doi-asserted-by":"crossref","unstructured":"142. \u3000Maron MS, Maron BJ, Harrigan C, Buros J, Gibson CM, et al. Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. <i>J Am Coll Cardiol<\/i> 2009; 54: 220\u2013228.","DOI":"10.1016\/j.jacc.2009.05.006"},{"key":"143","doi-asserted-by":"crossref","unstructured":"143. \u3000Olivotto I, Maron MS, Autore C, Lesser JR, Rega L, Casolo G, et al. Assessment and signi\ufb01cance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2008; 52: 559\u2013566.","DOI":"10.1016\/j.jacc.2008.04.047"},{"key":"144","doi-asserted-by":"crossref","unstructured":"144. \u3000Maron MS, Hauser TH, Dubrow E, Horst TA, Kissinger KV, Udelson JE, et al. Right ventricular involvement in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2007; 100: 1293\u20131298.","DOI":"10.1016\/j.amjcard.2007.05.061"},{"key":"145","doi-asserted-by":"crossref","unstructured":"145. \u3000Moon JC, Fisher NG, McKenna WJ, Pennell DJ. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. <i>Heart<\/i> 2004; 90: 645\u2013649.","DOI":"10.1136\/hrt.2003.014969"},{"key":"146","unstructured":"146. \u3000\u5bfa\u5ca1\u90a6\u5f66, \u5e73\u91ce\u96c5\u6625, \u5c0f\u5ddd\u9686, \u4ed6. \u78c1\u6c17\u5171\u9cf4\u753b\u50cf\u306b\u3088\u308a\u9045\u5ef6\u9020\u5f71 \u967d\u6027\u306e\u5fc3\u5c16\u90e8\u5fc3\u5ba4\u7624\u3092\u8a8d\u3081\u305f\u5fc3\u5ba4\u4e2d\u90e8\u9589\u585e\u6027\u80a5\u5927\u578b\u5fc3\u7b4b\u75c7\u306e2\u4f8b. <i>J Cardiol<\/i> 2003; 42: 87\u201394."},{"key":"147","doi-asserted-by":"crossref","unstructured":"147. \u3000Maron MS, Appelbaum E, Harrigan CJ, Buros J, Gibson CM, Hanna C, et al. Clinical pro\ufb01le and signi\ufb01cance of delayed enhancement in hypertrophic cardiomyopathy. <i>Circ Heart Fail<\/i> 2008; 1: 184\u2013191.","DOI":"10.1161\/CIRCHEARTFAILURE.108.768119"},{"key":"148","doi-asserted-by":"crossref","unstructured":"148. \u3000Karamitsos TD, Francis JM, Myerson S, Selvanayagam JB, Neubauer S. The role of cardiovascular magnetic resonance imaging in heart failure. <i>J Am Coll Cardiol<\/i> 2009; 54: 1407\u20131424.","DOI":"10.1016\/j.jacc.2009.04.094"},{"key":"149","doi-asserted-by":"crossref","unstructured":"149. \u3000Ismail TF, Jabbour A, Gulati A, Mallorie A, Raza S, Cowling TE, et al. Role of late gadolinium enhancement cardiovascular magnetic resonance in the risk stratification of hypertrophic cardiomyopathy. <i>Heart<\/i> 2014; 100: 1851\u20131858.","DOI":"10.1136\/heartjnl-2013-305471"},{"key":"150","doi-asserted-by":"crossref","unstructured":"150. \u3000Chan RH, Maron BJ, Olivotto I, Pencina MJ, Assenza GE, Haas T, et al. Prognostic value of quantitative contrast-enhanced cardiovascular magnetic resonance for the evaluation of sudden death risk in patients with hypertrophic cardiomyopathy. <i>Circulation<\/i> 2014; 130: 484\u2013495.","DOI":"10.1161\/CIRCULATIONAHA.113.007094"},{"key":"151","doi-asserted-by":"crossref","unstructured":"151. \u3000Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM, Lesser JR, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. <i>J Am Coll Cardiol<\/i> 2008; 51: 1369\u20131374.","DOI":"10.1016\/j.jacc.2007.11.071"},{"key":"152","doi-asserted-by":"crossref","unstructured":"152. \u3000Weng Z, Yao J, Chan RH, He J, Yang X, Zhou Y, et al. Prognostic value of LGE-CMR in HCM: A meta-analysis. <i>JACC Cardiovasc Imaging<\/i> 2016; 9: 1392\u20131402.","DOI":"10.1016\/j.jcmg.2016.02.031"},{"key":"153","doi-asserted-by":"crossref","unstructured":"153. \u3000Briasoulis A, Mallikethi-Reddy S, Palla M, Alesh I, Afonso L. Myocardial \ufb01brosis on cardiac magnetic resonance and cardiac outcomes in hypertrophic cardiomyopathy: A meta-analysis. <i>Heart<\/i> 2015; 101: 1406\u20131411.","DOI":"10.1136\/heartjnl-2015-307682"},{"key":"154","doi-asserted-by":"crossref","unstructured":"154. \u3000He D, Ye M, Zhang L, Jiang B. Prognostic signi\ufb01cance of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy. <i>Heart Lung<\/i> 2018; 47: 122\u2013126.","DOI":"10.1016\/j.hrtlng.2017.10.008"},{"key":"155","doi-asserted-by":"crossref","unstructured":"155. \u3000Rudolph A, Abdel-Aty H, Bohl S, Boy\u00e9 P, Zagrosek A, Dietz R, et al. Noninvasive detection of fibrosis applying contrast-enhanced cardiac magnetic resonance in different forms of left ventricular hypertrophy relation to remodeling. <i>J Am Coll Cardiol<\/i> 2009; 53: 284\u2013291.","DOI":"10.1016\/j.jacc.2008.08.064"},{"key":"156","doi-asserted-by":"crossref","unstructured":"156. \u3000Hinojar R, Varma N, Child N, Goodman B, Jabbour A, Yu CY, et al. T1 mapping in discrimination of hypertrophic phenotypes: Hypertensive heart disease and hypertrophic cardiomyopathy: Findings from the International T1 Multi-center Cardiovascular Magnetic Resonance Study. <i>Circ Cardiovasc Imaging<\/i> 2015; 8: E003285.","DOI":"10.1161\/CIRCIMAGING.115.003285"},{"key":"157","doi-asserted-by":"crossref","unstructured":"157. \u3000Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease: Evidence for a disease speci\ufb01c abnormality of the myocardial interstitium. <i>Eur Heart J<\/i> 2003; 24: 2151\u20132155.","DOI":"10.1016\/j.ehj.2003.09.017"},{"key":"158","doi-asserted-by":"crossref","unstructured":"158. \u3000Sado DM, White SK, Piechnik SK, Banypersad SM, Treibel T, Captur G, et al. Identi\ufb01cation and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. <i>Circ Cardiovasc Imaging<\/i> 2013; 6: 392\u2013398.","DOI":"10.1161\/CIRCIMAGING.112.000070"},{"key":"159","doi-asserted-by":"crossref","unstructured":"159. \u3000Pica S, Sado DM, Maestrini V, Fontana M, White SK, Treibel T, et al. Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonance. <i>J Cardiovasc Magn Reson<\/i> 2014; 16: 99.","DOI":"10.1186\/s12968-014-0099-4"},{"key":"160","doi-asserted-by":"crossref","unstructured":"160. \u3000Hughes DA, Elliott PM, Shah J, Zuckerman J, Coghlan G, Brookes J, Mehta A. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: A randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa. <i>Heart<\/i> 2008; 94: 153\u2013158.","DOI":"10.1136\/hrt.2006.104026"},{"key":"161","doi-asserted-by":"crossref","unstructured":"161. \u3000Syed IS, Martinez MW, Feng DL, Glockner JF. Cardiac magnetic resonance imaging of eosinophilic endomyocardial disease. <i>Int J Cardiol<\/i> 2008; 126: e50\u2013e52.","DOI":"10.1016\/j.ijcard.2007.01.019"},{"key":"162","doi-asserted-by":"crossref","unstructured":"162. \u3000Smedema JP, Snoep G, van Kroonenburgh MP, van Geuns RJ, Dassen WR, Gorgels AP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. <i>J Am Coll Cardiol<\/i> 2005; 45: 1683\u20131690.","DOI":"10.1016\/j.jacc.2005.01.047"},{"key":"163","doi-asserted-by":"crossref","unstructured":"163. \u3000Maceira AM, Joshi J, Prasad SK, Moon JC, Perugini E, Harding I, et al. Cardiovascular magnetic resonance in cardiac amyloidosis. <i>Circulation<\/i> 2005; 111: 186\u2013193.","DOI":"10.1161\/01.CIR.0000152819.97857.9D"},{"key":"164","doi-asserted-by":"crossref","unstructured":"164. \u3000Martinez-Naharro A, Treibel TA, Abdel-Gadir A, Bulluck H, Zumbo G, Knight DS, et al. Magnetic resonance in transthyretin cardiac amyloidosis. <i>J Am Coll Cardiol<\/i> 2017; 70: 466\u2013477.","DOI":"10.1016\/j.jacc.2017.05.053"},{"key":"165","doi-asserted-by":"crossref","unstructured":"165. \u3000Cannon RO III, Rosing DR, Maron BJ, Leon MB, Bonow RO, Watson RM, et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: Contribution of inadequate vasodilator reserve and elevated left ventricular \ufb01lling pressures. <i>Circulation<\/i> 1985; 71: 234\u2013243.","DOI":"10.1161\/01.CIR.71.2.234"},{"key":"166","doi-asserted-by":"crossref","unstructured":"166. \u3000Hanrath P, Mathey D, Montz R, Thiel U, Vorbringer H, Kupper W, et al. Myocardial thallium201 imaging in hypertrophic obstructive cardiomyopathy. <i>Eur Heart J<\/i> 1981; 2: 177\u2013185.","DOI":"10.1093\/oxfordjournals.eurheartj.a061192"},{"key":"167","doi-asserted-by":"crossref","unstructured":"167. \u3000Maron BJ, Bonow RO, Cannon RO 3rd, Leon MB, Epstein SE, et al. Hypertrophic cardiomyopathy: Interrelations of clinical manifestations, pathophysiology, and therapy (2). <i>N Engl J Med<\/i> 1987; 316: 844\u2013852.","DOI":"10.1056\/NEJM198704023161405"},{"key":"168","doi-asserted-by":"crossref","unstructured":"168. \u3000Conte MR, Bongioanni S, Chiribiri A, Leuzzi S, Lardone E, Di Donna P, et al. Late gadolinium enhancement on cardiac magnetic resonance and phenotypic expression in hypertrophic cardiomyopathy. <i>Am Heart J<\/i> 2011; 161: 1073\u20131077.","DOI":"10.1016\/j.ahj.2011.03.022"},{"key":"169","doi-asserted-by":"crossref","unstructured":"169. \u3000O\u2019Gara PT, Bonow RO, Maron BJ, Damske BA, Van Lingen A, Bacharach SL, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: Assessment with thallium-201 emission computed tomography. <i>Circulation<\/i> 1987; 76: 1214\u20131223.","DOI":"10.1161\/01.CIR.76.6.1214"},{"key":"170","doi-asserted-by":"crossref","unstructured":"170. \u3000Yamada M, Elliott PM, Kaski JC, Prasad K, Gane JN, Lowe CM, et al. Dipyridamole stress thallium-201 perfusion abnormalities in patients with hypertrophic cardiomyopathy: Relationship to clinical presentation and outcome. <i>Eur Heart J<\/i> 1998; 19: 500\u2013507.","DOI":"10.1053\/euhj.1997.0769"},{"key":"171","doi-asserted-by":"crossref","unstructured":"171. \u3000Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1993; 22: 796\u2013804.","DOI":"10.1016\/0735-1097(93)90193-5"},{"key":"172","doi-asserted-by":"crossref","unstructured":"172. \u3000Sorajja P, Chareonthaitawee P, Ommen SR, Miller TD, Hodge DO, Gibbons RJ. Prognostic utility of single-photon emission computed tomography in adult patients with hypertrophic cardiomyopathy. <i>Am Heart J<\/i> 2006; 151: 426\u2013435.","DOI":"10.1016\/j.ahj.2005.02.050"},{"key":"173","unstructured":"173. \u3000Ohtsuki K, Sugihara H, Kuribayashi T, Nakagawa M. Impairment of BMIPP accumulation at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. <i>J Nucl Med<\/i> 1999; 40: 2007\u20132013."},{"key":"174","doi-asserted-by":"crossref","unstructured":"174. \u3000Takeishi Y, Chiba J, Abe S, Tonooka I, Komatani A, Tomoike H. Heterogeneous myocardial distribution of iodine-123 15-(p-iodophenyl)-3-R,S-methylpentadecanoic acid (BMIPP) in patients with hypertrophic cardiomyopathy. <i>Eur J Nucl Med<\/i> 1992; 19: 775\u2013782.","DOI":"10.1007\/BF00182819"},{"key":"175","unstructured":"175. \u3000Kurata C, Tawarahara K, Taguchi T, Aoshima S, Kobayashi A, Yamazaki N, et al. Myocardial emission computed tomography with iodine-123-labeled beta-methyl-branched fatty acid in patients with hypertrophic cardiomyopathy. <i>J Nucl Med<\/i> 1992; 33: 6\u201313."},{"key":"176","doi-asserted-by":"crossref","unstructured":"176. \u3000Taki J, Nakajima K, Bunko H, Shimizu M, Taniguchi M, Hisada K. 123I-labelled BMIPP fatty acid myocardial scintigraphy in patients with hypertrophic cardiomyopathy: SPECT comparison with stress 201Tl. <i>Nucl Med Commun<\/i> 1993; 14: 181\u2013188.","DOI":"10.1097\/00006231-199303000-00006"},{"key":"177","doi-asserted-by":"crossref","unstructured":"177. \u3000Ohtsuki K, Sugihara H, Umamoto I, Nakamura T, Nakagawa T, Nakagawa M. Clinical evaluation of hypertrophic cardiomyopathy by myocardial scintigraphy using 123I-labelled 15-(p-iodophenyl)-3-R, S-methylpentadecanoic acid (123I-BMIPP). <i>Nucl Med Commun<\/i> 1994; 15: 441\u2013447.","DOI":"10.1097\/00006231-199406000-00008"},{"key":"178","doi-asserted-by":"crossref","unstructured":"178. \u3000Nishimura T, Nagata S, Uehara T, Morozumi T, Ishida Y, Nakata T, et al. Prognosis of hypertrophic cardiomyopathy: Assessment by 123I-BMIPP (\u03b2-methyl-p-(123I) iodophenyl pentadecanoic acid) myocardial single photon emission computed tomography. <i>Ann Nucl Med<\/i> 1996; 10: 71\u201378.","DOI":"10.1007\/BF03165056"},{"key":"179","doi-asserted-by":"crossref","unstructured":"179. \u3000Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I-15-(p-Iodophenyl)-3(R,S)-methylpentadecanoic acid myocardial scintigraphy. <i>Cardiology<\/i> 2000; 93: 43\u201349.","DOI":"10.1159\/000007001"},{"key":"180","doi-asserted-by":"crossref","unstructured":"180. \u3000Shimizu M, Sugihara N, Kita Y, Shimizu K, Horita Y, Nakajima K, et al. Long-term course and cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy. <i>Br Heart J<\/i> 1992; 67: 155\u2013160.","DOI":"10.1136\/hrt.67.2.155"},{"key":"181","unstructured":"181. \u3000Sipola P, Vanninen E, Aronen HJ, Lauerma K, Simula S, J\u00e4\u00e4skel\u00e4inen P, et al. Cardiac adrenergic activity is associated with left ventricular hypertrophy in genetically homogeneous subjects with hypertrophic cardiomyopathy. <i>J Nucl Med<\/i> 2003; 44: 487\u2013493."},{"key":"182","doi-asserted-by":"crossref","unstructured":"182. \u3000Nakajima K, Bunko H, Taki J, Shimizu M, Muramori A, Hisada K. Quantitative analysis of 123I-meta-iodobenzylguanidine (MIBG) uptake in hypertrophic cardiomyopathy. <i>Am Heart J<\/i> 1990; 119: 1329\u20131337.","DOI":"10.1016\/S0002-8703(05)80183-8"},{"key":"183","doi-asserted-by":"crossref","unstructured":"183. \u3000Terai H, Shimizu M, Ino H, Yamaguchi M, Hayashi K, Sakata K, et al. Cardiac sympathetic nerve activity in patients with hypertrophic cardiomyopathy with malignant ventricular tachyarrhythmias. <i>J Nucl Cardiol<\/i> 2003; 10: 304\u2013310.","DOI":"10.1016\/S1071-3581(03)00362-3"},{"key":"184","doi-asserted-by":"crossref","unstructured":"184. \u3000Nagueh SF, Mahmarian JJ. Noninvasive cardiac imaging in patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2006; 48: 2410\u20132422.","DOI":"10.1016\/j.jacc.2006.07.065"},{"key":"185","doi-asserted-by":"crossref","unstructured":"185. \u3000Chikamori T, Dickie S, Poloniecki JD, Myers MJ, Lavender JP, McKenna WJ. Prognostic signi\ufb01cance of radionuclide-assessed diastolic function in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1990; 65: 478\u2013482.","DOI":"10.1016\/0002-9149(90)90814-H"},{"key":"186","doi-asserted-by":"crossref","unstructured":"186. \u3000Grover-McKay M, Schwaiger M, Krivokapich J, Perloff JK, Phelps ME, Schelbert HR. Regional myocardial blood \ufb02ow and metabolism at rest in mildly symptomatic patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1989; 13: 317\u2013324.","DOI":"10.1016\/0735-1097(89)90505-6"},{"key":"187","doi-asserted-by":"crossref","unstructured":"187. \u3000Perrone-Filardi P, Bacharach SL, Dilsizian V, Panza JA, Maurea S, Bonow RO. Regional systolic function, myocardial blood \ufb02ow and glucose uptake at rest in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1993; 72: 199\u2013204.","DOI":"10.1016\/0002-9149(93)90160-E"},{"key":"188","unstructured":"188. \u3000Tadamura E, Tamaki N, Matsumori A, Magata Y, Yonekura Y, Nohara R, et al. Myocardial metabolic changes in hypertrophic cardiomyopathy. <i>J Nucl Med<\/i> 1996; 37: 572\u2013577."},{"key":"189","doi-asserted-by":"crossref","unstructured":"189. \u3000Nienaber CA, Gambhir SS, Mody FV, Ratib O, Huang SC, Phelps ME, et al. Regional myocardial blood \ufb02ow and glucose utilization in symptomatic patients with hypertrophic cardiomyopathy. <i>Circulation<\/i> 1993; 87: 1580\u20131590.","DOI":"10.1161\/01.CIR.87.5.1580"},{"key":"190","doi-asserted-by":"crossref","unstructured":"190. \u3000Bokhari S, Casta\u00f1o A, Pozniakoff T, Deslisle S, Latif F, Maurer MS. 99 mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. <i>Circ Cardiovasc Imaging<\/i> 2013; 6: 195\u2013201.","DOI":"10.1161\/CIRCIMAGING.112.000132"},{"key":"191","doi-asserted-by":"crossref","unstructured":"191. \u3000Casta\u00f1o A, Bokhari S, Brannagan TH 3rd, Wynn J, Maurer MS. Technetium pyrophosphate myocardial uptake and peripheral neuropathy in a rare variant of familial transthyretin (TTR) amyloidosis (Ser23Asn): A case report and literature review. <i>Amyloid<\/i> 2012; 19: 41\u201346.","DOI":"10.3109\/13506129.2011.638682"},{"key":"192","doi-asserted-by":"crossref","unstructured":"192. \u3000Maurer MS. Noninvasive Identi\ufb01cation of ATTRwt cardiac amyloid: The re-emergence of nuclear cardiology. <i>Am J Med<\/i> 2015; 128: 1275\u20131280.","DOI":"10.1016\/j.amjmed.2015.05.039"},{"key":"193","doi-asserted-by":"crossref","unstructured":"193. \u3000Hamatani Y, Amaki M, Kanzaki H, Yamashita K, Nakashima Y, Shibata A, et al. Contrast-enhanced computed tomography with myocardial three-dimensional printing can guide treatment in symptomatic hypertrophic obstructive cardiomyopathy. <i>Heart Fail<\/i> 2017; 4: 665\u2013669.","DOI":"10.1002\/ehf2.12178"},{"key":"194","doi-asserted-by":"crossref","unstructured":"194. \u3000Cooper RM, Binukrishnan SR, Shahzad A, Hasleton J, Sigwart U, Stables RH. Computed tomography angiography planning identi\ufb01es the target vessel for optimum infarct location and improves clinical outcome in alcohol septal ablation for hypertrophic obstructive cardiomyopathy. <i>EuroIntervention<\/i> 2017; 12: e2194\u2013e2203.","DOI":"10.4244\/EIJ-D-15-00159"},{"key":"195","doi-asserted-by":"crossref","unstructured":"195. \u3000Yang DH, Kang JW, Kim N, Song JK, Lee JW, Lim TH. Myocardial 3-dimensional printing for septal myectomy guidance in a patient with obstructive hypertrophic cardiomyopathy. <i>Circulation<\/i> 2015; 132: 300\u2013301.","DOI":"10.1161\/CIRCULATIONAHA.115.015842"},{"key":"196","doi-asserted-by":"crossref","unstructured":"196. \u3000Zhao L, Ma X, Feuchtner GM, Zhang C, Fan Z. Quanti\ufb01cation of myocardial delayed enhancement and wall thickness in hypertrophic cardiomyopathy: Multidetector computed tomography versus magnetic resonance imaging. <i>Eur J Radiol<\/i> 2014; 83: 1778\u20131785.","DOI":"10.1016\/j.ejrad.2014.05.035"},{"key":"197","doi-asserted-by":"crossref","unstructured":"197. \u3000Langer C, Lutz M, Eden M, L\u00fcdde M, Hohnhorst M, Gierloff C, et al. Hypertrophic cardiomyopathy in cardiac CT: A validation study on the detection of intramyocardial \ufb01brosis in consecutive patients. <i>Int J Cardiovasc Imaging<\/i> 2014; 30: 659\u2013667.","DOI":"10.1007\/s10554-013-0358-8"},{"key":"198","doi-asserted-by":"crossref","unstructured":"198. \u3000Zhao L, Ma X, Delano MC, Jiang T, Zhang C, Liu Y, et al. Assessment of myocardial \ufb01brosis and coronary arteries in hypertrophic cardiomyopathy using combined arterial and delayed enhanced CT: Comparison with MR and coronary angiography. <i>Eur Radiol<\/i> 2013; 23: 1034\u20131043.","DOI":"10.1007\/s00330-012-2674-0"},{"key":"199","doi-asserted-by":"crossref","unstructured":"199. \u3000Falicov RE, Resnekov L. Mid ventricular obstruction in hypertrophic obstructive cardiomyopathy: New diagnostic and therapeutic challenge. <i>Br Heart J<\/i> 1977; 39: 701\u2013705.","DOI":"10.1136\/hrt.39.7.701"},{"key":"200","doi-asserted-by":"crossref","unstructured":"200. \u3000Brockenbrough EC, Braunwald E, Morrow AG. A hemodynamic technic for the detection of hypertrophic subaortic stenosis. <i>Circulation<\/i> 1961; 23: 189\u2013194.","DOI":"10.1161\/01.CIR.23.2.189"},{"key":"201","doi-asserted-by":"crossref","unstructured":"201. \u3000Maron BJ, McIntosh CL, Klues HG, Cannon RO 3rd, Roberts WC. Morphologic basis for obstruction to right ventricular out\ufb02ow in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1993; 71: 1089\u20131094.","DOI":"10.1016\/0002-9149(93)90578-Z"},{"key":"202","doi-asserted-by":"crossref","unstructured":"202. \u3000Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Berger PB, Tajik AJ. Adverse prognosis of patients with hypertrophic cardiomyopathy who have epicardial coronary artery disease. <i>Circulation<\/i> 2003; 108: 2342\u20132348.","DOI":"10.1161\/01.CIR.0000097110.55312.BF"},{"key":"203","doi-asserted-by":"crossref","unstructured":"203. \u3000Basso C, Thiene G, Mackey-Bojack S, Frigo AC, Corrado D, Maron BJ. Myocardial bridging, a frequent component of the hypertrophic cardiomyopathy phenotype, lacks systematic association with sudden cardiac death. <i>Eur Heart J<\/i> 2009; 30: 1627\u20131634.","DOI":"10.1093\/eurheartj\/ehp121"},{"key":"204","doi-asserted-by":"crossref","unstructured":"204. \u3000Sorajja P, Ommen SR, Nishimura RA, Gersh BJ, Tajik AJ, Holmes DR. Myocardial bridging in adult patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2003; 42: 889\u2013894.","DOI":"10.1016\/S0735-1097(03)00854-4"},{"key":"205","doi-asserted-by":"crossref","unstructured":"205. \u3000Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. <i>J Am Coll Cardiol<\/i> 2000; 36: 2270\u20132278.","DOI":"10.1016\/S0735-1097(00)00987-6"},{"key":"206","doi-asserted-by":"crossref","unstructured":"206. \u3000Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. <i>Lancet<\/i> 1995; 346: 211\u2013214.","DOI":"10.1016\/S0140-6736(95)91267-3"},{"key":"207","doi-asserted-by":"crossref","unstructured":"207. \u3000Sakakibara S, Konno S. Endomyocardial biopsy. <i>Jpn Heart J<\/i> 1962; 3: 537\u2013543.","DOI":"10.1536\/ihj.3.537"},{"key":"208","doi-asserted-by":"crossref","unstructured":"208. \u3000Leone O, Veinot JP, Angelini A, Baandrup UT, Basso C, Berry G, et al. 2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. <i>Cardiovasc Pathol<\/i> 2012; 21: 245\u2013274.","DOI":"10.1016\/j.carpath.2011.10.001"},{"key":"209","unstructured":"209. \u3000Cooper LT, Baughman KL, Feldman AM, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: A scienti\ufb01c statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. <i>J Am Coll Cardiol<\/i> 2007; 50: 1914\u20131931."},{"key":"210","doi-asserted-by":"crossref","unstructured":"210. \u3000Ishibashi-Ueda H, Matsuyama TA, Ohta-Ogo K, Ikeda Y. Signi\ufb01cance and value of endomyocardial biopsy based on our own experience. <i>Circ J<\/i> 2017; 81: 417\u2013426.","DOI":"10.1253\/circj.CJ-16-0927"},{"key":"211","unstructured":"211. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u30b7\u30ea\u30fc\u30ba 2016\u5e74\u5ea6\u7248: \u5fc3\u81d3\u79fb\u690d\u306b\u95a2\u3059\u308b\u63d0\u8a00. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2016_isobe_h.pdf"},{"key":"212","doi-asserted-by":"crossref","unstructured":"212. \u3000Uemura A, Morimoto S, Hiramitsu S, Kato Y, Ito T, Hishida H. Histologic diagnostic rate of cardiac sarcoidosis: Evaluation of endomyocardial biopsies. <i>Am Heart J<\/i> 1999; 138: 299\u2013302.","DOI":"10.1016\/S0002-8703(99)70115-8"},{"key":"213","doi-asserted-by":"crossref","unstructured":"213. \u3000Yoshida A, Ishibashi-Ueda H, Yamada N, Kanzaki H, Hasegawa T, Takahama H, et al. Direct comparison of the diagnostic capability of cardiac magnetic resonance and endomyocardial biopsy in patients with heart failure. <i>Eur J Heart Fail<\/i> 2013; 15: 166\u2013175.","DOI":"10.1093\/eurjhf\/hfs206"},{"key":"214","doi-asserted-by":"crossref","unstructured":"214. \u3000Imaizumi Y, Eguchi K, Imada H, Hidano K, Niijima S, Kawata H, et al. Electron microscopy of contact between a monocyte and a multinucleated giant cell in cardiac sarcoidosis. <i>Can J Cardiol<\/i> 2016; 32: 1577.e19\u20131577.e20.","DOI":"10.1016\/j.cjca.2016.02.057"},{"key":"215","doi-asserted-by":"crossref","unstructured":"215. \u3000Casella M, Pizzamiglio F, Dello Russo A, Carbucicchio C, Al-Mohani G, Russo E, et al. Feasibility of combined unipolar and bipolar voltage maps to improve sensitivity of endomyocardial biopsy. <i>Circ Arrhythm Electrophysiol<\/i> 2015; 8: 625\u2013632.","DOI":"10.1161\/CIRCEP.114.002216"},{"key":"216","doi-asserted-by":"crossref","unstructured":"216. \u3000Hiramitsu S, Hiroe M, Uemura A, Kimura K, Hishida H, Morimoto S. National survey of the use of endomyocardial biopsy in Japan. <i>Jpn Circ J<\/i> 1998; 62: 909\u2013912.","DOI":"10.1253\/jcj.62.909"},{"key":"217","doi-asserted-by":"crossref","unstructured":"217. \u3000Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy: Differences in complication rate and diagnostic performance. <i>Circulation<\/i> 2010; 122: 900\u2013909.","DOI":"10.1161\/CIRCULATIONAHA.109.924167"},{"key":"218","doi-asserted-by":"crossref","unstructured":"218. \u3000Tsang TS, Freeman WK, Barnes ME, Reeder GS, Packer DL, Seward JB. Rescue echocardiographically guided pericardiocentesis for cardiac perforation complicating catheter-based procedures: The Mayo Clinic experience. <i>J Am Coll Cardiol<\/i> 1998; 32: 1345\u20131350.","DOI":"10.1016\/S0735-1097(98)00390-8"},{"key":"219","unstructured":"219. \u3000\u5fc3\u7b4b\u751f\u691c\u7814\u7a76\u4f1a\u7de8. \u8a3a\u65ad\u30e2\u30c0\u30ea\u30c6\u30a3\u3068\u3057\u3066\u306e\u5fc3\u7b4b\u75c5\u7406. \u5357\u6c5f\u5802 2017: 20\u201349."},{"key":"220","unstructured":"220. \u3000\u677e\u5c71\u9ad8\u660e, \u690d\u7530\u521d\u6c5f. \u5fc3\u5185\u819c\u5fc3\u7b4b\u751f\u691c\u6a19\u672c\u306e\u8a3a\u65ad\u3068\u6240\u898b\u306e\u8a18\u8f09\u65b9\u6cd5. \u8a3a\u65ad\u75c5\u74062014; 31: 75\u201387."},{"key":"221","unstructured":"221. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a\u5fc3\u81d3\u79fb\u690d\u59d4\u54e1\u4f1a. \u5fc3\u81d3\u79fb\u690d\u9069\u5fdc\u691c\u8a0e\u306e\u7533\u8acb\u306b\u3064\u3044\u3066. http:\/\/www.j-circ.or.jp\/hearttp\/ordersheet.html"},{"key":"222","unstructured":"222. \u3000Silver MM, Silver MD. Cardiomyopathies. <i>In<\/i>: Silver MD, editor. Cardiovascular pathology, 2nd edn. Churchill Livingstone, 1991; 743\u2013809."},{"key":"223","doi-asserted-by":"crossref","unstructured":"223. \u3000Vigliano CA, Cabeza Meckert PM, Diez M, Favaloro LE, Cortes C, Fazzi L, et al. Cardiomyocyte hypertrophy, oncosis, and autophagic vacuolization predict mortality in idiopathic dilated cardiomyopathy with advanced heart failure. <i>J Am Coll Cardiol<\/i> 2011; 57: 1523\u20131531.","DOI":"10.1016\/j.jacc.2010.09.080"},{"key":"224","doi-asserted-by":"crossref","unstructured":"224. \u3000Benvenuti LA, Freitas HF, Mansur AJ, Higuchi ML. Myocyte diameter and fractional area of collagen are not associated with survival time of outpatients with idiopathic dilated cardiomyopathy: A study based on right ventricular endomyocardial biopsies. <i>Int J Cardiol<\/i> 2007; 116: 279\u2013280.","DOI":"10.1016\/j.ijcard.2006.02.031"},{"key":"225","doi-asserted-by":"crossref","unstructured":"225. \u3000Grimm W, Rudolph S, Christ M, Pankuweit S, Maisch B. Prognostic significance of morphometric endomyocardial biopsy analysis in patients with idiopathic dilated cardiomyopathy. <i>Am Heart J<\/i> 2003; 146: 372\u2013376.","DOI":"10.1016\/S0002-8703(03)00148-0"},{"key":"226","doi-asserted-by":"crossref","unstructured":"226. \u3000Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemia. <i>Hum Pathol<\/i> 2000; 31: 988\u2013998.","DOI":"10.1053\/hupa.2000.16659"},{"key":"227","doi-asserted-by":"crossref","unstructured":"227. \u3000Gallego-Delgado M, Delgado JF, Brossa-Loidi V, Palomo J, Marzoa-Rivas R, Perez-Villa F, et al. Idiopathic restrictive cardiomyopathy is primarily a genetic disease. <i>J Am Coll Cardiol<\/i> 2016; 67: 3021\u20133023.","DOI":"10.1016\/j.jacc.2016.04.024"},{"key":"228","doi-asserted-by":"crossref","unstructured":"228. \u3000Flodrova P, Flodr P, Pika T, Vymetal J, Holub D, Dzubak P, et al. Cardiac amyloidosis: From clinical suspicion to morphological diagnosis. <i>Pathology<\/i> 2018; 50: 261\u2013268.","DOI":"10.1016\/j.pathol.2017.10.012"},{"key":"229","doi-asserted-by":"crossref","unstructured":"229. \u3000Endo Y, Furuta A, Nishino I. Danon disease: A phenotypic expression of LAMP-2 de\ufb01ciency. <i>Acta Neuropathol<\/i> 2015; 129: 391\u2013398.","DOI":"10.1007\/s00401-015-1385-4"},{"key":"230","doi-asserted-by":"crossref","unstructured":"230. \u3000El-Hattab AW, Scaglia F. Mitochondrial cardiomyopathies. <i>Front Cardiovasc Med<\/i> 2016; 3: 25.","DOI":"10.3389\/fcvm.2016.00025"},{"key":"231","unstructured":"231. \u3000\u907a\u4f1d\u533b\u5b66\u95a2\u902310\u5b66\u4f1a. \u907a\u4f1d\u5b66\u7684\u691c\u67fb\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2003\u5e748\u6708)."},{"key":"232","unstructured":"232. \u3000\u677e\u7530\u4e00\u90ce\u76e3\u4fee, \u798f\u5d8b\u7fa9\u5149\u7de8. \u907a\u4f1d\u533b\u5b66\u306b\u304a\u3051\u308b\u502b\u7406\u7684\u8af8\u554f\u984c\u306e\u518d\u691c\u8a0e (WHO\/HGN\/ETH\/00.4). 2002."},{"key":"233","unstructured":"233. \u3000World Health Organization, \u677e\u7530\u4e00\u90ce\u76e3\u4fee, \u798f\u5d8b\u7fa9\u5149\u7de8. \u907a\u4f1d\u533b\u5b66\u3068\u907a\u4f1d\u30b5\u30fc\u30d3\u30b9\u306b\u304a\u3051\u308b\u502b\u7406\u7684\u8af8\u554f\u984c\u306b\u95a2\u3057\u3066\u63d0\u6848\u3055\u308c\u305f\u56fd\u969b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 1998."},{"key":"234","unstructured":"234. \u3000UNESCO. \u30d2\u30c8\u30b2\u30ce\u30e0\u3068\u4eba\u6a29\u306b\u95a2\u3059\u308b\u4e16\u754c\u5ba3\u8a00. 1997 http:\/\/www.mext.go.jp\/unesco\/009\/1386506.htm"},{"key":"235","unstructured":"235. \u3000UNESCO. \u30d2\u30c8\u907a\u4f1d\u60c5\u5831\u306b\u95a2\u3059\u308b\u56fd\u969b\u5ba3\u8a00 (International Declaration on Human Genetic Data). 2003. http:\/\/www.unesco.org\/new\/en\/social-and-human-sciences\/themes\/bioethics\/human-genetic-data\/"},{"key":"236","unstructured":"236. \u3000\u6587\u90e8\u79d1\u5b66\u7701, \u539a\u751f\u52b4\u50cd\u7701, \u7d4c\u6e08\u7523\u696d\u7701. \u30d2\u30c8\u30b2\u30ce\u30e0\u30fb\u907a\u4f1d\u5b50\u89e3\u6790\u7814\u7a76\u306b\u95a2\u3059\u308b\u502b\u7406\u6307\u91dd (\u5e73\u621020\u5e74\u4e00\u90e8\u6539\u6b63). http:\/\/www.life-science.mext.go.jp\/bioethics\/hito_genom.html"},{"key":"237","unstructured":"237. \u3000\u65e5\u672c\u533b\u5b66\u4f1a. \u533b\u7642\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b66\u7684\u691c\u67fb\u30fb\u8a3a\u65ad\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. 2011. http:\/\/www.congre.co.jp\/gene\/pdf3\/guideline110218.pdf"},{"key":"238","unstructured":"238. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2010\u5e74\u5ea6\u5408\u540c\u7814\u7a76\u73ed\u5831\u544a): \u5fc3\u81d3\u8840\u7ba1\u75be\u60a3\u306b\u304a\u3051\u308b\u907a\u4f1d\u5b66\u7684\u691c\u67fb\u3068\u907a\u4f1d\u30ab\u30a6\u30f3\u30bb\u30ea\u30f3\u30b0\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2011\u5e74\u6539\u8a02\u7248). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2011_nagai_h.pdf"},{"key":"239","doi-asserted-by":"crossref","unstructured":"239. \u3000Seidman JG, Seidman C. The genetic basis for cardiomyopathy: From mutation identification to mechanistic paradigms. <i>Cell<\/i> 2001; 104: 557\u2013567.","DOI":"10.1016\/S0092-8674(01)00242-2"},{"key":"240","doi-asserted-by":"crossref","unstructured":"240. \u3000Kimura A. Molecular basis of hereditary cardiomyopathy: Abnormalities in calcium sensitivity, stretch response, stress response and beyond. <i>J Hum Genet<\/i> 2010; 55: 81\u201390.","DOI":"10.1038\/jhg.2009.138"},{"key":"241","doi-asserted-by":"crossref","unstructured":"241. \u3000Landstrom AP, Ackerman MJ. Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2010; 122: 2441\u20132450.","DOI":"10.1161\/CIRCULATIONAHA.110.954446"},{"key":"242","doi-asserted-by":"crossref","unstructured":"242. \u3000Bos JM, Towbin JA, Ackerman MJ. Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2009; 54: 201\u2013211.","DOI":"10.1016\/j.jacc.2009.02.075"},{"key":"243","doi-asserted-by":"crossref","unstructured":"243. \u3000Marian AJ. Hypertrophic cardiomyopathy: From genetics to treatment. <i>Eur J Clin Invest<\/i> 2010; 40: 360\u2013369.","DOI":"10.1111\/j.1365-2362.2010.02268.x"},{"key":"244","doi-asserted-by":"crossref","unstructured":"244. \u3000Ingles J, Burns C, Bagnall RD, Lam L, Yeates L, Sarina T, et al. Nonfamilial hypertrophic cardiomyopathy: Prevalence, natural history, and clinical implications. <i>Circ Cardiovasc Genet<\/i> 2017; 10: e001620.","DOI":"10.1161\/CIRCGENETICS.116.001620"},{"key":"245","doi-asserted-by":"crossref","unstructured":"245. \u3000Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B, et al. Clinicopathological pro\ufb01les of progressive heart failure in hypertrophic cardiomyopathy. <i>Eur Heart J<\/i> 2010; 31: 2111\u20132123.","DOI":"10.1093\/eurheartj\/ehq136"},{"key":"246","doi-asserted-by":"crossref","unstructured":"246. \u3000Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial \ufb01brillation on the clinical course of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2001; 104: 2517\u20132524.","DOI":"10.1161\/hc4601.097997"},{"key":"247","doi-asserted-by":"crossref","unstructured":"247. \u3000Yoshibayashi M, Kamiya T, Saito Y, Matsuo H. Increased plasma levels of brain natriuretic peptide in hypertrophic cardiomyopathy. <i>N Engl J Med<\/i> 1993; 329: 433\u2013434.","DOI":"10.1056\/NEJM199308053290614"},{"key":"248","doi-asserted-by":"crossref","unstructured":"248. \u3000Mizuno Y, Yoshimura M, Harada E, Nakayama M, Sakamoto T, Shimasaki Y, et al. Plasma levels of A- and B-type natriuretic peptides in patients with hypertrophic cardiomyopathy or idiopathic dilated cardiomyopathy. <i>Am J Cardiol<\/i> 2000; 86: 1036\u20131040.","DOI":"10.1016\/S0002-9149(00)01147-4"},{"key":"249","doi-asserted-by":"crossref","unstructured":"249. \u3000Hasegawa K, Fujiwara H, Doyama K, Miyamae M, Fujiwara T, Suga S, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. <i>Circulation<\/i> 1993; 88: 372\u2013380.","DOI":"10.1161\/01.CIR.88.2.372"},{"key":"250","doi-asserted-by":"crossref","unstructured":"250. \u3000Maron BJ, Tholakanahalli VN, Zenovich AG, Casey SA, Duprez D, Aeppli DM, et al. Usefulness of B-type natriuretic peptide assay in the assessment of symptomatic state in hypertrophic cardiomyopathy. <i>Circulation<\/i> 2004; 109: 984\u2013989.","DOI":"10.1161\/01.CIR.0000117098.75727.D8"},{"key":"251","doi-asserted-by":"crossref","unstructured":"251. \u3000Thaman R, Esteban MT, Barnes S, Gimeno JR, Mist B, Murphy R, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels to predict exercise capacity in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2006; 98: 515\u2013519.","DOI":"10.1016\/j.amjcard.2006.02.057"},{"key":"252","doi-asserted-by":"crossref","unstructured":"252. \u3000Geske JB, McKie PM, Ommen SR, Sorajja P. B-type natriuretic peptide and survival in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2013; 61: 2456\u20132460.","DOI":"10.1016\/j.jacc.2013.04.004"},{"key":"253","doi-asserted-by":"crossref","unstructured":"253. \u3000Alvares RF, Goodwin JF. Non-invasive assessment of diastolic function in hypertrophic cardiomyopathy on and off beta adrenergic blocking drugs. <i>Br Heart J<\/i> 1982; 48: 204\u2013212.","DOI":"10.1136\/hrt.48.3.204"},{"key":"254","doi-asserted-by":"crossref","unstructured":"254. \u3000Bourmayan C, Razavi A, Fournier C, Dussaule JC, Baragan J, Gerbaux A, et al. Effect of propranolol on left ventricular relaxation in hypertrophic cardiomyopathy: An echographic study. <i>Am Heart J<\/i> 1985; 109: 1311\u20131316.","DOI":"10.1016\/0002-8703(85)90357-6"},{"key":"255","doi-asserted-by":"crossref","unstructured":"255. \u3000Doiuchi J, Hamada M, Ito T, Kokubu T. Comparative effects of calcium-channel blockers and beta-adrenergic blocker on early diastolic time intervals and A-wave ratio in patients with hypertrophic cardiomyopathy. <i>Clin Cardiol<\/i> 1987; 10: 26\u201330.","DOI":"10.1002\/clc.4960100106"},{"key":"256","doi-asserted-by":"crossref","unstructured":"256. \u3000Braunwald E, Seidman CE, Sigwart U. Contemporary evaluation and management of hypertrophic cardiomyopathy. <i>Circulation<\/i> 2002; 106: 1312\u20131316.","DOI":"10.1161\/01.CIR.0000030314.11999.6A"},{"key":"257","doi-asserted-by":"crossref","unstructured":"257. \u3000Rosing DR, Condit JR, Maron BJ, Kent KM, Leon MB, Bonow RO, et al. Verapamil therapy: A new approach to the pharmacologic treatment of hypertrophic cardiomyopathy: III. Effects of long-term administration. <i>Am J Cardiol<\/i> 1981; 48: 545\u2013553.","DOI":"10.1016\/0002-9149(81)90086-2"},{"key":"258","doi-asserted-by":"crossref","unstructured":"258. \u3000Gilligan DM, Chan WL, Joshi J, Clarke P, Fletcher A, Krikler S, et al. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1993; 21: 1672\u20131679.","DOI":"10.1016\/0735-1097(93)90386-F"},{"key":"259","doi-asserted-by":"crossref","unstructured":"259. \u3000Nagao M, Omote S, Takizawa A, Yasue H. Effect of diltiazem on left ventricular isovolumic relaxation time in patients with hypertrophic cardiomyopathy. <i>Jpn Circ J<\/i> 1983; 47: 54\u201358.","DOI":"10.1253\/jcj.47.54"},{"key":"260","unstructured":"260. \u3000Betocchi S, Piscione F, Losi M-A, Pace L, Boccalatte M, Perrone-Filardi P, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1996; 78: 451\u2013457."},{"key":"261","doi-asserted-by":"crossref","unstructured":"261. \u3000Gwathmey JK, Warren SE, Briggs GM, Copelas L, Feldman MD, Phillips PJ, et al. Diastolic dysfunction in hypertrophic cardiomyopathy: Effect on active force generation during systole. <i>J Clin Invest<\/i> 1991; 87: 1023\u20131031.","DOI":"10.1172\/JCI115061"},{"key":"262","doi-asserted-by":"crossref","unstructured":"262. \u3000Bonow RO, Vitale DF, Maron BJ, Bacharach SL, Frederick TM, Green MV. Regional left ventricular asynchrony and impaired global left ventricular \ufb01lling in hypertrophic cardiomyopathy: Effect of verapamil. <i>J Am Coll Cardiol<\/i> 1987; 9: 1108\u20131116.","DOI":"10.1016\/S0735-1097(87)80315-7"},{"key":"263","doi-asserted-by":"crossref","unstructured":"263. \u3000Yamagishi T, Ozaki M, Kusukawa R. Oral verapamil effects on global and regional left ventricular diastolic \ufb01lling in hypertrophic cardiomyopathy. <i>Jpn Circ J<\/i> 1990; 54: 1365\u20131373.","DOI":"10.1253\/jcj.54.11_1365"},{"key":"264","unstructured":"264. \u3000\u8c37\u53e3\u6d0b\u5b50, \u6749\u539f\u6d0b\u6a39, \u5927\u69fb\u514b\u4e00, \u4ed6. \u80a5\u5927\u578b\u5fc3\u7b4b\u75c7\u306e\u5fc3\u7b4b\u865a\u8840\u306b\u5bfe\u3059\u308bverapamil\u306e\u52b9\u679c: \u904b\u52d5\u8ca0\u8377201Tl\u5fc3\u7b4bSPECT\u306b\u3088\u308b\u691c\u8a0e. <i>J Cardiol<\/i> 1994; 24: 45\u201351."},{"key":"265","doi-asserted-by":"crossref","unstructured":"265. \u3000Sonnenblick EH, Fein F, Capasso JM, Factor SM. Microvascular spasm as a cause of cardiomyopathies and the calcium-blocking agent verapamil as potential primary therapy. <i>Am J Cardiol<\/i> 1985; 55: B179\u2013B184.","DOI":"10.1016\/0002-9149(85)90629-0"},{"key":"266","doi-asserted-by":"crossref","unstructured":"266. \u3000Suwa M, Hirota Y, Kawamura K. Improvement in left ventricular diastolic function during intravenous and oral diltiazem therapy in patients with hypertrophic cardiomyopathy: An echocardiographic study. <i>Am J Cardiol<\/i> 1984; 54: 1047\u20131053.","DOI":"10.1016\/S0002-9149(84)80142-3"},{"key":"267","doi-asserted-by":"crossref","unstructured":"267. \u3000Iwase M, Sotobata I, Takagi S, Miyaguchi K, Jing HX, Yokota M. Effects of diltiazem on left ventricular diastolic behavior in patients with hypertrophic cardiomyopathy: Evaluation with exercise pulsed Doppler echocardiography. <i>J Am Coll Cardiol<\/i> 1987; 9: 1099\u20131105.","DOI":"10.1016\/S0735-1097(87)80313-3"},{"key":"268","doi-asserted-by":"crossref","unstructured":"268. \u3000Toshima H, Koga Y, Nagata H, Toyomasu K, Itaya K, Matoba T. Comparable effects of oral diltiazem and verapamil in the treatment of hypertrophic cardiomyopathy: Double-blind crossover study. <i>Jpn Heart J<\/i> 1986; 27: 701\u2013715.","DOI":"10.1536\/ihj.27.701"},{"key":"269","doi-asserted-by":"crossref","unstructured":"269. \u3000Sugihara H, Taniguchi Y, Ito K, Terada K, Matsumoto K, Kinoshita N, et al. Effects of diltiazem on myocardial perfusion abnormalities during exercise in patients with hyper- trophic cardiomyopathy. <i>Ann Nucl Med<\/i> 1998; 12: 349\u2013354.","DOI":"10.1007\/BF03164924"},{"key":"270","doi-asserted-by":"crossref","unstructured":"270. \u3000Matsuda M, Sekiguchi T, Sugishita Y, Ito I. Adverse effect of nifedipine on left ventricular obstruction detected by pulsed Doppler echocardiography. <i>Jpn Heart J<\/i> 1984; 25: 1081\u20131084.","DOI":"10.1536\/ihj.25.1081"},{"key":"271","doi-asserted-by":"crossref","unstructured":"271. \u3000Betocchi S, Cannon RO 3rd, Watson RM, Bonow RO, Ostrow HG, Epstein SE, et al. Effects of sublingual nifedipine on hemodynamics and systolic and diastolic function in patients with hypertrophic cardiomyopathy. <i>Circulation<\/i> 1985; 72: 1001\u20131007.","DOI":"10.1161\/01.CIR.72.5.1001"},{"key":"272","doi-asserted-by":"crossref","unstructured":"272. \u3000Yamakado T, Okano H, Higashiyama S, Hamada M, Nakano T, Takezawa H. Effects of nifedipine on left ventricular diastolic function in patients with asymptomatic or minimally symptomatic hypertrophic cardiomyopathy. <i>Circulation<\/i> 1990; 81: 593\u2013601.","DOI":"10.1161\/01.CIR.81.2.593"},{"key":"273","doi-asserted-by":"crossref","unstructured":"273. \u3000Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M, et al. Angiotensin II blockade reverses myocardial \ufb01brosis in a transgenic mouse model of human hypertrophic cardiomyopathy. <i>Circulation<\/i> 2001; 103: 789\u2013791.","DOI":"10.1161\/01.CIR.103.6.789"},{"key":"274","doi-asserted-by":"crossref","unstructured":"274. \u3000Osterop AP, Kof\ufb02ard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA, et al. AT1 receptor A\/C1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. <i>Hypertension<\/i> 1998; 32: 825\u2013830.","DOI":"10.1161\/01.HYP.32.5.825"},{"key":"275","doi-asserted-by":"crossref","unstructured":"275. \u3000Maron BJ, Olivotto I, Spirito P, Casey SA, Bellone P, Gohman TE, et al. Epidemiology of hypertrophic cardiomyopathy-related death: Revisited in a large non-referral-based patient population. <i>Circulation<\/i> 2000; 102: 858\u2013864.","DOI":"10.1161\/01.CIR.102.8.858"},{"key":"276","doi-asserted-by":"crossref","unstructured":"276. \u3000Cecchi F, Olivotto I, Betocchi S, Rapezzi C, Conte MR, Sinagra G, et al. The Italian Registry for hypertrophic cardiomyopathy: A nationwide survey. <i>Am Heart J<\/i> 2005; 150: 47\u2013954.","DOI":"10.1016\/j.ahj.2005.01.005"},{"key":"277","doi-asserted-by":"crossref","unstructured":"277. \u3000Elliott PM, Gimeno JR, Thaman R, Shah J, Ward D, Dickie S, et al. Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy. <i>Heart<\/i> 2006; 92: 785\u2013791.","DOI":"10.1136\/hrt.2005.068577"},{"key":"278","doi-asserted-by":"crossref","unstructured":"278. \u3000Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. <i>JAMA<\/i> 2007; 298: 405\u2013412.","DOI":"10.1001\/jama.298.4.405"},{"key":"279","doi-asserted-by":"crossref","unstructured":"279. \u3000Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE, et al. American College of Cardiology\/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2003; 42: 1687\u20131713.","DOI":"10.1016\/S0195-668X(03)00479-2"},{"key":"280","doi-asserted-by":"crossref","unstructured":"280. \u3000Maron BJ. Risk strati\ufb01cation and role of implantable de\ufb01brillators for prevention of sudden death in patients with hypertrophic cardiomyopathy. <i>Circ J<\/i> 2010; 74: 2271\u20132282.","DOI":"10.1253\/circj.CJ-10-0921"},{"key":"281","doi-asserted-by":"crossref","unstructured":"281. \u3000Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: An independent marker of sudden death risk in young patients. <i>J Am Coll Cardiol<\/i> 2003; 42: 873\u2013879.","DOI":"10.1016\/S0735-1097(03)00827-1"},{"key":"282","doi-asserted-by":"crossref","unstructured":"282. \u3000Kawarai H, Kajimoto K, Minami Y, Hagiwara N, Kasanuki H. Risk of sudden death in end-stage hypertrophic cardiomyopathy. <i>J Card Fail<\/i> 2011; 17: 459\u2013464.","DOI":"10.1016\/j.cardfail.2011.01.015"},{"key":"283","doi-asserted-by":"crossref","unstructured":"283. \u3000Jacoby D, McKenna WJ. Genetics of inherited cardiomyopathy. <i>Eur Heart J<\/i> 2012; 33: 296\u2013304.","DOI":"10.1093\/eurheartj\/ehr260"},{"key":"284","doi-asserted-by":"crossref","unstructured":"284. \u3000O\u2019Mahony C, Tome-Esteban M, Lambiase PD, Pantazis A, Dickie S, McKenna WJ, et al. A validation study of the 2003 American College of Cardiology\/European Society of Cardiology and 2011 American College of Cardiology Foundation\/American Heart Association risk stratification and treatment algorithms for sudden cardiac death in patients with hypertrophic cardiomyopathy. <i>Heart<\/i> 2013; 99: 534\u2013541.","DOI":"10.1136\/heartjnl-2012-303271"},{"key":"285","doi-asserted-by":"crossref","unstructured":"285. \u3000Maron BJ, Casey SA, Chan RH, Garberich RF, Rowin EJ, Maron MS. Independent assessment of the European Society of Cardiology Sudden Death Risk Model for Hypertrophic Cardiomyopathy. <i>Am J Cardiol<\/i> 2015; 116: 757\u2013764.","DOI":"10.1016\/j.amjcard.2015.05.047"},{"key":"286","doi-asserted-by":"crossref","unstructured":"286. \u3000O\u2019Mahony C, Jichi F, Ommen SR, Christiaans I, Arbustini E, Garcia-Pavia P, et al. International external validation study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM). <i>Circulation<\/i> 2018; 137: 1015\u20131023.","DOI":"10.1161\/CIRCULATIONAHA.117.030437"},{"key":"287","doi-asserted-by":"crossref","unstructured":"287. \u3000Maki S, Ikeda H, Muro A, Yoshida N, Shibata A, Koga Y, et al. Predictors of sudden cardiac death in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1998; 82: 774\u2013778.","DOI":"10.1016\/S0002-9149(98)00455-X"},{"key":"288","doi-asserted-by":"crossref","unstructured":"288. \u3000Chida A, Inai K, Sato H, Shimada E, Nishizawa T, Shimada M, et al. Prognostic predictive value of gene mutations in Japanese patients with hypertrophic cardiomyopathy. <i>Heart Vessels<\/i> 2017; 32: 700\u2013707.","DOI":"10.1007\/s00380-016-0920-0"},{"key":"289","doi-asserted-by":"crossref","unstructured":"289. \u3000Hen Y, Tsugu-Yagawa M, Iguchi N, Utanohara Y, Takada K, Machida H, et al. Prognostic value of cardiovascular magnetic resonance imaging for life-threatening arrhythmia detected by implantable cardioverter-de\ufb01brillator in Japanese patients with hypertrophic cardiomyopathy. <i>Heart Vessels<\/i> 2018; 33: 49\u201357.","DOI":"10.1007\/s00380-017-1030-3"},{"key":"290","doi-asserted-by":"crossref","unstructured":"290. \u3000O\u2019Mahony C, Lambiase PD, Quarta G, Cardona M, Calcagnino M, Tsovolas K, et al. The long-term survival and the risks and bene\ufb01ts of implantable cardioverter de\ufb01brillators in patients with hypertrophic cardiomyopathy. <i>Heart<\/i> 2012; 98: 116\u2013125.","DOI":"10.1136\/hrt.2010.217182"},{"key":"291","doi-asserted-by":"crossref","unstructured":"291. \u3000McKenna WJ, Oakley CM, Krikler DM, Goodwin JF. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. <i>Br Heart J<\/i> 1985; 53: 412\u2013416.","DOI":"10.1136\/hrt.53.4.412"},{"key":"292","doi-asserted-by":"crossref","unstructured":"292. \u3000Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial \ufb01brillation and hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1986; 7: 701\u2013704.","DOI":"10.1016\/S0735-1097(86)80484-3"},{"key":"293","doi-asserted-by":"crossref","unstructured":"293. \u3000Weinstock J, Bader YH, Maron MS, Rowin EJ, Link MS. Subcutaneous implantable cardioverter de\ufb01brillator in patients with hypertrophic cardiomyopathy: An initial experience. <i>J Am Heart Assoc<\/i> 2016; 5: e002488.","DOI":"10.1161\/JAHA.115.002488"},{"key":"294","doi-asserted-by":"crossref","unstructured":"294. \u3000Nistri S, Olivotto I, Maron MS, Ferrantini C, Coppini R, Grifoni C, et al. \u03b2 Blockers for prevention of exercise-induced left ventricular out\ufb02ow tract obstruction in patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2012; 110: 715\u2013719.","DOI":"10.1016\/j.amjcard.2012.04.051"},{"key":"295","doi-asserted-by":"crossref","unstructured":"295. \u3000Epstein SE, Rosing DR. Verapamil: Its potential for causing serious complications in patients with hypertrophic cardiomyopathy. <i>Circulation<\/i> 1981; 64: 437\u2013441.","DOI":"10.1161\/01.CIR.64.3.437"},{"key":"296","doi-asserted-by":"crossref","unstructured":"296. \u3000Hamada M, Ikeda S, Shigematsu Y. Advances in medical treatment of hypertrophic cardiomyopathy. <i>J Cardiol<\/i> 2014; 64: 1\u201310.","DOI":"10.1016\/j.jjcc.2014.02.022"},{"key":"297","doi-asserted-by":"crossref","unstructured":"297. \u3000Hamada M, Ikeda S, Ohshima K, Nakamura M, Kubota N, Ogimoto A, et al. Impact of chronic use of cibenzoline on left ventricular pressure gradient and left ventricular remodeling in patients with hypertrophic obstructive cardiomyopathy. <i>J Cardiol<\/i> 2016; 67: 279\u2013286.","DOI":"10.1016\/j.jjcc.2015.05.014"},{"key":"298","doi-asserted-by":"crossref","unstructured":"298. \u3000Sherrid MV, Barac I, McKenna WJ, Elliot PM, Dickie S, Chojnowska L, et al. Multicenter study of the ef\ufb01cacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2005; 45: 1251\u20131258.","DOI":"10.1016\/j.jacc.2005.01.012"},{"key":"299","doi-asserted-by":"crossref","unstructured":"299. \u3000Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to \ufb01rst-line therapy with \u03b2-blockade or verapamil. <i>Circ Heart Fail<\/i> 2013; 6: 694\u2013702.","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122"},{"key":"300","unstructured":"300. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u30ac\u30a4\u30c9\u30b7\u30ea\u30fc\u30ba 2014\u5e74\u5ea6\u7248: \u5148\u5929\u6027\u5fc3\u75be\u60a3, \u5fc3\u81d3\u5927\u8840\u7ba1\u306e\u69cb\u9020\u7684\u75be\u60a3 (structural heart disease) \u306b\u5bfe\u3059\u308b\u30ab\u30c6\u30fc\u30c6\u30eb\u6cbb\u7642\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2014_nakanishi_h.pdf"},{"key":"301","doi-asserted-by":"crossref","unstructured":"301. \u3000Sorajja P, Ommen SR, Holmes DR Jr, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Circulation<\/i> 2012; 126: 2374\u20132380.","DOI":"10.1161\/CIRCULATIONAHA.111.076257"},{"key":"302","doi-asserted-by":"crossref","unstructured":"302. \u3000Sorajja P, Binder J, Nishimura RA, Holmes DR Jr, Rihal CS, Gersh BJ, et al. Predictors of an optimal clinical outcome with alcohol septal ablation for obstructive hypertrophic cardiomyopathy. <i>Catheter Cardiovasc Interv<\/i> 2013; 81: E58\u2013E67.","DOI":"10.1002\/ccd.24328"},{"key":"303","doi-asserted-by":"crossref","unstructured":"303. \u3000Morrow AG, Reitz BA, Epstein SE, Henry WL, Conkle DM, Itscoitz SB, et al. Operative treatment in hypertrophic subaortic stenosis: Techniques, and the results of pre and postoperative assessments in 83 patients. <i>Circulation<\/i> 1975; 52: 88\u2013102.","DOI":"10.1161\/01.CIR.52.1.88"},{"key":"304","doi-asserted-by":"crossref","unstructured":"304. \u3000Morrow AG. Hypertrophic subaortic stenosis: Operative methods utilized to relieve left ventricular out\ufb02ow obstruction. <i>J Thorac Cardiovasc Surg<\/i> 1978; 76: 423\u2013430.","DOI":"10.1016\/S0022-5223(19)41066-0"},{"key":"305","doi-asserted-by":"crossref","unstructured":"305. \u3000Kotkar KD, Said SM, Dearani JA, Schaff HV. Hypertrophic obstructive cardiomyopathy: The Mayo Clinic experience. <i>Ann Cardiothorac Surg<\/i> 2017; 6: 329\u2013336.","DOI":"10.21037\/acs.2017.07.03"},{"key":"306","doi-asserted-by":"crossref","unstructured":"306. \u3000Hang D, Schaff HV, Ommen SR, Dearani JA, Nishimura RA. Combined transaortic and transapical approach to septal myectomy in patients with complex hypertrophic cardiomyopathy. <i>J Thorac Cardiovasc Surg<\/i> 2018; 155: 2096\u20132102.","DOI":"10.1016\/j.jtcvs.2017.10.054"},{"key":"307","doi-asserted-by":"crossref","unstructured":"307. \u3000Patel P, Dhillon A, Popovic ZB, Smedira NG, Rizzo J, Thamilarasan M, et al. Left ventricular out\ufb02ow tract obstruction in hypertrophic cardiomyopathy patients without severe septal hypertrophy: Implications of mitral valve and papillary muscle abnormalities assessed using cardiac magnetic resonance and echocardiography. <i>Circ Cardiovasc Imaging<\/i> 2015; 8: E003132.","DOI":"10.1161\/CIRCIMAGING.115.003132"},{"key":"308","doi-asserted-by":"crossref","unstructured":"308. \u3000Henein M, Arvidsson S, Pilebro B, Backman C, M\u00f6rner S, Lindqvist P. Long mitral valve lea\ufb02ets determine left ventricular out\ufb02ow tract obstruction during exercise in hypertrophic cardiomyopathy. <i>Int J Cardiol<\/i> 2016; 212: 47\u201353.","DOI":"10.1016\/j.ijcard.2016.03.041"},{"key":"309","doi-asserted-by":"crossref","unstructured":"309. \u3000Morant K, Mikami Y, Nevis I, McCarty D, Stirrat J, Scholl D, et al. Contribution of mitral valve lea\ufb02et length and septal wall thickness to out\ufb02ow tract obstruction in patients with hypertrophic cardiomyopathy. <i>Int J Cardiovasc Imaging<\/i> 2017; 33: 1201\u20131211.","DOI":"10.1007\/s10554-017-1103-5"},{"key":"310","doi-asserted-by":"crossref","unstructured":"310. \u3000Swistel DG, Balaram SK. Surgical myectomy for hypertrophic cardiomyopathy in the 21st century, the evolution of the \u201cRPR\u201d repair: Resection, plication, and release. <i>Prog Cardiovasc Dis<\/i> 2012; 54: 498\u2013502.","DOI":"10.1016\/j.pcad.2012.03.001"},{"key":"311","doi-asserted-by":"crossref","unstructured":"311. \u3000Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2005; 46: 470\u2013476.","DOI":"10.1016\/j.jacc.2005.02.090"},{"key":"312","doi-asserted-by":"crossref","unstructured":"312. \u3000Maron BJ, Nishimura RA. Surgical septal myectomy versus alcohol septal ablation: Assessing the status of the controversy in 2014. <i>Circulation<\/i> 2014; 130: 1617\u20131624.","DOI":"10.1161\/CIRCULATIONAHA.114.011580"},{"key":"313","doi-asserted-by":"crossref","unstructured":"313. \u3000Heric B, Lytle BW, Miller DP, Rosenkranz ER, Lever HM, Cosgrove DM. Surgical management of hypertrophic obstructive cardiomyopathy. Early and late results. <i>J Thorac Cardiovasc Surg<\/i> 1995; 110: 195\u2013208.","DOI":"10.1016\/S0022-5223(05)80026-1"},{"key":"314","doi-asserted-by":"crossref","unstructured":"314. \u3000Robbins RC, Stinson EB. Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy. <i>J Thorac Cardiovasc Surg<\/i> 1996; 111: 586\u2013594.","DOI":"10.1016\/S0022-5223(96)70310-0"},{"key":"315","doi-asserted-by":"crossref","unstructured":"315. \u3000Liebregts M, Vriesendorp PA, Mahmoodi BK, Schinkel AFL, Michels M, ten Berg JM. A systematic review and meta-analysis of long-term outcomes after septal reduction therapy in patients with hypertrophic cardiomyopathy. <i>JACC Heart Fail<\/i> 2015; 3: 896\u2013905.","DOI":"10.1016\/j.jchf.2015.06.011"},{"key":"316","doi-asserted-by":"crossref","unstructured":"316. \u3000Rigopoulos AG, Seggewiss H. A decade of percutaneous septal ablation in hypertrophic cardiomyopathy. <i>Circ J<\/i> 2011; 75: 28\u201337.","DOI":"10.1253\/circj.CJ-10-0962"},{"key":"317","doi-asserted-by":"crossref","unstructured":"317. \u3000Matsuda J, Kitamura M, Takayama M, Imori Y, Shibuya J, Kubota Y, et al. Chronic phase improvements in electrocardiographic and echocardiographic manifestations of left ventricular hypertrophy after alcohol septal ablation for drug-refractory hypertrophic obstructive cardiomyopathy. <i>Heart Vessels<\/i> 2018; 33: 246\u2013254.","DOI":"10.1007\/s00380-017-1053-9"},{"key":"318","doi-asserted-by":"crossref","unstructured":"318. \u3000Seggewiss H, Rigopoulos A, Welge D, Ziemssen P, Faber L. Long-term follow-up after percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. <i>Clin Res Cardiol<\/i> 2007; 96: 856\u2013863.","DOI":"10.1007\/s00392-007-0579-8"},{"key":"319","doi-asserted-by":"crossref","unstructured":"319. \u3000Fernandes VL, Nielsen C, Nagueh SF, Herrin AE, Slifka C, Franklin J, et al. Follow-up of alcohol septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor and Medical University of South Carolina experience 1996 to 2007. <i>JACC Cardiovasc Interv<\/i> 2008; 1: 561\u2013570.","DOI":"10.1016\/j.jcin.2008.07.005"},{"key":"320","doi-asserted-by":"crossref","unstructured":"320. \u3000ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML, et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: A word of caution. <i>Circ Heart Fail<\/i> 2010; 3: 362\u2013369.","DOI":"10.1161\/CIRCHEARTFAILURE.109.862359"},{"key":"321","doi-asserted-by":"crossref","unstructured":"321. \u3000Jensen MK, Havndrup O, Christiansen M, Andersen PS, Diness B, Axelsson A, et al. Penetrance of hypertrophic cardiomyopathy in children and adolescents: A 12-year follow-up study of clinical screening and predictive genetic testing. <i>Circulation<\/i> 2013; 127: 48\u201354.","DOI":"10.1161\/CIRCULATIONAHA.111.090514"},{"key":"322","doi-asserted-by":"crossref","unstructured":"322. \u3000Veselka J, Krej\u010d\u00ed J, Toma\u0161ov P, Zem\u00e1nek D. Long-term survival after alcohol septal ablation for hypertrophic obstructive cardiomyopathy: A comparison with general population. <i>Eur Heart J<\/i> 2014; 35: 2040\u20132045.","DOI":"10.1093\/eurheartj\/eht495"},{"key":"323","doi-asserted-by":"crossref","unstructured":"323. \u3000Veselka J, Jensen MK, Liebregts M, Januska J, Krejci J, Bartel T, et al. Long-term clinical outcome after alcohol septal ablation for obstructive hypertrophic cardiomyopathy: Results from the Euro-ASA registry. <i>Eur Heart J<\/i> 2016; 37: 1517\u20131523.","DOI":"10.1093\/eurheartj\/ehv693"},{"key":"324","doi-asserted-by":"crossref","unstructured":"324. \u3000Veselka J, Krej\u010d\u00ed J, Toma\u0161ov P, Jahnlov\u00e1 D, Hon\u011bk T, Janu\u0161ka J, et al. Survival of patients \u226450 years of age after alcohol septal ablation for hypertrophic obstructive cardiomyopathy. <i>Can J Cardiol<\/i> 2014; 30: 634\u2013638.","DOI":"10.1016\/j.cjca.2014.03.041"},{"key":"325","doi-asserted-by":"crossref","unstructured":"325. \u3000Maekawa Y, Jinzaki M, Anzai A, Tsuruta H, Matsumura K, Yamada Y, et al. Successful second attempt multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation for an octogenarian with hypertrophic obstructive cardiomyopathy. <i>Int J Cardiol<\/i> 2014; 176: e131\u2013e132.","DOI":"10.1016\/j.ijcard.2014.07.211"},{"key":"326","doi-asserted-by":"crossref","unstructured":"326. \u3000Maekawa Y, Jinzaki M, Tsuruta H, Tsuruta H, Yamada Y, Kishino Y, et al. Multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation in a Noonan syndrome patient with hypertrophic obstructive cardiomyopathy. <i>Int J Cardiol<\/i> 2014; 172: e79\u2013e81.","DOI":"10.1016\/j.ijcard.2013.12.045"},{"key":"327","doi-asserted-by":"crossref","unstructured":"327. \u3000Maekawa Y, Akita K, Tsuruta H, Yamada Y, Hayashida K, Yuasa S, et al. Signi\ufb01cant reduction of left atrial volume concomitant with clinical improvement after percutaneous transluminal septal myocardial ablation for drug-refractory hypertrophic obstructive cardiomyopathy, and its precise detection with multidetector CT. <i>Open Heart<\/i> 2016; 3: E000359.","DOI":"10.1136\/openhrt-2015-000359"},{"key":"328","doi-asserted-by":"crossref","unstructured":"328. \u3000Linde C, Gadler F, Kappenberger L, Ryd\u00e9n L; PIC Study Group. Pacing in cardiomyopathy: Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1999; 83: 903\u2013907.","DOI":"10.1016\/S0002-9149(98)01065-0"},{"key":"329","doi-asserted-by":"crossref","unstructured":"329. \u3000Maron BJ, Nishimura RA, McKenna WJ, Rakowski H, Josephson ME, Kieval RS; M-PATHY Study Investigators. Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: A randomized, double-blind, cross-over study (M-PATHY). <i>Circulation<\/i> 1999; 99: 2927\u20132933.","DOI":"10.1161\/01.CIR.99.22.2927"},{"key":"330","doi-asserted-by":"crossref","unstructured":"330. \u3000Kappenberger L, Linde C, Daubert C, McKenna W, Meisel E, Sadoul N, et al; PIC Study Group. Pacing in hypertrophic obstructive cardiomyopathy: A randomized crossover study. <i>Eur Heart J<\/i> 1997; 18: 1249\u20131256.","DOI":"10.1093\/oxfordjournals.eurheartj.a015435"},{"key":"331","doi-asserted-by":"crossref","unstructured":"331. \u3000Guttmann OP, Rahman MS, O\u2019Mahony C, Anastasakis A, Elliott PM. Atrial \ufb01brillation and thromboembolism in patients with hypertrophic cardiomyopathy: Systematic review. <i>Heart<\/i> 2014; 100: 465\u2013472.","DOI":"10.1136\/heartjnl-2013-304276"},{"key":"332","unstructured":"332. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. 2020\u5e74\u6539\u8a02\u7248 \u4e0d\u6574\u8108\u85ac\u7269\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 JCS\/JHRS 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/01\/JCS2020_Ono.pdf"},{"key":"333","doi-asserted-by":"crossref","unstructured":"333. \u3000Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, et al. Clinical pro\ufb01le of stroke in 900 patients with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 39: 301\u2013307.","DOI":"10.1016\/S0735-1097(01)01727-2"},{"key":"334","doi-asserted-by":"crossref","unstructured":"334. \u3000Dominguez F, Climent V, Zorio E, Ripoll-Vera T, Salazar-Mendiguch\u00eda J, Garc\u00eda-Pinilla JM, et al. Direct oral anticoagulants in patients with hypertrophic cardiomyopathy and atrial \ufb01brillation. <i>Int J Cardiol<\/i> 2017; 248: 232\u2013238.","DOI":"10.1016\/j.ijcard.2017.08.010"},{"key":"335","doi-asserted-by":"crossref","unstructured":"335. \u3000McKenna WJ, Harris L, Rowland E, Kleinebenne A, Krikler DM, Oakley CM, et al. Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1984; 54: 802\u2013810.","DOI":"10.1016\/S0002-9149(84)80212-X"},{"key":"336","doi-asserted-by":"crossref","unstructured":"336. \u3000Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ. Atrial fibrillation in hypertrophic cardiomyopathy: A longitudinal study. <i>J Am Coll Cardiol<\/i> 1990; 15: 1279\u20131285.","DOI":"10.1016\/S0735-1097(10)80014-2"},{"key":"337","doi-asserted-by":"crossref","unstructured":"337. \u3000Zhao DS, Shen Y, Zhang Q, Lin G, Lu YH, Chen BT, et al. Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: A systematic review and meta-analysis. <i>Europace<\/i> 2016; 18: 508\u2013520.","DOI":"10.1093\/europace\/euv339"},{"key":"338","doi-asserted-by":"crossref","unstructured":"338. \u3000Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, et al. Catheter ablation for atrial \ufb01brillation in hypertrophic cardiomyopathy: A systematic review and meta-analysis. <i>Heart<\/i> 2016; 102: 1533\u20131543.","DOI":"10.1136\/heartjnl-2016-309406"},{"key":"339","doi-asserted-by":"crossref","unstructured":"339. \u3000Chen MS, McCarthy PM, Lever HM, Smedira NG, Lytle BL. Effectiveness of atrial \ufb01brillation surgery in patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2004; 93: 373\u2013375.","DOI":"10.1016\/j.amjcard.2003.10.025"},{"key":"340","doi-asserted-by":"crossref","unstructured":"340. \u3000Drazner MH. The progression of hypertensive heart disease. <i>Circulation<\/i> 2011; 123: 327\u2013334.","DOI":"10.1161\/CIRCULATIONAHA.108.845792"},{"key":"341","doi-asserted-by":"crossref","unstructured":"341. \u3000Pewsner D, J\u00fcni P, Egger M, Battaglia M, Sundstr\u00f6m J, Bachmann LM. Accuracy of electrocardiography in diagnosis of left ventricular hypertrophy in arterial hypertension: Systematic review. <i>BMJ<\/i> 2007; 335: 711.","DOI":"10.1136\/bmj.39276.636354.AE"},{"key":"342","doi-asserted-by":"crossref","unstructured":"342. \u3000Montgomery JV, Harris KM, Casey SA, Zenovich AG, Maron BJ. Relation of electrocardiographic patterns to phenotypic expression and clinical outcome in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2005; 96: 270\u2013275.","DOI":"10.1016\/j.amjcard.2005.03.058"},{"key":"343","doi-asserted-by":"crossref","unstructured":"343. \u3000Cuspidi C, Negri F, Muiesan ML, Capra A, Lonati L, Milan A, et al; Working Group on Heart and Hypertension, Italian Society of Hypertension. Prevalence and severity of echocardiographic left ventricular hypertrophy in hypertensive patients in clinical practice. <i>Blood Press<\/i> 2011; 20: 3\u20139.","DOI":"10.3109\/08037051.2010.514713"},{"key":"344","doi-asserted-by":"crossref","unstructured":"344. \u3000Kato TS, Noda A, Izawa H, Yamada A, Obata K, Nagata K, et al. Discrimination of nonobstructive hypertrophic cardiomyopathy from hypertensive left ventricular hypertrophy on the basis of strain rate imaging by tissue Doppler ultrasonography. <i>Circulation<\/i> 2004; 110: 3808\u20133814.","DOI":"10.1161\/01.CIR.0000150334.69355.00"},{"key":"345","doi-asserted-by":"crossref","unstructured":"345. \u3000Sipola P, Magga J, Husso M, J\u00e4\u00e4skel\u00e4inen P, Peuhkurinen K, Kuusisto J. Cardiac MRI assessed left ventricular hypertrophy in differentiating hypertensive heart disease from hypertrophic cardiomyopathy attributable to a sarcomeric gene mutation. <i>Eur Radiol<\/i> 2011; 21: 1383\u20131389.","DOI":"10.1007\/s00330-011-2065-y"},{"key":"346","doi-asserted-by":"crossref","unstructured":"346. \u3000Puntmann VO, Jahnke C, Gebker R, Schnackenburg B, Fox KF, Fleck E, et al. Usefulness of magnetic resonance imaging to distinguish hypertensive and hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2010; 106: 1016\u20131022.","DOI":"10.1016\/j.amjcard.2010.05.036"},{"key":"347","doi-asserted-by":"crossref","unstructured":"347. \u3000Amano Y, Kitamura M, Takano H, Yanagisawa F, Tachi M, Suzuki Y, et al. Cardiac MR imaging of hypertrophic cardiomyopathy: Techniques, findings, and clinical relevance. <i>Magn Reson Med Sci<\/i> 2018; 17: 120\u2013131.","DOI":"10.2463\/mrms.rev.2017-0145"},{"key":"348","doi-asserted-by":"crossref","unstructured":"348. \u3000Savage DD, Seides SF, Clark CE, Maron BJ, Robinson FC, Epstein SE. Electrocardiographic \ufb01ndings in patients with obstructive and nonobstructive hypertrophic cardiomyopathy. <i>Circulation<\/i> 1978; 58: 402\u2013408.","DOI":"10.1161\/01.CIR.58.3.402"},{"key":"349","doi-asserted-by":"crossref","unstructured":"349. \u3000Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: A meta-analysis of randomized double-blind studies. <i>JAMA<\/i> 1996; 275: 1507\u20131513.","DOI":"10.1001\/jama.275.19.1507"},{"key":"350","doi-asserted-by":"crossref","unstructured":"350. \u3000Verdecchia P, Angeli F, Gattobigio R, Sardone M, Porcellati C. Asymptomatic left ventricular systolic dysfunction in essential hypertension: prevalence, determinants, and prognostic value. <i>Hypertension<\/i> 2005; 45: 412\u2013418.","DOI":"10.1161\/01.HYP.0000154822.37141.f6"},{"key":"351","doi-asserted-by":"crossref","unstructured":"351. \u3000Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmeider RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. <i>Am J Med<\/i> 2003; 115: 41\u201346.","DOI":"10.1016\/S0002-9343(03)00158-X"},{"key":"352","doi-asserted-by":"crossref","unstructured":"352. \u3000Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al; LIFE Study Investigators. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. <i>JAMA<\/i> 2004; 292: 2343\u20132349.","DOI":"10.1001\/jama.292.19.2343"},{"key":"353","doi-asserted-by":"crossref","unstructured":"353. \u3000Hess OM, Schneider J, Turina M, Carroll JD, Rothlin M, Krayenbuehl H. Asymmetric septal hypertrophy in patients with aortic stenosis: An adaptive mechanism or a coexistence of hypertrophic cardiomyopathy? <i>J Am Coll Cardiol<\/i> 1983; 1: 783\u2013789.","DOI":"10.1016\/S0735-1097(83)80191-0"},{"key":"354","doi-asserted-by":"crossref","unstructured":"354. \u3000Panza JA, Maron BJ. Valvular aortic stenosis and asymmetric septal hypertrophy: Diagnostic considerations and clinical and therapeutic implications. <i>Eur Heart J<\/i> 1988; 9(Suppl E): 71\u201376.","DOI":"10.1093\/eurheartj\/9.suppl_E.71"},{"key":"355","unstructured":"355. \u3000Schulte HD, Bircks W, Horstkotte D, Kerstholt J, Preusse CJ, Winter J. Asymmetric septal hypertrophy (ASH) in valvular aortic stenosis should not be resected at the time of surgery. <i>Z Kardiol<\/i> 1986; 75(Suppl 2): 201\u2013206."},{"key":"356","doi-asserted-by":"crossref","unstructured":"356. \u3000Kayalar N, Schaff HV, Daly RC, Dearani JA, Park SJ. Concomitant septal myectomy at the time of aortic valve replacement for severe aortic stenosis. <i>Ann Thorac Surg<\/i> 2010; 89: 459\u2013464.","DOI":"10.1016\/j.athoracsur.2009.10.065"},{"key":"357","doi-asserted-by":"crossref","unstructured":"357. \u3000Di Tommaso L, Stassano P, Mannacio V, Russolillo V, Monaco M, Pinna G, et al. Asymmetric septal hypertrophy in patients with severe aortic stenosis: The usefulness of associated septal myectomy. <i>J Thorac Cardiovasc Surg<\/i> 2013; 145: 171\u2013175.","DOI":"10.1016\/j.jtcvs.2011.10.096"},{"key":"358","doi-asserted-by":"crossref","unstructured":"358. \u3000Sorajja P, Booker JD, Rihal CS. Alcohol septal ablation after transaortic valve implantation: The dynamic nature of left out\ufb02ow tract obstruction. <i>Catheter Cardiovasc Interv<\/i> 2013; 81: 387\u2013391.","DOI":"10.1002\/ccd.23454"},{"key":"359","doi-asserted-by":"crossref","unstructured":"359. \u3000Spirito P, Rapezzi C, Bellone P, Betocchi S, Autore C, Conte MR, et al. Infective endocarditis in hypertrophic cardiomyopathy: Prevalence, incidence, and indications for antibiotic prophylaxis. <i>Circulation<\/i> 1999; 99: 2132\u20132137.","DOI":"10.1161\/01.CIR.99.16.2132"},{"key":"360","doi-asserted-by":"crossref","unstructured":"360. \u3000Roberts WC, Kishel JC, McIntosh CL, Cannon RO 3rd, Maron BJ. Severe mitral or aortic valve regurgitation, or both, requiring valve replacement for infective endocarditis complicating hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1992; 19: 365\u2013371.","DOI":"10.1016\/0735-1097(92)90493-7"},{"key":"361","doi-asserted-by":"crossref","unstructured":"361. \u3000Alessandri N, Pannarale G, del Monte F, Moretti F, Marino B, Reale A. Hypertrophic obstructive cardiomyopathy and infective endocarditis: A report of seven cases and a review of the literature. <i>Eur Heart J<\/i> 1990; 11: 1041\u20131048.","DOI":"10.1093\/oxfordjournals.eurheartj.a059632"},{"key":"362","unstructured":"362. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u611f\u67d3\u6027\u5fc3\u5185\u819c\u708e\u306e\u4e88\u9632\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2017\u5e74\u6539\u8a02\u7248) Guidelines for Prevention and Treatment of Infective Endocarditis (JCS 2017). https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2017\/07\/JCS2017_nakatani_h.pdf"},{"key":"363","unstructured":"363. \u3000\u65e5\u672c\u5c0f\u5150\u5faa\u74b0\u5668\u5b66\u4f1a. \u5e73\u6210 26 \u5e74\u5ea6\u7a00\u5c11\u75be\u60a3\u30b5\u30fc\u30d9\u30a4\u30e9\u30f3\u30b9\u8abf\u67fb\u7d50\u679c. http:\/\/jspccs.wdcjp.com\/member\/report\/database\/index.php?download=rare_disease_surveillance_h26.pdf"},{"key":"364","doi-asserted-by":"crossref","unstructured":"364. \u3000Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-speci\ufb01c outcome of hypertrophic cardiomyopathy in children: Findings from the Pediatric Cardiomyopathy Registry. <i>Circulation<\/i> 2007; 115: 773\u2013781.","DOI":"10.1161\/CIRCULATIONAHA.106.621185"},{"key":"365","doi-asserted-by":"crossref","unstructured":"365. \u3000Colan SD. Hypertrophic cardiomyopathy in childhood. <i>Heart Fail Clin<\/i> 2010; 6: 433\u2013444.","DOI":"10.1016\/j.hfc.2010.05.004"},{"key":"366","doi-asserted-by":"crossref","unstructured":"366. \u3000Lipshultz SE, Orav EJ, Wilkinson D, Towbin JA, Messere JE, Lowe AM, et al; Pediatric Cardiomyopathy Registry Study Group. Risk strati\ufb01cation at diagnosis for children with hypertrophic cardiomyopathy: An analysis of data from the Pediatric Cardiomyopathy Registry. <i>Lancet<\/i> 2013; 382: 1889\u20131897.","DOI":"10.1016\/S0140-6736(13)61685-2"},{"key":"367","doi-asserted-by":"crossref","unstructured":"367. \u3000Alexander PMA, Nugent AW, Daubeney PEF, Lee KJ, Sleeper LA, Schuster T, et al; National Australian Childhood Cardiomyopathy Study. Long-term outcomes of hypertrophic cardiomyopathy diagnosed during childhood: Results from a national population-based study. <i>Circulation<\/i> 2018; 138: 29\u201336.","DOI":"10.1161\/CIRCULATIONAHA.117.028895"},{"key":"368","doi-asserted-by":"crossref","unstructured":"368. \u3000Pedra SR, Smallhorn JF, Ryan G, Chitayat D, Taylor GP, Khan R, et al. Fetal cardiomyopathies: Pathogenic mechanisms, hemodynamic findings, and clinical outcome. <i>Circulation<\/i> 2002; 106: 585\u2013591.","DOI":"10.1161\/01.CIR.0000023900.58293.FE"},{"key":"369","doi-asserted-by":"crossref","unstructured":"369. \u3000Moak JP, Kaski JP. Hypertrophic cardiomyopathy in children. <i>Heart<\/i> 2012; 98: 1044\u20131054.","DOI":"10.1136\/heartjnl-2011-300531"},{"key":"370","doi-asserted-by":"crossref","unstructured":"370. \u3000\u5927\u56fd\u771f\u5f66, \u672c\u7530\u60b3, \u539f\u7530\u7814\u4ecb, \u4ed6. \u5b66\u6821\u5fc3\u81d3\u691c\u8a3a \u4e8c\u6b21\u691c\u8a3a\u5bfe\u8c61\u8005\u62bd\u51fa\u306e\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3: \u4e00\u6b21\u691c\u8a3a\u306e\u5fc3\u96fb\u56f3\u6240\u898b\u304b\u3089. \u65e5\u5c0f\u5faa\u8a8c1996; 12: 725\u2013730.","DOI":"10.13031\/2013.25705"},{"key":"371","doi-asserted-by":"crossref","unstructured":"371. \u3000Brothers MB, Oster ME, Ehrlich A, Strieper MJ, Mahle WT. Novel electrocardiographic screening criterion for hypertrophic cardiomyopathy in children. <i>Am J Cardiol<\/i> 2014; 113: 1246\u20131249.","DOI":"10.1016\/j.amjcard.2013.12.039"},{"key":"372","doi-asserted-by":"crossref","unstructured":"372. \u3000Yoshinaga M, Iwamoto M, Horigome H, Sumitomo N, Ushinohama H, Izumida N, et al. Standard values and characteristics of electrocardiographic findings in children and adolescents. <i>Circ J<\/i> 2018; 82: 831\u2013839.","DOI":"10.1253\/circj.CJ-17-0735"},{"key":"373","doi-asserted-by":"crossref","unstructured":"373. \u3000Axelsson Raja A, Farhad H, Valente AM, Couce JP, Jefferies JL, Bundgaard H, et al. Prevalence and progression of late gadolinium enhancement in children and adolescents with hypertrophic cardiomyopathy. <i>Circulation<\/i> 2018; 138: 782\u2013792.","DOI":"10.1161\/CIRCULATIONAHA.117.032966"},{"key":"374","doi-asserted-by":"crossref","unstructured":"374. \u3000Maron BJ. Hypertrophic cardiomyopathy. <i>Lancet<\/i> 1997; 350: 127\u2013133.","DOI":"10.1016\/S0140-6736(97)01282-8"},{"key":"375","doi-asserted-by":"crossref","unstructured":"375. \u3000Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: Improved survival following high-dose beta-adrenoceptor antagonist treatment. <i>J Am Coll Cardiol<\/i> 1999; 34: 1813\u20131822.","DOI":"10.1016\/S0735-1097(99)00421-0"},{"key":"376","doi-asserted-by":"crossref","unstructured":"376. \u3000\u00d6stman-Smith I. Beta-blockers in pediatric hypertrophic cardiomyopathies. <i>Rev Recent Clin Trials<\/i> 2014; 9: 82\u201385.","DOI":"10.2174\/1574887109666140908125158"},{"key":"377","doi-asserted-by":"crossref","unstructured":"377. \u3000Spicer RL, Rocchini AP, Crowley DC, Rosenthal A. Chronic verapamil therapy in pediatric and young adult patients with hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1984; 53: 1614\u20131619.","DOI":"10.1016\/0002-9149(84)90589-7"},{"key":"378","doi-asserted-by":"crossref","unstructured":"378. \u3000O\u2019Connor MJ, Miller K, Shaddy RE, Lin KY, Hanna BD, Ravishankar C, et al. Disopyramide use in infants and children with hypertrophic cardiomyopathy. <i>Cardiol Young<\/i> 2018; 28: 530\u2013535.","DOI":"10.1017\/S1047951117002384"},{"key":"379","doi-asserted-by":"crossref","unstructured":"379. \u3000Theodoro DA, Danielson GK, Feldt RH, Anderson BJ. Hypertrophic obstructive cardiomyopathy in pediatric patients: Results of surgical treatment. <i>J Thorac Cardiovasc Surg<\/i> 1996; 112: 1589\u20131599.","DOI":"10.1016\/S0022-5223(96)70018-1"},{"key":"380","doi-asserted-by":"crossref","unstructured":"380. \u3000Vouh\u00e9 PR, Ouaknine R, Poulain H, Mauriat P, Pouard P, Tamisier D, et al. Diffuse subaortic stenosis: Modified Konno procedures with aortic valve preservation. <i>Eur J Cardiothorac Surg<\/i> 1993; 7: 132\u2013136.","DOI":"10.1016\/1010-7940(93)90035-A"},{"key":"381","doi-asserted-by":"crossref","unstructured":"381. \u3000McKenna WJ, Franklin RC, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1988; 11: 147\u2013153.","DOI":"10.1016\/0735-1097(88)90181-7"},{"key":"382","doi-asserted-by":"crossref","unstructured":"382. \u3000Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes NAM 3rd et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2013; 61: 1527\u20131535.","DOI":"10.1016\/j.jacc.2013.01.037"},{"key":"383","doi-asserted-by":"crossref","unstructured":"383. \u3000Maron BJ, Cecchi F, McKenna WJ. Risk factors and strati\ufb01cation for sudden cardiac death in patients with hypertrophic cardiomyopathy. <i>Br Heart J<\/i> 1994; 72(Suppl): S13\u2013S18.","DOI":"10.1136\/hrt.72.6_Suppl.S13"},{"key":"384","doi-asserted-by":"crossref","unstructured":"384. \u3000Maron BJ. Cardiovascular risks to young persons on the athletic \ufb01eld. <i>Ann Intern Med<\/i> 1998; 129: 379\u2013386.","DOI":"10.7326\/0003-4819-129-5-199809010-00006"},{"key":"385","doi-asserted-by":"crossref","unstructured":"385. \u3000Frenneaux MP. Assessing the risk of sudden cardiac death in a patient with hypertrophic cardiomyopathy. <i>Heart<\/i> 2004; 90: 570\u2013575.","DOI":"10.1136\/hrt.2003.020529"},{"key":"386","doi-asserted-by":"crossref","unstructured":"386. \u3000Norrish, G, Ding T, Field E, Ziolkowksa L, Olivotto I, Limongelli G, et al. Development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM Risk-Kids). <i>JAMA Cardiol<\/i> 2019; 4: 918\u2013927.","DOI":"10.1001\/jamacardio.2019.2861"},{"key":"387","doi-asserted-by":"crossref","unstructured":"387. \u3000Maron BJ, Isner JM, McKenna WJ. 26th Bethesda conference: Recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task Force 3: Hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. <i>J Am Coll Cardiol<\/i> 1994; 24: 880\u2013885.","DOI":"10.1016\/0735-1097(94)90844-3"},{"key":"388","doi-asserted-by":"crossref","unstructured":"388. \u3000\u00d6stman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence: Strategies to prevent sudden death. <i>Fundam Clin Pharmacol<\/i> 2010; 24: 637\u2013652.","DOI":"10.1111\/j.1472-8206.2010.00869.x"},{"key":"389","doi-asserted-by":"crossref","unstructured":"389. \u3000Wilkinson JD, Sleeper LA, Alvarez JA, Bublik N, Lipshultz SE; the Pediatric Cardiomyopathy Study Group. The Pediatric Cardiomyopathy Registry: 1995\u20132007. <i>Prog Pediatr Cardiol<\/i> 2008; 25: 31\u201336.","DOI":"10.1016\/j.ppedcard.2007.11.006"},{"key":"390","doi-asserted-by":"crossref","unstructured":"390. \u3000Schaffer MS, Freedom RM, Rowe RD. Hypertrophic cardiomyopathy presenting before 2 years of age in 13 patients. <i>Pediatr Cardiol<\/i> 1983; 4: 113\u2013119.","DOI":"10.1007\/BF02076335"},{"key":"391","doi-asserted-by":"crossref","unstructured":"391. \u3000Towbin JA. Hypertrophic cardiomyopathy. <i>Pacing Clin Electrophysiol<\/i> 2009; 32(Suppl 2): S23\u2013S31.","DOI":"10.1111\/j.1540-8159.2009.02381.x"},{"key":"392","doi-asserted-by":"crossref","unstructured":"392. \u3000Calcagni G, Adorisio R, Martinelli S, Grutter G, Baban A, Versacci P, et al. Clinical presentation and natural history of hypertrophic cardiomyopathy in RASopathies. <i>Heart Fail Clin<\/i> 2018; 14: 225\u2013235.","DOI":"10.1016\/j.hfc.2017.12.005"},{"key":"393","doi-asserted-by":"crossref","unstructured":"393. \u3000Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: A study from the Pediatric Cardiomyopathy Registry. <i>Am Heart J<\/i> 2012; 164: 442\u2013448.","DOI":"10.1016\/j.ahj.2012.04.018"},{"key":"394","doi-asserted-by":"crossref","unstructured":"394. \u3000Takahashi K, Kogaki S, Kurotobi S, Nasuno S, Ohta M, Okabe H, et al. A novel mutation in the PTPN11 gene in a patient with Noonan syndrome and rapidly progressive hypertrophic cardiomyopathy. <i>Eur J Pediatr<\/i> 2005; 164: 497\u2013500.","DOI":"10.1007\/s00431-005-1679-y"},{"key":"395","doi-asserted-by":"crossref","unstructured":"395. \u3000Hahn A, Lauriol J, Thul J, Behnke-Hall K, Logeswaran T, Schanzer A, et al. Rapidly progressive hypertrophic cardiomyopathy in an infant with Noonan syndrome with multiple lentigines: Palliative treatment with a rapamycin analog. <i>Am J Med Genet A<\/i> 2015; 167: 744\u2013751.","DOI":"10.1002\/ajmg.a.36982"},{"key":"396","doi-asserted-by":"crossref","unstructured":"396. \u3000Chien YH, Hwu WL, Lee NC. Pompe disease: Early diagnosis and early treatment make a difference. <i>Pediatr Neonatol<\/i> 2013; 54: 219\u2013227.","DOI":"10.1016\/j.pedneo.2013.03.009"},{"key":"397","doi-asserted-by":"crossref","unstructured":"397. \u3000Tsuboi K, Yamamoto H. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-na\u00efve Fabry disease patients. <i>BMC Pharmacol Toxicol<\/i> 2017; 18: 43.","DOI":"10.1186\/s40360-017-0152-7"},{"key":"398","doi-asserted-by":"crossref","unstructured":"398. \u3000Cheng Z, Fang Q. Danon disease: Focusing on heart. <i>J Hum Genet<\/i> 2012; 57: 407\u2013410.","DOI":"10.1038\/jhg.2012.72"},{"key":"399","doi-asserted-by":"crossref","unstructured":"399. \u3000Valayannopoulos V, Bajolle F, Arnoux JB, Dubois S, Sannier N, Baussan C, et al. Successful treatment of severe cardiomyopathy in glycogen storage disease type III with D,L-3-hydroxybutyrate, ketogenic and high-protein diet. <i>Pediatr Res<\/i> 2011; 70: 638\u2013641.","DOI":"10.1203\/PDR.0b013e318232154f"},{"key":"400","doi-asserted-by":"crossref","unstructured":"400. \u3000Mayorandan S, Meyer U, Hartmann H, Das AM. Glycogen storage disease type III: Modi\ufb01ed Atkins diet improves myopathy. <i>Orphanet J Rare Dis<\/i> 2014; 9: 196.","DOI":"10.1186\/s13023-014-0196-3"},{"key":"401","doi-asserted-by":"crossref","unstructured":"401. \u3000Elmekkawi SF, Mansour GM, Elsafty MS, Hassanin AS, Laban M, Elsayed HM. Prediction of fetal hypertrophic cardiomyopathy in diabetic pregnancies compared with postnatal outcome. <i>Clin Med Insights Womens Health<\/i> 2015; 8: 39\u201343.","DOI":"10.4137\/CMWH.S32825"},{"key":"402","doi-asserted-by":"crossref","unstructured":"402. \u3000Pilania R, Sikka P, Rohit MK, Suri V, Kumar P. Fetal cardiodynamics by echocardiography in insulin dependent maternal diabetes and its correlation with pregnancy outcome. <i>J Clin Diagn Res<\/i> 2016; 10: QC01\u2013QC04.","DOI":"10.7860\/JCDR\/2016\/17993.8079"},{"key":"403","doi-asserted-by":"crossref","unstructured":"403. \u3000Manning N, Archer N. Cardiac manifestations of twin-to-twin transfusion syndrome. <i>Twin Res Hum Genet<\/i> 2016; 19: 246\u2013254.","DOI":"10.1017\/thg.2016.20"},{"key":"404","doi-asserted-by":"crossref","unstructured":"404. \u3000Maron BJ, Doerer JJ, Haas TS, Tierney DM, Mueller F. Sudden deaths in young competitive athletes: Analysis of 1866 deaths in the United States, 1980\u20132006. <i>Circulation<\/i> 2009; 119: 1085\u20131092.","DOI":"10.1161\/CIRCULATIONAHA.108.804617"},{"key":"405","doi-asserted-by":"crossref","unstructured":"405. \u3000Dimitrow PP, Cotrim C, Cheng TO. Importance of upright posture during exercise in detection of provocable left ventricular outflow tract gradient in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 2011; 108: 614.","DOI":"10.1016\/j.amjcard.2011.05.018"},{"key":"406","doi-asserted-by":"crossref","unstructured":"406. \u3000Corrado D, Basso C, Rizzoli G, Schiavon M, Thiene G. Does sports activity enhance the risk of sudden death in adolescents and young adults? <i>J Am Coll Cardiol<\/i> 2003; 42: 1959\u20131963.","DOI":"10.1016\/j.jacc.2003.03.002"},{"key":"407","doi-asserted-by":"crossref","unstructured":"407. \u3000Wigle ED. Impaired left ventricular relaxation in hypertrophic cardiomyopathy: Relation to extent of hypertrophy. <i>J Am Coll Cardiol<\/i> 1990; 5: 814\u2013815.","DOI":"10.1016\/0735-1097(90)90279-X"},{"key":"408","doi-asserted-by":"crossref","unstructured":"408. \u3000Maron BJ, Epstein SE. Clinical signi\ufb01cance and therapeutic implications of the left ventricular out\ufb02ow tract pressure gradient in hypertrophic cardiomyopathy. <i>Am J Cardiol<\/i> 1986; 58: 1093\u20131096.","DOI":"10.1016\/0002-9149(86)90118-9"},{"key":"409","doi-asserted-by":"crossref","unstructured":"409. \u3000Prasad K, Williams L, Campbell R, McKenna WJ, Frenneaux M. Episodic syncope in hypertrophic cardiomyopathy: Evidence for inappropriate vasodilation. <i>Heart<\/i> 2008; 94: 1312\u20131317.","DOI":"10.1136\/hrt.2008.141507"},{"key":"410","doi-asserted-by":"crossref","unstructured":"410. \u3000Plehn G, Vormbrock J, Meissner A, Trappe HJ. Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: Relationship to cardiac output reserve. <i>J Nucl Cardiol<\/i> 2009; 16: 233\u2013243.","DOI":"10.1007\/s12350-008-9031-3"},{"key":"411","doi-asserted-by":"crossref","unstructured":"411. \u3000Klempfner R, Kamerman T, Schwammenthal E, Nahshon A, Hay I, Goldenberg I, et al. Ef\ufb01cacy of exercise training in symptomatic patients with hypertrophic cardiomyopathy: Results of a structured exercise training program in a cardiac rehabilitation center. <i>Eur J Prev Cardiol<\/i> 2015; 22: 13\u201319.","DOI":"10.1177\/2047487313501277"},{"key":"412","doi-asserted-by":"crossref","unstructured":"412. \u3000Saberi S, Wheeler M, Bragg-Gresham J, Hornsby W, Agarwal PP, Attili A, et al. Effect of moderate-intensity exercise training on peak oxygen consumption in patients with hypertrophic cardiomyopathy: A randomized clinical trial. <i>JAMA<\/i> 2017; 317: 1349\u20131357.","DOI":"10.1001\/jama.2017.2503"},{"key":"413","doi-asserted-by":"crossref","unstructured":"413. \u3000Robson SC, Hunter S, Boys RJ, Dunlop W. Serial study of factors in\ufb02uencing changes in cardiac output during human pregnancy. <i>Am J Physiol<\/i> 1989; 256: H1060\u2013H1065.","DOI":"10.1152\/ajpheart.1989.256.4.H1060"},{"key":"414","doi-asserted-by":"crossref","unstructured":"414. \u3000Ruys TP, Roos-Hesselink JW, Hall R, Subirana-Dom\u00e8nech MT, Grando-Ting J, Estensen M, et al. Heart failure in pregnant women with cardiac disease: Data from the ROPAC. <i>Heart<\/i> 2014; 100: 231\u2013238.","DOI":"10.1136\/heartjnl-2013-304888"},{"key":"415","doi-asserted-by":"crossref","unstructured":"415. \u3000Schinkel AF. Pregnancy in women with hypertrophic cardiomyopathy. <i>Cardiol Rev<\/i> 2014; 22: 217\u2013222.","DOI":"10.1097\/CRD.0000000000000010"},{"key":"416","doi-asserted-by":"crossref","unstructured":"416. \u3000Autore C, Conte MR, Piccininno M, Baernabo P, Bonfiglio G, Bruzzi P, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 40: 1864\u20131869.","DOI":"10.1016\/S0735-1097(02)02495-6"},{"key":"417","doi-asserted-by":"crossref","unstructured":"417. \u3000Goland S, van Hagen IM, Elbaz-Greener G, Elkayam U, Shotan A, Merz WM, et al. Pregnancy in women with hypertrophic cardiomyopathy: Data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC). <i>Eur Heart J<\/i> 2017; 38: 2683\u20132690.","DOI":"10.1093\/eurheartj\/ehx189"},{"key":"418","doi-asserted-by":"crossref","unstructured":"418. \u3000Thaman R, Varnava A, Hamid MS, Firoozi S, Sachdev B, Condon M, et al. Pregnancy related complications in women with hypertrophic cardiomyopathy. <i>Heart<\/i> 2003; 89: 752\u2013756.","DOI":"10.1136\/heart.89.7.752"},{"key":"419","doi-asserted-by":"crossref","unstructured":"419. \u3000Tanaka H, Kamiya C, Katsuragi S, Tanaka K, Miyoshi T, Tsuritani M, et al. Cardiovascular events in pregnancy with hypertrophic cardiomyopathy. <i>Circ J<\/i> 2014; 78: 2501\u20132506.","DOI":"10.1253\/circj.CJ-14-0541"},{"key":"420","doi-asserted-by":"crossref","unstructured":"420. \u3000Siu SC, Sermer M, Colman JM, Alvarez AN, Mercier LA, Morton BC, et al; Cardiac Disease in Pregnancy (CARPREG) Investigators. Prospective multicenter study of pregnancy outcomes in women with heart disease. <i>Circulation<\/i> 2001; 104: 515\u2013521.","DOI":"10.1161\/hc3001.093437"},{"key":"421","unstructured":"421. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5fc3\u75be\u60a3\u60a3\u8005\u306e\u598a\u5a20\u30fb\u51fa\u7523\u306e\u9069\u5fdc\uff0c\u7ba1\u7406\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3(2018\u5e74\u6539\u8a02\u7248) JCS 2018 Guideline on Indication and Management of Pregnancy and Delivery in Women with Heart Disease"},{"key":"422","doi-asserted-by":"crossref","unstructured":"422. \u3000Regitz-Zagrosek V, Blomstrom Lundqvist C, Borghi C, Cifkova R, Ferreira R, Foidart JM, et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2011; 32: 3147\u20133197.","DOI":"10.1093\/eurheartj\/ehr218"},{"key":"423","doi-asserted-by":"crossref","unstructured":"423. \u3000Rowe GT. Hypertrophic cardiomyopathy in pregnancy: A case study. <i>J Cardiovasc Nurs<\/i> 1994; 8: 69\u201373.","DOI":"10.1097\/00005082-199401000-00007"},{"key":"424","doi-asserted-by":"crossref","unstructured":"424. \u3000Piacenza JM, Kirkorian G, Audra PH, Mellier G. Hypertrophic cardiomyopathy and pregnancy. <i>Eur J Obstet Gynecol Reprod Biol<\/i> 1998; 80: 17\u201323.","DOI":"10.1016\/S0301-2115(98)00076-1"},{"key":"425","doi-asserted-by":"crossref","unstructured":"425. \u3000Pinto YM, Elliott PM, Arbustini E, Adler Y, Anastasakis A, B\u00f6hm M, et al. Proposal for a revised de\ufb01nition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: A position statement of the ESC working group on myocardial and pericardial diseases. <i>Eur Heart J<\/i> 2016; 37: 1850\u20131858.","DOI":"10.1093\/eurheartj\/ehv727"},{"key":"426","doi-asserted-by":"crossref","unstructured":"426. \u3000Keren A, Billingham ME, Weintraub D, Stinson EB, Popp RL. Mildly dilated congestive cardiomyopathy. <i>Circulation<\/i> 1985; 72: 302\u2013309.","DOI":"10.1161\/01.CIR.72.2.302"},{"key":"427","doi-asserted-by":"crossref","unstructured":"427. \u3000Mahon NG, Murphy RT, MacRae CA, Caforio ALP, Elliot PM, McKenna WJ. Echocardiographic evaluation in asymptomatic relatives of patients with dilated cardiomyopathy reveals preclinical disease. <i>Ann Intern Med<\/i> 2005; 143: 108\u2013115.","DOI":"10.7326\/0003-4819-143-2-200507190-00009"},{"key":"428","doi-asserted-by":"crossref","unstructured":"428. \u3000Fatkin D, Yeoh T, Hayward CS, Benson V, Sheu A, Richmond Z, et al. Evaluation of left ventricular enlargement as a marker of early disease in familial dilated cardiomyopathy. <i>Circ Cardiovasc Genet<\/i> 2011; 4: 342\u2013348.","DOI":"10.1161\/CIRCGENETICS.110.958918"},{"key":"429","doi-asserted-by":"crossref","unstructured":"429. \u3000Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The diagnosis and evaluation of dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2016; 67: 2996\u20133010.","DOI":"10.1016\/j.jacc.2016.03.590"},{"key":"430","doi-asserted-by":"crossref","unstructured":"430. \u3000Haas J, Frese KS, Peil B, Kloos W, Keller A, Nietsch R, et al. Atlas of the clinical genetics of human dilated cardiomyopathy. <i>Eur Heart J<\/i> 2015; 36: 1123\u20131135.","DOI":"10.1093\/eurheartj\/ehu301"},{"key":"431","doi-asserted-by":"crossref","unstructured":"431. \u3000Warren M. The approach to predictive medicine that is taking genomics research by storm. <i>Nature<\/i> 2018; 562: 181\u2013183.","DOI":"10.1038\/d41586-018-06956-3"},{"key":"432","doi-asserted-by":"crossref","unstructured":"432. \u3000K\u00fchl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with \u201cidiopathic\u201d left ventricular dysfunction. <i>Circulation<\/i> 2005; 111: 887\u2013893.","DOI":"10.1161\/01.CIR.0000155616.07901.35"},{"key":"433","doi-asserted-by":"crossref","unstructured":"433. \u3000Jahns R, Boivin V, Siegmund C, Inselmann G, Lohse MJ, Boege F. Autoantibodies activating human beta1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. <i>Circulation<\/i> 1999; 99: 649\u2013654.","DOI":"10.1161\/01.CIR.99.5.649"},{"key":"434","doi-asserted-by":"crossref","unstructured":"434. \u3000Jahns R, Boivin V, Hein L, Triebel S, Angermann CE, Ertl G, et al. Direct evidence for a \u03b21-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. <i>J Clin Invest<\/i> 2004; 113: 1419\u20131429.","DOI":"10.1172\/JCI200420149"},{"key":"435","doi-asserted-by":"crossref","unstructured":"435. \u3000Baba A, Yoshikawa T, Fukuda Y, Sugiyama T, Shimada M, Akaishi M, et al. Autoantibodies against M2-muscarinic acetylcholine receptors: New upstream targets in atrial \ufb01brillation in patients with dilated cardiomyopathy. <i>Eur Heart J<\/i> 2004; 25: 1108\u20131115.","DOI":"10.1016\/j.ehj.2004.05.012"},{"key":"436","doi-asserted-by":"crossref","unstructured":"436. \u3000Okazaki T, Tanaka Y, Nishio R, Mitsuiye T, Mizoguchi A, Wang J, et al. Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-de\ufb01cient mice. <i>Nat Med<\/i> 2003; 9: 1477\u20131483.","DOI":"10.1038\/nm955"},{"key":"437","doi-asserted-by":"crossref","unstructured":"437. \u3000Baba A, Yoshikawa T, Ogawa S. Autoantibodies produced against sarcolemmal Na-K-ATPase: Possible upstream targets of arrhythmias and sudden death in patients with dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2002; 40: 1153\u20131159.","DOI":"10.1016\/S0735-1097(02)02075-2"},{"key":"438","doi-asserted-by":"crossref","unstructured":"438. \u3000Wolff PG, K\u00fchl U, Schultheiss HP. Laminin distribution and auto-antibodies to laminin in dilated cardiomyopathy and myocarditis. <i>Am Heart J<\/i> 1989; 117: 1303\u20131309.","DOI":"10.1016\/0002-8703(89)90410-9"},{"key":"439","doi-asserted-by":"crossref","unstructured":"439. \u3000Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac auto-antibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical signi\ufb01cance. <i>Eur J Heart Fail<\/i> 2002; 4: 411\u2013417.","DOI":"10.1016\/S1388-9842(02)00010-7"},{"key":"440","doi-asserted-by":"crossref","unstructured":"440. \u3000Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A; JCARE-CARD Investigators. Clinical characteristics and outcome of hospitalized patients with heart failure in Japan. <i>Circ J<\/i> 2006; 70: 1617\u20131623.","DOI":"10.1253\/circj.70.1617"},{"key":"441","doi-asserted-by":"crossref","unstructured":"441. \u3000Shiba N, Watanabe J, Shinozaki T, Koseki Y, Sakuma M, Kagaya Y, et al; CHART Investigators. Analysis of chronic heart failure registry in the Tohoku district: Third year follow-up. <i>Circ J<\/i> 2004; 68: 427\u2013434.","DOI":"10.1253\/circj.68.427"},{"key":"442","doi-asserted-by":"crossref","unstructured":"442. \u3000Shiba N, Nochioka K, Miura M, Kohno H, Shimokawa H; CHART-2 Investigators. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan: First report from the CHART-2 study. <i>Circ J<\/i> 2011; 75: 823\u2013833.","DOI":"10.1253\/circj.CJ-11-0135"},{"key":"443","doi-asserted-by":"crossref","unstructured":"443. \u3000Miura M, Sakata Y, Miyata S, Nochioka K, Takada T, Tadaki S, et al; CHART-2 Investigators. Usefulness of combined risk strati\ufb01cation with heart rate and systolic blood pressure in the management of chronic heart failure: A report from the CHART-2 study. <i>Circ J<\/i> 2013; 77: 2954\u20132962.","DOI":"10.1253\/circj.CJ-13-0725"},{"key":"444","doi-asserted-by":"crossref","unstructured":"444. \u3000Tsutsui H, Tsuchihashi-Makaya M, Kinugawa S, Goto D, Takeshita A; JCARE-GENERAL Investigators. Characteristics and outcomes of patients with heart failure in general practices and hospitals. <i>Circ J<\/i> 2007; 71: 449\u2013454.","DOI":"10.1253\/circj.71.449"},{"key":"445","doi-asserted-by":"crossref","unstructured":"445. \u3000Tsuchihashi-Makaya M, Hamaguchi S, Kinugawa S, Yokota T, Goto D, Yokoshiki H, et al; JCARE-CARD Investigators. Characteristics and outcomes of hospitalized patients with heart failure and reduced vs preserved ejection fraction: Report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD). <i>Circ J<\/i> 2009; 73: 1893\u20131900.","DOI":"10.1253\/circj.CJ-09-0254"},{"key":"446","doi-asserted-by":"crossref","unstructured":"446. \u3000Nakada Y, Kawakami R, Nakano T, Takitsume A, Nakagawa H, Ueda T, et al. Sex differences in clinical characteristics and long-term outcome in acute decompensated heart failure patients with preserved and reduced ejection fraction. <i>Am J Physiol Heart Circ Physiol<\/i> 2016; 310: H813\u2013H820.","DOI":"10.1152\/ajpheart.00602.2015"},{"key":"447","doi-asserted-by":"crossref","unstructured":"447. \u3000Shiraishi Y, Kohsaka S, Abe T, Mizuno A, Goda A, Izumi Y, et al; West Tokyo Heart Failure Registry Investigators. Validation of the Get with The Guideline-Heart Failure risk score in Japanese patients and the potential improvement of its discrimination ability by the inclusion of B-type natriuretic peptide level. <i>Am Heart J<\/i> 2016; 171: 33\u201339.","DOI":"10.1016\/j.ahj.2015.10.008"},{"key":"448","doi-asserted-by":"crossref","unstructured":"448. \u3000Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. <i>N Engl J Med<\/i> 2003; 348: 1647\u20131655.","DOI":"10.1056\/NEJMoa021715"},{"key":"449","unstructured":"449. \u3000\u65e5\u672c\u5fc3\u81d3\u79fb\u690d\u7814\u7a76\u4f1a. \u5fc3\u81d3\u79fb\u690d\u306e\u73fe\u72b6 20191231 \u73fe\u5728. http:\/\/www.jsht.jp\/registry\/japan\/"},{"key":"450","doi-asserted-by":"crossref","unstructured":"450. \u3000Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. <i>J Am Coll Cardiol<\/i> 1992; 19: 1550\u20131558.","DOI":"10.1016\/0735-1097(92)90617-V"},{"key":"451","doi-asserted-by":"crossref","unstructured":"451. \u3000Matsui Y, Iwai K, Tachibana T, Fruie T, Shigematsu N, Izumi T, et al. Clinicopathological study of fatal myocardial sarcoidosis. <i>Ann NY Acad Sci<\/i> 1976; 278: 455\u2013469.","DOI":"10.1111\/j.1749-6632.1976.tb47058.x"},{"key":"452","doi-asserted-by":"crossref","unstructured":"452. \u3000Valantine H, McKenna WJ, Nihoyannopoulos P, Mitchell A, Foale RA, Davies MJ, et al. Sarcoidosis: A pattern of clinical and morphological presentation. <i>Br Heart J<\/i> 1987; 57: 256\u2013263.","DOI":"10.1136\/hrt.57.3.256"},{"key":"453","doi-asserted-by":"crossref","unstructured":"453. \u3000Iwai K, Takemura T, Kitaichi M, Kawabata Y, Matsui Y. Pathological studies on sarcoidosis autopsy. II: Early change, mode of progression and death pattern. <i>Acta Pathol Jpn<\/i> 1993; 43: 377\u2013385.","DOI":"10.1111\/j.1440-1827.1993.tb01149.x"},{"key":"454","unstructured":"454. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3\u30b7\u30ea\u30fc\u30ba 2016\u5e74\u5ea6\u7248: \u5fc3\u81d3\u30b5\u30eb\u30b3\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2016_terasaki_h.pdf"},{"key":"455","doi-asserted-by":"crossref","unstructured":"455. \u3000Kosuge H, Noda M, Kakuta T, Kishi Y, Isobe M, Numano F. Left ventricular apical aneurysm in cardiac sarcoidosis. <i>Jpn Heart J<\/i> 2001; 42: 265\u2013269.","DOI":"10.1536\/jhj.42.265"},{"key":"456","doi-asserted-by":"crossref","unstructured":"456. \u3000Falk RH, Plehn JF, Deering T, Schick EC Jr, Boinay P, Rubinow A, et al. Sensitivity and speci\ufb01city of the echocardiographic features of cardiac amyloidosis. <i>Am J Cardiol<\/i> 1987; 59: 418\u2013422.","DOI":"10.1016\/0002-9149(87)90948-9"},{"key":"457","doi-asserted-by":"crossref","unstructured":"457. \u3000Patel AR, Dubrey SW, Mendes LA, Skinner M, Cupples A, Falk RH, et al. Right ventricular dilation in primary amyloidosis: An independent predictor of survival. <i>Am J Cardiol<\/i> 1997; 80: 486\u2013492.","DOI":"10.1016\/S0002-9149(97)00400-1"},{"key":"458","doi-asserted-by":"crossref","unstructured":"458. \u3000Klein AL, Hatle LK, Taliercio CP, aylor CL, Kyle RA, Bailey KR, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. <i>J Am Coll Cardiol<\/i> 1990; 16: 1135\u20131141.","DOI":"10.1016\/0735-1097(90)90545-Z"},{"key":"459","doi-asserted-by":"crossref","unstructured":"459. \u3000Kholov\u00e1 I, Niessen HW. Amyloid in the cardiovascular system: A review. <i>J Clin Pathol<\/i> 2005; 58: 125\u2013133.","DOI":"10.1136\/jcp.2004.017293"},{"key":"460","unstructured":"460. \u3000\u5b89\u6771\u7531\u559c\u96c4 \u76e3\u4fee, \u690d\u7530\u5149\u6674 \u7de8. \u6700\u65b0\u30a2\u30df\u30ed\u30a4\u30c9\u30fc\u30b7\u30b9\u306e\u3059\u3079\u3066: \u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32017\u3068Q\uff06A. \u533b\u6b6f\u85ac\u51fa\u7248\u682a\u5f0f\u4f1a\u793e 2017."},{"key":"461","doi-asserted-by":"crossref","unstructured":"461. \u3000Trachtenberg BH, Hare JM. Inflammatory cardiomyopathic syndromes. <i>Circ Res<\/i> 2017; 121: 803\u2013818.","DOI":"10.1161\/CIRCRESAHA.117.310221"},{"key":"462","doi-asserted-by":"crossref","unstructured":"462. \u3000Kindermann I, Barth C, Mahfoud F, Ukena C, Lenski M, Yilmaz A, et al. Update on myocarditis. <i>J Am Coll Cardiol<\/i> 2012; 59: 779\u2013792.","DOI":"10.1016\/j.jacc.2011.09.074"},{"key":"463","doi-asserted-by":"crossref","unstructured":"463. \u3000D\u2019Ambrosio A, Patti G, Manzoli A, Sinagra G, Di Lenarda A, Silvestri F, et al. The fate of acute myocarditis between spontaneous improvement and evolution to dilated cardiomyopathy: A review. <i>Heart<\/i> 2001; 85: 499\u2013504.","DOI":"10.1136\/hrt.85.5.499"},{"key":"464","unstructured":"464. \u3000\u65e5\u672c\u795e\u7d4c\u5b66\u4f1a, \u65e5\u672c\u5c0f\u5150\u795e\u7d4c\u5b66\u4f1a, \u56fd\u7acb\u7cbe\u795e\u30fb\u795e\u7d4c\u533b\u7642\u7814\u7a76\u30bb\u30f3\u30bf\u30fc\u76e3\u4fee. \u30c7\u30e5\u30b7\u30a7\u30f3\u30cc\u578b\u7b4b\u30b8\u30b9\u30c8\u30ed\u30d5\u30a3\u30fc\u8a3a\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f32014. \u5357\u6c5f\u5802 2014."},{"key":"465","doi-asserted-by":"crossref","unstructured":"465. \u3000Rajdev A, Groh WJ. Arrhythmias in the muscular dystrophies. <i>Card Electrophysiol Clin<\/i> 2015; 7: 303\u2013308.","DOI":"10.1016\/j.ccep.2015.03.011"},{"key":"466","doi-asserted-by":"crossref","unstructured":"466. \u3000Ho R, Nguyen ML, Mather P. Cardiomyopathy in Becker muscular dystrophy: Overview. <i>World J Cardiol<\/i> 2016; 8: 356\u2013361.","DOI":"10.4330\/wjc.v8.i6.356"},{"key":"467","doi-asserted-by":"crossref","unstructured":"467. \u3000Schade van Westrum SM, Hoogerwaard EM, Dekker L, Standaar TS, Bakker E, Ippel PF, et al. Cardiac abnormalities in a follow-up study on carriers of Duchenne and Becker muscular dystrophy. <i>Neurology<\/i> 2011; 77: 62\u201366.","DOI":"10.1212\/WNL.0b013e318221ad14"},{"key":"468","unstructured":"468. \u3000\u65e5\u672c\u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u5b66\u4f1a\u7de8. \u30df\u30c8\u30b3\u30f3\u30c9\u30ea\u30a2\u75c5\u8a3a\u7642\u30de\u30cb\u30e5\u30a2\u30eb2017. \u8a3a\u65ad\u3068\u6cbb\u7642\u793e 2016."},{"key":"469","doi-asserted-by":"crossref","unstructured":"469. \u3000Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. <i>Ann Oncol<\/i> 2012; 23(Suppl 7): vii155\u2013vii166.","DOI":"10.1093\/annonc\/mds293"},{"key":"470","doi-asserted-by":"crossref","unstructured":"470. \u3000Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. <i>J Am Soc Echocardiogr<\/i> 2014; 27: 911\u2013939.","DOI":"10.1016\/j.echo.2014.07.012"},{"key":"471","doi-asserted-by":"crossref","unstructured":"471. \u3000Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. <i>J Clin Oncol<\/i> 2017; 35: 893\u2013911.","DOI":"10.1200\/JCO.2016.70.5400"},{"key":"472","doi-asserted-by":"crossref","unstructured":"472. \u3000Zamorano JL, Lancellotti P, Rodriguez Mu\u00f1oz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2016; 37: 2768\u20132801.","DOI":"10.1093\/eurheartj\/ehw211"},{"key":"473","doi-asserted-by":"crossref","unstructured":"473. \u3000Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y, et al. Fulminant myocarditis with combination immune checkpoint blockade. <i>N Engl J Med<\/i> 2016; 375: 1749\u20131755.","DOI":"10.1056\/NEJMoa1609214"},{"key":"474","doi-asserted-by":"crossref","unstructured":"474. \u3000Sliwa K, Hil\ufb01ker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: A position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. <i>Eur J Heart Fail<\/i> 2010; 12: 767\u2013778.","DOI":"10.1093\/eurjhf\/hfq120"},{"key":"475","doi-asserted-by":"crossref","unstructured":"475. \u3000Gemayel C, Pelliccia A, Thompson PD. Arrhythmogenic right ventricular cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2001; 38: 1773\u20131781.","DOI":"10.1016\/S0735-1097(01)01654-0"},{"key":"476","doi-asserted-by":"crossref","unstructured":"476. \u3000Hulot JS, Jouven X, Empana JP, Frank R, Fontaine G. Natural history and risk strati\ufb01cation of arrhythmogenic right ventricular dysplasia\/cardiomyopathy. <i>Circulation<\/i> 2004; 110: 1879\u20131884.","DOI":"10.1161\/01.CIR.0000143375.93288.82"},{"key":"477","doi-asserted-by":"crossref","unstructured":"477. \u3000Ikeda U, Minamisawa M, Koyama J. Isolated left ventricular non-compaction cardiomyopathy in adults. <i>J Cardiol<\/i> 2015; 65: 91\u201397.","DOI":"10.1016\/j.jjcc.2014.10.005"},{"key":"478","doi-asserted-by":"crossref","unstructured":"478. \u3000Arbustini E, Weidemann F, Hazll JL. Left ventricular noncompaction: A distinct cardiomyopathy or a trait shared by different cardiac diseases? <i>J Am Coll Cardiol<\/i> 2014; 64: 1840\u20131850.","DOI":"10.1016\/j.jacc.2014.08.030"},{"key":"479","doi-asserted-by":"crossref","unstructured":"479. \u3000Lee RJ, Kalman JM, Fitzpatrick AP, Epstein LM, Fisher WG, Olgin JE, et al. Radiofrequency catheter modi\ufb01cation of the sinus node for \u201cinappropriate\u201d sinus tachycardia. <i>Circulation<\/i> 1995; 92: 2919\u20132928.","DOI":"10.1161\/01.CIR.92.10.2919"},{"key":"480","doi-asserted-by":"crossref","unstructured":"480. \u3000Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al. 2009 focused update: ACCF\/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines: Developed in collaboration with the International Society for Heart and Lung Transplantation. <i>Circulation<\/i> 2009; 119: 1977\u20132016.","DOI":"10.1161\/CIRCULATIONAHA.109.192065"},{"key":"481","doi-asserted-by":"crossref","unstructured":"481. \u3000Frolkis JP, Pothier CE, Blackstone EH, Lauer MS. Frequent ventricular ectopy after exercise as a predictor of death. <i>N Engl J Med<\/i> 2003; 348: 781\u2013790.","DOI":"10.1056\/NEJMoa022353"},{"key":"482","doi-asserted-by":"crossref","unstructured":"482. \u3000Eckart RE, Field ME, Hruczkowski TW, Forman DE, Dorbala S, Di Carli MF, et al. Association of electrocardiographic morphology of exercise-induced ventricular arrhythmia with mortality. <i>Ann Intern Med<\/i> 2008; 149: 451\u2013460.","DOI":"10.7326\/0003-4819-149-7-200810070-00005"},{"key":"483","doi-asserted-by":"crossref","unstructured":"483. \u3000Lipkin DP, Scriven AJ, Crake T, Poole-Wilson PA. Six minute walking test for assessing exercise capacity in chronic heart failure. <i>BMJ (Clin Res Ed)<\/i> 1986; 292: 653\u2013655.","DOI":"10.1136\/bmj.292.6521.653"},{"key":"484","doi-asserted-by":"crossref","unstructured":"484. \u3000Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JGF. Six minute corridor walk test as an outcome measure for the assessment of treatment in randomized, blinded intervention trials of chronic heart failure: A systematic review. <i>Eur Heart J<\/i> 2005; 26: 778\u2013793.","DOI":"10.1093\/eurheartj\/ehi162"},{"key":"485","doi-asserted-by":"crossref","unstructured":"485. \u3000Grimm W, Hoffmann J, Menz V, Luck K, Maisch B. Programmed ventricular stimulation for arrhythmia risk prediction in patients with idiopathic dilated cardiomyopathy and nonsustained ventricular tachycardia. <i>J Am Coll Cardiol<\/i> 1998; 32: 739\u2013745.","DOI":"10.1016\/S0735-1097(98)00306-4"},{"key":"486","doi-asserted-by":"crossref","unstructured":"486. \u3000Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Gettes LS, et al. ACC\/AHA\/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC\/AHA\/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): Developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. <i>Circulation<\/i> 2008; 117: e350\u2013e408.","DOI":"10.1161\/CIRCUALTIONAHA.108.189741"},{"key":"487","unstructured":"487. \u3000\u65e5\u672c\u5fc3\u4e0d\u5168\u5b66\u4f1a\u4e88\u9632\u59d4\u54e1\u4f1a. \u8840\u4e2dBNP\u3084NT-proBNP\u5024\u3092\u7528\u3044\u305f\u5fc3\u4e0d\u5168\u8a3a\u7642\u306e\u7559\u610f\u70b9\u306b\u3064\u3044\u3066. http:\/\/www.asas.or.jp\/jhfs\/topics\/bnp201300403.html"},{"key":"488","doi-asserted-by":"crossref","unstructured":"488. \u3000Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic signi\ufb01cance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. <i>Am Heart J<\/i> 2002; 144: 524\u2013529.","DOI":"10.1067\/mhj.2002.123575"},{"key":"489","doi-asserted-by":"crossref","unstructured":"489. \u3000Otsuji Y, Levine RA, Takeuchi M, Sakata R, Tei C. Mechanism of ischemic mitral regurgitation. <i>J Cardiol<\/i> 2008; 51: 145\u2013156.","DOI":"10.1016\/j.jjcc.2008.03.005"},{"key":"490","doi-asserted-by":"crossref","unstructured":"490. \u3000Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino J, et al. Results of the Predictors of Response to CRT (PROSPECT) trial. <i>Circulation<\/i> 2008; 117: 2608\u20132616.","DOI":"10.1161\/CIRCULATIONAHA.107.743120"},{"key":"491","doi-asserted-by":"crossref","unstructured":"491. \u3000Jansen AH, van Dantzig Jm, Bracke F, Meijer A, Peels KH, van den Brink RB, et al. Qualitative observation of left ventricular multiphasic septal motion and septal-to-lateral apical shuf\ufb02e predicts left ventricular reverse remodeling after cardiac resynchronization therapy. <i>Am J Cardiol<\/i> 2007; 99: 966\u2013969.","DOI":"10.1016\/j.amjcard.2006.11.044"},{"key":"492","doi-asserted-by":"crossref","unstructured":"492. \u3000Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Cleland JG, et al. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance: Are they interchangeable? <i>Eur Heart J<\/i> 2000; 21: 1387\u20131396.","DOI":"10.1053\/euhj.2000.2011"},{"key":"493","doi-asserted-by":"crossref","unstructured":"493. \u3000Kim RJ, Fieno DS, Parrish TB, Harris K, Chen EL, Simonetti O, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. <i>Circulation<\/i> 1999; 100: 1992\u20132002.","DOI":"10.1161\/01.CIR.100.19.1992"},{"key":"494","doi-asserted-by":"crossref","unstructured":"494. \u3000Wagner A, Mahrholdt H, Thomson L, Hager S, Meinhardt G, Rehwald W, et al. Effects of time, dose, and inversion time for acute myocardial infarct size measurements based on magnetic resonance imaging-delayed contrast enhancement. <i>J Am Coll Cardiol<\/i> 2006; 47: 2027\u20132033.","DOI":"10.1016\/j.jacc.2006.01.059"},{"key":"495","doi-asserted-by":"crossref","unstructured":"495. \u3000Ricciardi MJ, Wu E, Davidson CJ, Choi KM, Klocke FJ, Bonow RO, et al. Visualization of discrete microinfarction after percutaneous coronary intervention associated with mild creatine kinase-MB elevation. <i>Circulation<\/i> 2001; 103: 2780\u20132783.","DOI":"10.1161\/hc2301.092121"},{"key":"496","doi-asserted-by":"crossref","unstructured":"496. \u3000Kim RJ, Wu E, Rafael A, Chen EL, Parker MA, Simonetti O, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. <i>N Engl J Med<\/i> 2000; 343: 1445\u20131453.","DOI":"10.1056\/NEJM200011163432003"},{"key":"497","doi-asserted-by":"crossref","unstructured":"497. \u3000K\u00fchl HP, Lipke CS, Krombach GA, Katoh M, Battenberg TF, Nowak B, et al. Assessment of reversible myocardial dysfunction in chronic ischaemic heart disease: Comparison of contrast-enhanced cardiovascular magnetic resonance and a combined positron emission tomography-single photon emission computed tomography imaging protocol. <i>Eur Heart J<\/i> 2006; 27: 846\u2013853.","DOI":"10.1093\/eurheartj\/ehi747"},{"key":"498","doi-asserted-by":"crossref","unstructured":"498. \u3000Abdel-Aty H, Zagrosek A, Schulz-Menger J, Taylor AJ, Messroghli D, Kumar A, et al. Delayed enhancement and T2-weighted cardiovascular magnetic resonance imaging differentiate acute from chronic myocardial infarction. <i>Circulation<\/i> 2004; 109: 2411\u20132416.","DOI":"10.1161\/01.CIR.0000127428.10985.C6"},{"key":"499","doi-asserted-by":"crossref","unstructured":"499. \u3000Yelgec NS, Dymarkowski S, Ganame J, Bogaert J. Value of MRI in patients with a clinical suspicion of acute myocarditis. <i>Eur Radiol<\/i> 2007; 17: 2211\u20132217.","DOI":"10.1007\/s00330-007-0612-3"},{"key":"500","doi-asserted-by":"crossref","unstructured":"500. \u3000Vignaux O. Cardiac sarcoidosis: Spectrum of MRI features. <i>Am J Roentgenol<\/i> 2005; 184: 249\u2013254.","DOI":"10.2214\/ajr.184.1.01840249"},{"key":"501","doi-asserted-by":"crossref","unstructured":"501. \u3000Mahrholdt H, Goedecke C, Wagner A, MeinhardtG, Athanasiadis A, Vogelsberg H, et al. Cardiovascular magnetic resonance assessment of human myocarditis: A comparison to histology and molecular pathology. <i>Circulation<\/i> 2004; 109: 1250\u20131258.","DOI":"10.1161\/01.CIR.0000118493.13323.81"},{"key":"502","doi-asserted-by":"crossref","unstructured":"502. \u3000Moon JC, Reed E, Sheppard MN, Elkington AG, Ho SY, Burke M, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2004; 43: 2260\u20132264.","DOI":"10.1016\/j.jacc.2004.03.035"},{"key":"503","doi-asserted-by":"crossref","unstructured":"503. \u3000McCrohon JA, Moon JC, Prasad SK, McKenna WJ, Lorenz CH, Coats AJ, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. <i>Circulation<\/i> 2003; 108: 54\u201359.","DOI":"10.1161\/01.CIR.0000078641.19365.4C"},{"key":"504","doi-asserted-by":"crossref","unstructured":"504. \u3000Mahrholdt H, Wagner A, Judd RM, Sechtem U, Kim RJ. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. <i>Eur Heart J<\/i> 2005; 26: 1461\u20131474.","DOI":"10.1093\/eurheartj\/ehi258"},{"key":"505","doi-asserted-by":"crossref","unstructured":"505. \u3000Soriano CJ, Ridocci F, Estornell J, Jimenez J, Martinez V, De Velasco JA. Noninvasive diagnosis of coronary artery disease in patients with heart failure and systolic dysfunction of uncertain etiology, using late gadolinium-enhanced cardiovascular magnetic resonance. <i>J Am Coll Cardiol<\/i> 2005; 45: 743\u2013748.","DOI":"10.1016\/j.jacc.2004.11.037"},{"key":"506","doi-asserted-by":"crossref","unstructured":"506. \u3000Assomull RG, Prasad SK, Lyne J, Smith G, Burman ED, Khan M, et al. Cardiovascular magnetic resonance, \ufb01brosis, and prognosis in dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2006; 48: 1977\u20131985.","DOI":"10.1016\/j.jacc.2006.07.049"},{"key":"507","doi-asserted-by":"crossref","unstructured":"507. \u3000Matoh F, Satoh H, Shiraki K, Saitoh T, Urushida T, Katoh H, et al. Usefulness of delayed enhancement magnetic resonance imaging to differentiate dilated phase of hypertrophic cardiomyopathy and dilated cardiomyopathy. <i>J Card Fail<\/i> 2007; 13: 372\u2013379.","DOI":"10.1016\/j.cardfail.2007.02.001"},{"key":"508","doi-asserted-by":"crossref","unstructured":"508. \u3000Bohl S, Wassmuth R, Abdel-Aty H, Rudolph A, Messroghli D, Dietz R, et al. Delayed enhancement cardiac magnetic resonance imaging reveals typical patterns of myocardial injury in patients with various forms of non-ischemic heart disease. <i>Int J Cardiovasc Imaging<\/i> 2008; 24: 597\u2013607.","DOI":"10.1007\/s10554-008-9300-x"},{"key":"509","doi-asserted-by":"crossref","unstructured":"509. \u3000Gulati A, Jabbour A, Ismail TF, Guha K, Khwaja J, Raza S, et al. Association of fibrosis with mortality and sudden cardiac death in patients with nonischemic dilated cardiomyopathy. <i>JAMA<\/i> 2013; 309: 896\u2013908.","DOI":"10.1001\/jama.2013.1363"},{"key":"510","doi-asserted-by":"crossref","unstructured":"510. \u3000Kubanek M, Sramko M, Maluskova J, Kautznerova D, Weichet J, Lupinek P, et al. Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2013; 61: 54\u201363.","DOI":"10.1016\/j.jacc.2012.07.072"},{"key":"511","doi-asserted-by":"crossref","unstructured":"511. \u3000Nakamori S, Dohi K, Ishida M, Goto Y, Imanaka-Yoshida K, Omori T, et al. Native T1 mapping and extracellular volume mapping for the assessment of diffuse myocardial fibrosis in dilated cardiomyopathy. <i>JACC Cardiovasc Imaging<\/i> 2018; 11: 48\u201359.","DOI":"10.1016\/j.jcmg.2017.04.006"},{"key":"512","doi-asserted-by":"crossref","unstructured":"512. \u3000Petersen SE, Selvanayagam JB, Wiesmann F, Robson MD, Francis JM, Anderson RH, et al. Left ventricular non-compaction: Insights from cardiovascular magnetic resonance imaging. <i>J Am Coll Cardiol<\/i> 2005; 46: 101\u2013105.","DOI":"10.1016\/j.jacc.2005.03.045"},{"key":"513","doi-asserted-by":"crossref","unstructured":"513. \u3000Andreini D, Pontone G, Bogaert J, Roghi A, Barison A, Schwitter J, et al. Long-term prognostic value of cardiac magnetic resonance in left ventricle noncompaction: A prospective multicenter study. <i>J Am Coll Cardiol<\/i> 2016; 68: 2166\u20132181.","DOI":"10.1016\/j.jacc.2016.08.053"},{"key":"514","doi-asserted-by":"crossref","unstructured":"514. \u3000Ivanov A, Dabiesingh DS, Bhumireddy GP, Mohamed A, Asfour A, Briggs WM, et al. Prevalence and prognostic significance of left ventricular noncompaction in patients referred for cardiac magnetic resonance imaging. <i>Circ Cardiovasc Imaging<\/i> 2017; 10: e006174.","DOI":"10.1161\/CIRCIMAGING.117.006174"},{"key":"515","doi-asserted-by":"crossref","unstructured":"515. \u3000Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. <i>Circulation<\/i> 2015; 132: 1570\u20131579.","DOI":"10.1161\/CIRCULATIONAHA.115.016567"},{"key":"516","doi-asserted-by":"crossref","unstructured":"516. \u3000Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. <i>JACC Cardiovasc Imaging<\/i> 2013; 6: 488\u2013497.","DOI":"10.1016\/j.jcmg.2012.11.013"},{"key":"517","doi-asserted-by":"crossref","unstructured":"517. \u3000Dungu JN, Valencia O, Pinney JH, Gibbs SDJ, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. <i>JACC Cardiovasc Imaging<\/i> 2014; 7: 133\u2013142.","DOI":"10.1016\/j.jcmg.2013.08.015"},{"key":"518","doi-asserted-by":"crossref","unstructured":"518. \u3000Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B, Bluemke DA, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy\/dysplasia: Proposed modi\ufb01cation of the Task Force Criteria. <i>Circulation<\/i> 2010; 121: 1533\u20131541.","DOI":"10.1161\/CIRCULATIONAHA.108.840827"},{"key":"519","doi-asserted-by":"crossref","unstructured":"519. \u3000Liu T, Pursnani A, Sharma UC, Vorasettakarnkij Y, Verdini D, Deeprasertkul P, et al. Effect of the 2010 task force criteria on reclassi\ufb01cation of cardiovascular magnetic resonance criteria for arrhythmogenic right ventricular cardiomyopathy. <i>J Cardiovasc Magn Reson<\/i> 2014; 16: 47.","DOI":"10.1186\/1532-429X-16-47"},{"key":"520","doi-asserted-by":"crossref","unstructured":"520. \u3000Femia G, Hsu C, Singarayar S, Sy RW, Kilborn M, Parker G, et al. Impact of new task force criteria in the diagnosis of arrhythmogenic right ventricular cardiomyopathy. <i>Int J Cardiol<\/i> 2014; 171: 179\u2013183.","DOI":"10.1016\/j.ijcard.2013.11.092"},{"key":"521","doi-asserted-by":"crossref","unstructured":"521. \u3000Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. <i>J Am Coll Cardiol<\/i> 2007; 49: 1874\u20131879.","DOI":"10.1016\/j.jacc.2006.10.078"},{"key":"522","doi-asserted-by":"crossref","unstructured":"522. \u3000Yilmaz A, Gdynia HJ, Baccouche H, da Silva MM, Campos AF, Barbosa Mde M, et al. Cardiac involvement in patients with Becker muscular dystrophy: New diagnostic and pathophysiological insights by a CMR approach. <i>J Cardiovasc Magn Reson<\/i> 2008; 10: 50.","DOI":"10.1186\/1532-429X-10-50"},{"key":"523","doi-asserted-by":"crossref","unstructured":"523. \u3000Puchalski MD, Williams RV, Askovich B, Sower CT, Hor KH, Su JT, et al. Late gadolinium enhancement: Precursor to cardiomyopathy in Duchenne muscular dystrophy? <i>Int J Cardiovasc Imaging<\/i> 2009; 25: 57\u201363.","DOI":"10.1007\/s10554-008-9352-y"},{"key":"524","doi-asserted-by":"crossref","unstructured":"524. \u3000Walcher T, Steinbach P, Spiess J, Kunze M, Gradinger R, Walcher D, et al. Detection of long-term progression of myocardial \ufb01brosis in Duchenne muscular dystrophy in an affected family: A cardiovascular magnetic resonance study. <i>Eur J Radiol<\/i> 2011; 80: 115\u2013119.","DOI":"10.1016\/j.ejrad.2010.07.005"},{"key":"525","doi-asserted-by":"crossref","unstructured":"525. \u3000Florian A, Ludwig A, Engelen M, Waltenberger J, Rosch S, Sechtem U, et al. Left ventricular systolic function and the pattern of late-gadolinium-enhancement independently and additively predict adverse cardiac events in muscular dystrophy patients. <i>J Cardiovasc Magn Reson<\/i> 2014; 16: 81.","DOI":"10.1186\/s12968-014-0081-1"},{"key":"526","doi-asserted-by":"crossref","unstructured":"526. \u3000Fallah-Rad N, Lytwyn M, Fang T, Kirkpatrick I, Jassal DS. Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy. <i>J Cardiovasc Magn Reson<\/i> 2008; 10: 5.","DOI":"10.1186\/1532-429X-10-5"},{"key":"527","doi-asserted-by":"crossref","unstructured":"527. \u3000Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, et al. The utility of cardiac bio- markers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. <i>J Am Coll Cardiol<\/i> 2011; 57: 2263\u20132270.","DOI":"10.1016\/j.jacc.2010.11.063"},{"key":"528","doi-asserted-by":"crossref","unstructured":"528. \u3000Arora NP, Mohamad T, Mahajan N, Danrad R, Kottam A, Li T, et al. Cardiac magnetic resonance imaging in peripartum cardiomyopathy. <i>Am J Med Sci<\/i> 2014; 347: 112\u2013117.","DOI":"10.1097\/MAJ.0b013e31828155e3"},{"key":"529","doi-asserted-by":"crossref","unstructured":"529. \u3000Wu YW, Yen RF, Chieng PU, Huang PJ. Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. <i>J Nucl Cardiol<\/i> 2003; 10: 369\u2013374.","DOI":"10.1016\/S1071-3581(03)00456-2"},{"key":"530","doi-asserted-by":"crossref","unstructured":"530. \u3000Danias PG, Papaioannou GI, Ahlberg AW, O\u2019Sullivan DM, Mann A, Boden WE, et al. Usefulness of electrocardiographic-gated stress technetium-99 m sestamibi single-photon emission computed tomography to differentiate ischemic from nonischemic cardiomyopathy. <i>Am J Cardiol<\/i> 2004; 94: 14\u201319.","DOI":"10.1016\/j.amjcard.2004.03.022"},{"key":"531","doi-asserted-by":"crossref","unstructured":"531. \u3000Tamai J, Nagata S, Nishimura T, Yutani C, Sakakibara H, Nimura Y. Hemodynamic and prognostic value of thallium-201 myocardial imaging in patients with dilated cardiomyopathy. <i>Int J Cardiol<\/i> 1989; 24: 219\u2013224.","DOI":"10.1016\/0167-5273(89)90307-0"},{"key":"532","doi-asserted-by":"crossref","unstructured":"532. \u3000Li LX, Nohara R, Okuda K, Hosokawa R, Hata T, Tanaka M, et al. Comparative study of 201Tl-scintigraphic image and myocardial pathologic \ufb01ndings in patients with dilated cardiomyopathy. <i>Ann Nucl Med<\/i> 1996; 10: 307\u2013314.","DOI":"10.1007\/BF03164737"},{"key":"533","doi-asserted-by":"crossref","unstructured":"533. \u3000Ito T, Hoshida S, Nishino M, Aoi T, Egami Y, Takeda T, et al. Relationship between evaluation by quantitative fatty acid myocardial scintigraphy and response to beta-blockade therapy in patients with dilated cardiomyopathy. <i>Eur J Nucl Med<\/i> 2001; 28: 1811\u20131816.","DOI":"10.1007\/s00259-001-0668-2"},{"key":"534","doi-asserted-by":"crossref","unstructured":"534. \u3000Inoue A, Fujimoto S, Yamashina S, Yamazaki J. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. <i>Ann Nucl Med<\/i> 2007; 21: 399\u2013404.","DOI":"10.1007\/s12149-007-0045-8"},{"key":"535","doi-asserted-by":"crossref","unstructured":"535. \u3000Kasama S, Toyama T, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, et al. Effect of spironolactone on cardiac sympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2003; 41: 574\u2013581.","DOI":"10.1016\/S0735-1097(02)02855-3"},{"key":"536","doi-asserted-by":"crossref","unstructured":"536. \u3000Kasama S, Toyama T, Sumino H, Nakazawa M, Matsumoto N, Sato Y, et al. Prognostic value of serial cardiac 123I-MIBG imaging in patients with stabilized chronic heart failure and reduced left ventricular ejection fraction. <i>J Nucl Med<\/i> 2008; 49: 907\u2013914.","DOI":"10.2967\/jnumed.107.047548"},{"key":"537","doi-asserted-by":"crossref","unstructured":"537. \u3000van den Heuvel AF, van Veldhuise DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM, et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2000; 35: 19\u201328.","DOI":"10.1016\/S0735-1097(99)00499-4"},{"key":"538","doi-asserted-by":"crossref","unstructured":"538. \u3000Hasegawa S, Kusuoka H, Maruyama K, Nishimura T, Hori M, Hatazawa J. Myocardial positron emission computed tomographic images obtained with fluorine-18 \ufb02uoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers. <i>J Am Coll Cardiol<\/i> 2004; 43: 224\u2013233.","DOI":"10.1016\/j.jacc.2003.09.025"},{"key":"539","unstructured":"539. \u3000Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with 13N-NH3\/18F-FDG PET. <i>J Nucl Med<\/i> 2003; 44: 1030\u20131036."},{"key":"540","unstructured":"540. \u3000Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. <i>J Nucl Med<\/i> 2004; 45: 1989\u20131998."},{"key":"541","doi-asserted-by":"crossref","unstructured":"541. \u3000Ishimaru S, Tsujino I, Takei T, Tsukamoto E, Sakaue S, Kamigaki M, et al. Focal uptake on 18F-\ufb02uoro-2-de-oxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis. <i>Eur Heart J<\/i> 2005; 26: 1538\u20131543.","DOI":"10.1093\/eurheartj\/ehi180"},{"key":"542","doi-asserted-by":"crossref","unstructured":"542. \u3000Tahara N, Tahara A, Nitta Y, Kodama N, Mizoguchi M, Kaida H, et al. Heterogeneous myocardial FDG uptake and the disease activity in cardiac sarcoidosis. <i>JACC Cardiovasc Imaging<\/i> 2010; 3: 1219\u20131228.","DOI":"10.1016\/j.jcmg.2010.09.015"},{"key":"543","doi-asserted-by":"crossref","unstructured":"543. \u3000Andreini D, Pontone G, Pepi M, Ballerini G, Bartorelli AL, Magini A, et al. Diagnostic accuracy of multi-detector computed tomography coronary angiography in patients with dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2007; 49: 2044\u20132050.","DOI":"10.1016\/j.jacc.2007.01.086"},{"key":"544","doi-asserted-by":"crossref","unstructured":"544. \u3000Andreini D, Pontone G, Bartorelli AL, Agostoni P, Mushtaq S, Bertella E, et al. Sixty-four-slice multidetector computed tomography: An accurate imaging modality for the evaluation of coronary arteries in dilated cardiomyopathy of unknown etiology. <i>Circ Cardiovasc Imaging<\/i> 2009; 2: 199\u2013205.","DOI":"10.1161\/CIRCIMAGING.108.822809"},{"key":"545","doi-asserted-by":"crossref","unstructured":"545. \u3000Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. <i>Circulation<\/i> 1991; 83: 778\u2013786.","DOI":"10.1161\/01.CIR.83.3.778"},{"key":"546","unstructured":"546. \u3000Fleisher LA, Beckman JA, Brown KA, Calkins H, Chaikof E, Fleischmann KE, et al. ACC\/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: A report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): Developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. <i>Circulation<\/i> 2007; 116: e418\u2013e499."},{"key":"547","doi-asserted-by":"crossref","unstructured":"547. \u3000Sasayama S, Asanoi H, Ishizaka S, Miyagi K. Evaluation of functional capacity of patients with congestive heart failure.<i>In<\/i>: Yasuda H, Kawaguchi H, editors. New aspects in the treatment of failing heart syndrome. Springer, 1992; 113\u2013117.","DOI":"10.1007\/978-4-431-68219-6_19"},{"key":"548","unstructured":"548. \u3000\u96e3\u75c5\u60c5\u5831\u30bb\u30f3\u30bf\u30fc. \u7279\u767a\u6027\u62e1\u5f35\u578b\u5fc3\u7b4b\u75c7 (\u6307\u5b9a\u96e3\u75c557). http:\/\/www.nanbyou.or.jp\/entry\/3986"},{"key":"549","doi-asserted-by":"crossref","unstructured":"549. \u3000Goldman L, Hashimoto B, Cook EF, Loscalzo A. Comparative reproducibility and validity of systems for assessing cardiovascular functional class: Advantages of a new speci\ufb01c activity scale. <i>Circulation<\/i> 1981; 64: 1227\u20131234.","DOI":"10.1161\/01.CIR.64.6.1227"},{"key":"550","unstructured":"550. \u3000\u5927\u897f\u6d0b\u4e09, \u4f50\u85e4\u79c0\u5e78, \u662f\u6052\u4e4b\u5b8f, \u4ed6. 6\u5206\u9593\u6b69\u884c\u8a66\u9a13\u306e\u6b63\u5e38\u5024\u306e\u5206\u5e03\u3068\u305d\u306e\u898f\u5b9a\u56e0\u5b50\u306b\u95a2\u3059\u308b\u691c\u8a0e. <i>Jpn Circ J<\/i> 1998; 61(Suppl III): 857."},{"key":"551","doi-asserted-by":"crossref","unstructured":"551. \u3000Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI, et al; SOLVD Investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction. <i>JAMA<\/i> 1993; 270: 1702\u20131707.","DOI":"10.1001\/jama.270.14.1702"},{"key":"552","doi-asserted-by":"crossref","unstructured":"552. \u3000Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM, McKelvie RS, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic heart failure. <i>J Am Coll Cardiol<\/i> 2012; 60: 2653\u20132661.","DOI":"10.1016\/j.jacc.2012.08.1010"},{"key":"553","unstructured":"553. \u3000Wasserman K, Sue D. Physiology of exercise.<i>In<\/i>: Wasserman K, editor. Principles of exercise testing and interpretation, 2nd edn. Lea &amp; Febiger, 1994."},{"key":"554","doi-asserted-by":"crossref","unstructured":"554. \u3000Nakanishi M, Takaki H, Kumasaka R, Arakawa T, Noguchi T, Sugimachi M, et al. Targeting of high peak respiratory exchange ratio is safe and enhances the prognostic power of peak oxygen uptake for heart failure patients. <i>Circ J<\/i> 2014; 78: 2268\u20132275.","DOI":"10.1253\/circj.CJ-14-0047"},{"key":"555","doi-asserted-by":"crossref","unstructured":"555. \u3000Koike A, Koyama Y, Itoh H, Adachi H, Marumo F, Hiroe M. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild to moderate heart failure. <i>Jpn Circ J<\/i> 2000; 64: 915\u2013920.","DOI":"10.1253\/jcj.64.915"},{"key":"556","doi-asserted-by":"crossref","unstructured":"556. \u3000Aaronson KD, Schwartz JS, Chen TM, Wong KL, Goin JE, Mancini DM. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. <i>Circulation<\/i> 1997; 95: 2660\u20132667.","DOI":"10.1161\/01.CIR.95.12.2660"},{"key":"557","doi-asserted-by":"crossref","unstructured":"557. \u3000Mudge GH, Goldstein S, Addonizio LJ, Caplan A, Mancini DM, Levine TB, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient guidelines\/prioritization. <i>J Am Coll Cardiol<\/i> 1993; 22: 21\u201331.","DOI":"10.1016\/0735-1097(93)90812-F"},{"key":"558","doi-asserted-by":"crossref","unstructured":"558. \u3000Fletcher GF, Ades PA, Klig\ufb01eld P, Arena R, Balady GJ, Bittner VA, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Exercise standards for testing and training: A scienti\ufb01c statement from the American Heart Association. <i>Circulation<\/i> 2013; 128: 873\u2013934.","DOI":"10.1161\/CIR.0b013e31829b5b44"},{"key":"559","doi-asserted-by":"crossref","unstructured":"559. \u3000Matsumura N, Nishijima H, Kojima S, Hashimoto F, Minami M, Yasuda H. Determination of anaerobic threshold for assessment of functional state in patients with chronic heart failure. <i>Circulation<\/i> 1983; 68: 360\u2013367.","DOI":"10.1161\/01.CIR.68.2.360"},{"key":"560","doi-asserted-by":"crossref","unstructured":"560. \u3000Stelken AM, Younis LT, Jennison SH, Miller DD, Miller LW, Shaw LJ, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1996; 27: 345\u2013352.","DOI":"10.1016\/0735-1097(95)00464-5"},{"key":"561","unstructured":"561. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2007\u5e74\u5ea6\u5408\u540c\u7814\u7a76\u73ed\u5831\u544a): \u5fc3\u75be\u60a3\u60a3\u8005\u306e\u5b66\u6821, \u8077\u57df, \u30b9\u30dd\u30fc\u30c4\u306b\u304a\u3051\u308b\u904b\u52d5\u8a31\u5bb9\u6761\u4ef6\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2008\u5e74\u6539\u8a02\u7248). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2008_nagashima_h.pdf"},{"key":"562","doi-asserted-by":"crossref","unstructured":"562. \u3000Arena R, Myers J, Aslam SS, Varughese EB, Peberdy MA. Peak VO2 and VE\/VCO2 slope in patients with heart failure: A prognostic comparison. <i>Am Heart J<\/i> 2004; 147: 354\u2013360.","DOI":"10.1016\/j.ahj.2003.07.014"},{"key":"563","doi-asserted-by":"crossref","unstructured":"563. \u3000Binanay C, Califf RM, Hasselblad V, O\u2019Connor CM, Shah MR, Sopko G, et al; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. <i>JAMA<\/i> 2005; 294: 1625\u20131633.","DOI":"10.1001\/jama.294.13.1625"},{"key":"564","doi-asserted-by":"crossref","unstructured":"564. \u3000Shah MR, Hasselblad V, Stevenson LW, Binanay C, O\u2019Connor CM, Sopko G, et al. Impact of the pulmonary artery catheter in critically ill patients: Meta-analysis of randomized clinical trials. <i>JAMA<\/i> 2005; 294: 1664\u20131670.","DOI":"10.1001\/jama.294.13.1664"},{"key":"565","doi-asserted-by":"crossref","unstructured":"565. \u3000Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. <i>Circulation<\/i> 2013; 128: e240\u2013e327.","DOI":"10.1161\/CIR.0b013e31829e8776"},{"key":"566","doi-asserted-by":"crossref","unstructured":"566. \u3000Costanzo-Nordin MR, O\u2019Connell JB, Engelmeier RS, Moran JF, Scanlon PJ. Dilated cardiomyopathy: functional status, hemodynamics, arrhythmias, and prognosis. <i>Cathet Cardiovasc Diagn<\/i> 1985; 11: 445\u2013453.","DOI":"10.1002\/ccd.1810110502"},{"key":"567","doi-asserted-by":"crossref","unstructured":"567. \u3000Balik M, Pachl J, Hendl J. Effect of the degree of tricuspid regurgitation on cardiac output measurements by thermodilution. <i>Intensive Care Med<\/i> 2002; 28: 1117\u20131121.","DOI":"10.1007\/s00134-002-1352-0"},{"key":"568","doi-asserted-by":"crossref","unstructured":"568. \u3000Gonzalez J, Delafosse C, Fartoukh M, Capderou A, Straus C, Zelter M, et al. Comparison of bedside measurement of cardiac output with the thermodilution method and the Fick method in mechanically ventilated patients. <i>Crit Care<\/i> 2003; 7: 171\u2013178.","DOI":"10.1186\/cc1848"},{"key":"569","unstructured":"569. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u6162\u6027\u51a0\u52d5\u8108\u75be\u60a3\u8a3a\u65ad\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3(2018\u5e74\u6539\u8a02\u7248) JCS 2018 Guideline on Diagnosis of Chronic Coronary Heart Diseases. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/02\/JCS2018_yamagishi_tamaki.pdf"},{"key":"570","unstructured":"570. \u3000Paterick TE, Gerber TC, Pradhan SR, Lindor NM, Tajik AJ. Left ventricular noncompaction cardiomyopathy: what do we know? <i>Rev Cardiovasc Med<\/i> 2010; 11: 92\u201399."},{"key":"571","unstructured":"571. \u3000Koga Y, Miyamoto T, Ohtsuki T, Toshima H. Natural history of hypertrophic cardiomyopathy: Japanese experience. <i>J Cardiol<\/i> 2001; 37(Suppl 1): 147\u2013154."},{"key":"572","unstructured":"572. \u3000Iida K, Yutani C, Imakita M, Ishibashi-Ueda H. Comparison of percentage area of myocardial \ufb01brosis and disarray in patients with classical form and dilated phase of hypertrophic cardiomyopathy. <i>J Cardiol<\/i> 1998; 32: 173\u2013180."},{"key":"573","doi-asserted-by":"crossref","unstructured":"573. \u3000Basso C, Corrado D, Marcus FI, Nava A, Thiene G. Arrhythmogenic right ventricular cardiomyopathy. <i>Lancet<\/i> 2009; 373: 1289\u20131300.","DOI":"10.1016\/S0140-6736(09)60256-7"},{"key":"574","unstructured":"574. \u3000Virmani R. Cardiomyopathy, ischemic.<i>In<\/i>: Bloom S, editor. Diagnostic criteria for cardiovascular pathology: Acquired diseases. Lippincott-Raven, 1997; 28\u201329."},{"key":"575","doi-asserted-by":"crossref","unstructured":"575. \u3000Kajihara H, Yokozaki H, Yamahara M, Kadomoto Y, Tahara E. Anthracycline induced myocardial damage: An analysis of 16 autopsy cases. <i>Pathol Res Pract<\/i> 1986; 181: 434\u2013441.","DOI":"10.1016\/S0344-0338(86)80079-6"},{"key":"576","doi-asserted-by":"crossref","unstructured":"576. \u3000Lampert MB, Lang RM. Peripartum cardiomyopathy. <i>Am Heart J<\/i> 1995; 130: 860\u2013870.","DOI":"10.1016\/0002-8703(95)90089-6"},{"key":"577","unstructured":"577. \u3000Factor SM. Cardiomyopathy, Alcohol-associated.<i>In<\/i>: Bloom S, editor. Diagnostic criteria for cardiovascular pathology: Acquired diseases. Lippincott-Raven, 1997; 12\u201313."},{"key":"578","doi-asserted-by":"crossref","unstructured":"578. \u3000Kawano H, Hayashi T, Koide Y, Toda G, Yano K. Histopathological changes of biopsied myocardium in Shoshin beriberi. <i>Int Heart J<\/i> 2005; 46: 751\u2013759.","DOI":"10.1536\/ihj.46.751"},{"key":"579","doi-asserted-by":"crossref","unstructured":"579. \u3000Japanese Circulation Society (JCS) Task Force Committee on Chronic Myocarditis. Guideline for diagnosing chronic myocarditis. <i>Jpn Circ J<\/i> 1996; 60: 263\u2013264.","DOI":"10.1253\/jcj.60.263"},{"key":"580","unstructured":"580. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u6025\u6027\u304a\u3088\u3073\u6162\u6027\u5fc3\u7b4b\u708e\u306e\u8a3a\u65ad\u30fb\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3(2009\u5e74\u6539\u8a02\u7248). https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/02\/JCS2009_izumi_h.pdf"},{"key":"581","doi-asserted-by":"crossref","unstructured":"581. \u3000Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. <i>Mayo Clin Proc<\/i> 1999; 74: 275\u2013284.","DOI":"10.4065\/74.3.275"},{"key":"582","doi-asserted-by":"crossref","unstructured":"582. \u3000Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. <i>Circulation<\/i> 1964; 30: 698\u2013705.","DOI":"10.1161\/01.CIR.30.5.698"},{"key":"583","doi-asserted-by":"crossref","unstructured":"583. \u3000Seward JB, Casaclang-Verzosa G. In\ufb01ltrative cardiovascular diseases: Cardiomyopathies that look alike. <i>J Am Coll Cardiol<\/i> 2010; 55: 1769\u20131779.","DOI":"10.1016\/j.jacc.2009.12.040"},{"key":"584","doi-asserted-by":"crossref","unstructured":"584. \u3000Maisch B, Alter P, Pankuweit S. Diabetic cardiomyopathy: Fact or \ufb01ction? <i>Herz<\/i> 2011; 36: 102\u2013115.","DOI":"10.1007\/s00059-011-3429-4"},{"key":"585","doi-asserted-by":"crossref","unstructured":"585. \u3000Foley RN, Parfrey PS, Kent GM, Harnett JD, Murray DC, Barre PE. Long-term evolution of cardiomyopathy in dialysis patients. <i>Kidney Int<\/i> 1998; 54: 1720\u20131725.","DOI":"10.1046\/j.1523-1755.1998.00154.x"},{"key":"586","doi-asserted-by":"crossref","unstructured":"586. \u3000Saito M, Kawai H, Akaike M, Adachi K, Nishida Y, Saito S. Cardiac dysfunction with Becker muscular dystrophy. <i>Am Heart J<\/i> 1996; 132: 642\u2013647.","DOI":"10.1016\/S0002-8703(96)90250-1"},{"key":"587","unstructured":"587. \u3000Yan SM, Finato N, Di Loreto C, Beltrami CA. Nuclear size of myocardial cells in end-stage cardiomyopathies. <i>Anal Quant Cytol Histol<\/i> 1999; 21: 174\u2013180."},{"key":"588","doi-asserted-by":"crossref","unstructured":"588. \u3000Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural (\u201csmall vessel\u201d) coronary artery disease in hypertrophic cardiomyopathy. <i>J Am Coll Cardiol<\/i> 1986; 8: 545\u2013557.","DOI":"10.1016\/S0735-1097(86)80181-4"},{"key":"589","doi-asserted-by":"crossref","unstructured":"589. \u3000Maisch B, Richter A, Koelsch S, Alter P, Funck R, Pankuweit S. Management of patients with suspected (peri-)myocarditis and in\ufb02ammatory dilated cardiomyopathy. <i>Herz<\/i> 2006; 31: 881\u2013890.","DOI":"10.1007\/s00059-006-2941-4"},{"key":"590","doi-asserted-by":"crossref","unstructured":"590. \u3000Imanaka-Yoshida K. Tenascin-C in cardiovascular tissue remodeling: From development to in\ufb02ammation and repair. <i>Circ J<\/i> 2012; 76: 2513\u20132520.","DOI":"10.1253\/circj.CJ-12-1033"},{"key":"591","doi-asserted-by":"crossref","unstructured":"591. \u3000B\u00fcltmann BD, Klingel K, N\u00e4bauer M, Wallwiener D, Kandolf R. High prevalence of viral genomes and inflammation in peripartum cardiomyopathy. <i>Am J Obstet Gynecol<\/i> 2005; 193: 363\u2013365.","DOI":"10.1016\/j.ajog.2005.01.022"},{"key":"592","doi-asserted-by":"crossref","unstructured":"592. \u3000Nef HM, M\u00f6llmann H, Kostin S, Troidl C, Voss S, Weber M, et al. Tako-tsubo cardiomyopathy: Intraindividual structural analysis in the acute phase and after functional recovery. <i>Eur Heart J<\/i> 2007; 28: 2456\u20132464.","DOI":"10.1093\/eurheartj\/ehl570"},{"key":"593","doi-asserted-by":"crossref","unstructured":"593. \u3000\u68ee\u7530\u5553\u884c. \u907a\u4f1d\u5b50\u304b\u3089\u5fc3\u7b4b\u75c7\u3092\u307f\u308b. \u65e5\u5185\u4f1a\u8a8c2014; 103: 285\u2013292.","DOI":"10.2169\/naika.103.285"},{"key":"594","doi-asserted-by":"crossref","unstructured":"594. \u3000Herman DS, Lam L, Taylor MR, Wang L, Teekakirikul P, Christodoulou D, et al. Truncations of titin causing dilated cardiomyopathy. <i>N Engl J Med<\/i> 2012; 366: 619\u2013628.","DOI":"10.1056\/NEJMoa1110186"},{"key":"595","doi-asserted-by":"crossref","unstructured":"595. \u3000Norton N, Li D, Rampersaud E, Morales A, Martin ER, Zuchner S, et al; National Heart, Lung, and Blood Institute GO Exome Sequencing Project and the Exome Sequencing Project Family Studies Project Team. Exome sequencing and genome-wide linkage analysis in 17 families illustrate the complex contribution of TTN truncating variants to dilated cardiomyopathy. <i>Circ Cardiovasc Genet<\/i> 2013; 6: 144\u2013153.","DOI":"10.1161\/CIRCGENETICS.111.000062"},{"key":"596","doi-asserted-by":"crossref","unstructured":"596. \u3000Tobita T, Nomura S, Fujita T, Morita H, Asano Y, Onoue K, et al. Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling. <i>Sci Rep<\/i> 2018; 8: 1998.","DOI":"10.1038\/s41598-018-20114-9"},{"key":"597","doi-asserted-by":"crossref","unstructured":"597. \u3000Rijsingen IA, Arbustini E, Elliott PM, Mogensen J, Hermans-van Ast JF, van der Kooi AJ, et al. Risk factors for malignant ventricular arrhythmias in lamin a\/c mutation carriers a European cohort study. <i>J Am Coll Cardiol<\/i> 2012; 59: 493\u2013500.","DOI":"10.1016\/j.jacc.2011.08.078"},{"key":"598","doi-asserted-by":"crossref","unstructured":"598. \u3000Halliday BP, Wassall R, Lota AS, Khalique Z, Gregson J, Newsome S, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): An open-label, pilot, randomised trial. <i>Lancet<\/i> 2019; 393: 61\u201373.","DOI":"10.1016\/S0140-6736(18)32484-X"},{"key":"599","doi-asserted-by":"crossref","unstructured":"599. \u3000Jones RH, Velazquez EJ, Michler RE, Sopko G, Oh JK, O\u2019Connor CM, et al; STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. <i>N Engl J Med<\/i> 2009; 360: 1705\u20131717.","DOI":"10.1056\/NEJMoa0900559"},{"key":"600","doi-asserted-by":"crossref","unstructured":"600. \u3000Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>Eur Heart J<\/i> 2016; 37: 2129\u20132200.","DOI":"10.1093\/eurheartj\/ehw128"},{"key":"601","doi-asserted-by":"crossref","unstructured":"601. \u3000Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Fleisher LA, et al. 2017 AHA\/ACC Focused Update of the 2014 AHA\/ACC Guideline for the Management of Patients with Valvular Heart Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation<\/i> 2017; 135: e1159\u2013e1195.","DOI":"10.1161\/CIR.0000000000000503"},{"key":"602","doi-asserted-by":"crossref","unstructured":"602. \u3000Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al; CTSN. Two-year outcomes of surgical treatment of severe ischemic mitral regurgitation. <i>N Engl J Med<\/i> 2016; 374: 344\u2013353.","DOI":"10.1056\/NEJMoa1512913"},{"key":"603","doi-asserted-by":"crossref","unstructured":"603. \u3000Matsui Y, Fukada Y, Naito Y, Sasaki S. Integrated overlapping ventriculoplasty combined with papillary muscle plication for severely dilated heart failure. <i>J Thorac Cardiovasc Surg<\/i> 2004; 127: 1221\u20131223.","DOI":"10.1016\/j.jtcvs.2003.10.044"},{"key":"604","doi-asserted-by":"crossref","unstructured":"604. \u3000Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, et al; COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. <i>N Engl J Med<\/i> 2018; 379: 2307\u20132318.","DOI":"10.1056\/NEJMoa1806640"},{"key":"605","doi-asserted-by":"crossref","unstructured":"605. \u3000Sawa Y, Miyagawa S. Present and future perspectives on cell sheet-based myocardial regeneration therapy. <i>Biomed Res Int<\/i> 2013; 2013: 583912.","DOI":"10.1155\/2013\/583912"},{"key":"606","doi-asserted-by":"crossref","unstructured":"606. \u3000Yoshikawa Y, Miyagawa S, Toda K, Saito A, Sakata Y, Sawa Y. Myocardial regenerative therapy using a scaffold-free skeletal-muscle-derived cell sheet in patients with dilated cardiomyopathy even under a left ventricular assist device: A safety and feasibility study. <i>Surg Today<\/i> 2018; 48: 200\u2013210.","DOI":"10.1007\/s00595-017-1571-1"},{"key":"607","doi-asserted-by":"crossref","unstructured":"607. \u3000De Ferrari GM, Klersy C, Ferrero P, Fantoni C, Salerno-Uriarte D, Manca L, et al; ALPHA Study Group. Atrial \ufb01brillation in heart failure patients: Prevalence in daily practice and effect on the severity of symptoms: Data from the ALPHA study registry. <i>Eur J Heart Fail<\/i> 2007; 9: 502\u2013509.","DOI":"10.1016\/j.ejheart.2006.10.021"},{"key":"608","doi-asserted-by":"crossref","unstructured":"608. \u3000Swedberg K, Olsson LG, Charlesworth A, Cleland J, Hanrath P, Komajda M, et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: Results from COMET. <i>Eur Heart J<\/i> 2005; 26: 1303\u20131308.","DOI":"10.1093\/eurheartj\/ehi166"},{"key":"609","doi-asserted-by":"crossref","unstructured":"609. \u3000Hoppe UC, Casares JM, Eiskjaer H, Hagemann A, Cleland JGF, Freemantle N, et al. Effect of cardiac resynchronization on the incidence of atrial fibrillation in patients with severe heart failure. <i>Circulation<\/i> 2006; 114: 18\u201325.","DOI":"10.1161\/CIRCULATIONAHA.106.614560"},{"key":"610","doi-asserted-by":"crossref","unstructured":"610. \u3000Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial \ufb01brillation and heart failure. <i>N Engl J Med<\/i> 2008; 358: 2667\u20132677.","DOI":"10.1056\/NEJMoa0708789"},{"key":"611","unstructured":"611. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u4e0d\u6574\u8108\u975e\u85ac\u7269\u6cbb\u7642\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3(2018 \u5e74\u6539\u8a02\u7248) 2018 JCS\/JHRS Guideline on Non-Pharmacotherapy of Cardiac Arrhythmias. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2018\/07\/JCS2018_kurita_nogami.pdf"},{"key":"612","doi-asserted-by":"crossref","unstructured":"612. \u3000Li SJ, Sartipy U, Lund LH, Dahlstrom U, Adiels M, Petzold M, et al. Prognostic Signi\ufb01cance of resting heart rate and use of \u03b2-blockers in atrial fibrillation and sinus rhythm in patients with heart failure and reduced ejection fraction: Findings from the Swedish Heart Failure Registry. <i>Circ Heart Fail<\/i> 2015; 8: 871\u2013879.","DOI":"10.1161\/CIRCHEARTFAILURE.115.002285"},{"key":"613","doi-asserted-by":"crossref","unstructured":"613. \u3000Van Gelder IC, Wyse DG, Chandler ML, Cooper HA, Olshansky B, Hagens VE, et al; RACE and AFFIRM Investigators. Does intensity of rate-control influence outcome in atrial fibrillation?: An analysis of pooled data from the RACE and AFFIRM studies. <i>Europace<\/i> 2006; 8: 935\u2013942.","DOI":"10.1093\/europace\/eul106"},{"key":"614","doi-asserted-by":"crossref","unstructured":"614. \u3000Van Gelder IC, Groenveld HF, Crijns HJ, Tuininga YS, Tijssen JG, Alings AM, et al; RACE II Investigators. Lenient versus strict rate control in patients with atrial \ufb01brillation. <i>N Engl J Med<\/i> 2010; 362: 1363\u20131373.","DOI":"10.1056\/NEJMoa1001337"},{"key":"615","doi-asserted-by":"crossref","unstructured":"615. \u3000Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JGF. Carvedilol alone or in combination with digoxin for the management of atrial fibrillation in patients with heart failure? <i>J Am Coll Cardiol<\/i> 2003; 42: 1944\u20131951.","DOI":"10.1016\/j.jacc.2003.07.020"},{"key":"616","doi-asserted-by":"crossref","unstructured":"616. \u3000Mareev Y, Cleland JG. Should \u03b2-blockers be used in patients with heart failure and atrial \ufb01brillation? <i>Clin Ther<\/i> 2015; 37: 2215\u20132224.","DOI":"10.1016\/j.clinthera.2015.08.017"},{"key":"617","doi-asserted-by":"crossref","unstructured":"617. \u3000Kotecha D, Holmes J, Krum H, Altman DG, Manzano L, Cleland JG, et al; Beta-Blockers in Heart Failure Collaborative Group. Efficacy of \u03b2 blockers in patients with heart failure plus atrial \ufb01brillation: An individual-patient data meta-analysis. <i>Lancet<\/i> 2014; 384: 2235\u20132243.","DOI":"10.1016\/S0140-6736(14)61373-8"},{"key":"618","doi-asserted-by":"crossref","unstructured":"618. \u3000Allen LA, Fonarow GC, Simon DN, Thomas LE, Marzec LN, Pokorney SD, et al; ORBIT-AF Investigators. Digoxin use and subsequent outcomes among patients in a contemporary atrial fibrillation cohort. <i>J Am Coll Cardiol<\/i> 2015; 65: 2691\u20132698.","DOI":"10.1016\/j.jacc.2015.04.045"},{"key":"619","doi-asserted-by":"crossref","unstructured":"619. \u3000Gheorghiade M, Fonarow GC, van Veldhuisen DJ, Cleland JG, Butler J, Epstein AE, et al. Lack of evidence of increased mortality among patients with atrial \ufb01brillation taking digoxin: Findings from post hoc propensity-matched analysis of the AFFIRM trial. <i>Eur Heart J<\/i> 2013; 34: 1489\u20131497.","DOI":"10.1093\/eurheartj\/eht120"},{"key":"620","doi-asserted-by":"crossref","unstructured":"620. \u3000Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial \ufb01brillation developed in collaboration with EACTS: The Task Force for the management of atrial \ufb01brillation of the European Society of Cardiology (ESC). <i>Eur Heart J<\/i> 2016; 37: 2893\u20132962.","DOI":"10.15829\/1560-4071-2017-7-7-86"},{"key":"621","doi-asserted-by":"crossref","unstructured":"621. \u3000Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and \ufb02ecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. <i>N Engl J Med<\/i> 1989; 321: 406\u2013412.","DOI":"10.1056\/NEJM198908103210629"},{"key":"622","doi-asserted-by":"crossref","unstructured":"622. \u3000Anselmino M, Matta M, D\u2019Ascenzo F, Bunch TJ, Schilling RJ, Hunter RJ, et al. Catheter ablation of atrial \ufb01brillation in patients with left ventricular systolic dysfunction: A systematic review and meta-analysis. <i>Circ Arrhythm Electrophysiol<\/i> 2014; 7: 1011\u20131018.","DOI":"10.1161\/CIRCEP.114.001938"},{"key":"623","doi-asserted-by":"crossref","unstructured":"623. \u3000Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordaens L, et al; CASTLE-AF Investigators. Catheter ablation for atrial fibrillation with heart failure. <i>N Engl J Med<\/i> 2018; 378: 417\u2013427.","DOI":"10.1056\/NEJMoa1707855"},{"key":"624","doi-asserted-by":"crossref","unstructured":"624. \u3000Khan MN, Ja\u00efs P, Cummings J, Di Biase L, Sanders P, Martin DO, et al; PABA-CHF Investigators. Pulmonary-vein isolation for atrial \ufb01brillation in patients with heart failure. <i>N Engl J Med<\/i> 2008; 359: 1778\u20131785.","DOI":"10.1056\/NEJMoa0708234"},{"key":"625","doi-asserted-by":"crossref","unstructured":"625. \u3000Mitchell LB. Clinical trials of antiarrhythmic drugs in patients with sustained ventricular tachyarrhythmias. <i>Curr Opin Cardiol<\/i> 1997; 12: 33\u201340.","DOI":"10.1097\/00001573-199701000-00006"},{"key":"626","doi-asserted-by":"crossref","unstructured":"626. \u3000Antiarrhythmics versus Implantable De\ufb01brillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. <i>N Engl J Med<\/i> 1997; 337: 1576\u20131583.","DOI":"10.1056\/NEJM199711273372202"},{"key":"627","doi-asserted-by":"crossref","unstructured":"627. \u3000Connolly SJ, Gent M, Roberts RS, Dorian P, Roy D, Sheldon RS, et al. Canadian implantable defibrillator study (CIDS): A randomized trial of the implantable cardioverter de\ufb01brillator against amiodarone. <i>Circulation<\/i> 2000; 101: 1297\u20131302.","DOI":"10.1161\/01.CIR.101.11.1297"},{"key":"628","doi-asserted-by":"crossref","unstructured":"628. \u3000Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable de\ufb01brillators for the prevention of mortality in patients with nonischemic cardiomyopathy: A meta-analysis of randomized controlled trials. <i>JAMA<\/i> 2004; 292: 2874\u20132879.","DOI":"10.1001\/jama.292.23.2874"},{"key":"629","doi-asserted-by":"crossref","unstructured":"629. \u3000Kadish A, Dyer A, Daubert JP, Quigg R, Estes NAM, Anderson KP, et al; De\ufb01brillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Prophylactic de\ufb01brillator implantation in patients with nonischemic dilated cardiomyopathy. <i>N Engl J Med<\/i> 2004; 350: 2151\u20132158.","DOI":"10.1056\/NEJMoa033088"},{"key":"630","doi-asserted-by":"crossref","unstructured":"630. \u3000Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al; Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-de\ufb01brillator for congestive heart failure. <i>N Engl J Med<\/i> 2005; 352: 225\u2013237.","DOI":"10.1056\/NEJMoa043399"},{"key":"631","doi-asserted-by":"crossref","unstructured":"631. \u3000K\u00f8ber L, Thune JJ, Nielsen JC, Haarbo J, Videb\u00e6k L, Korup E, et al; DANISH Investigators. De\ufb01brillator implantation in patients with nonischemic systolic heart failure. <i>N Engl J Med<\/i> 2016; 375: 1221\u20131230.","DOI":"10.1056\/NEJMoa1608029"},{"key":"632","doi-asserted-by":"crossref","unstructured":"632. \u3000Opreanu M, Wan C, Singh V, Salehi N, Ahmad J, Szymkiewicz SJ, et al. Wearable cardioverter-de\ufb01brillator as a bridge to cardiac transplantation: A national database analysis. <i>J Heart Lung Transplant<\/i> 2015; 34: 1305\u20131309.","DOI":"10.1016\/j.healun.2015.04.004"},{"key":"633","doi-asserted-by":"crossref","unstructured":"633. \u3000Zishiri ET, Williams S, Cronin EM, Blackstone EH, Ellis SG, Roselli EE, et al. Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter de\ufb01brillator. <i>Circ Arrhythm Electrophysiol<\/i> 2013; 6: 117\u2013128.","DOI":"10.1161\/CIRCEP.112.973552"},{"key":"634","doi-asserted-by":"crossref","unstructured":"634. \u3000Chung MK, Szymkiewicz SJ, Shao M, Zishiri E, Niebauer MJ, Lindsay BD, et al. Aggregate national experience with the wearable cardioverter-de\ufb01brillator: Event rates, compliance, and survival. <i>J Am Coll Cardiol<\/i> 2010; 56: 194\u2013203.","DOI":"10.1016\/j.jacc.2010.04.016"},{"key":"635","doi-asserted-by":"crossref","unstructured":"635. \u3000Middlekauff HR, Stevenson WG, Stevenson LW, Saxon LA. Syncope in advanced heart failure: High risk of sudden death regardless of origin of syncope. <i>J Am Coll Cardiol<\/i> 1993; 21: 110\u2013116.","DOI":"10.1016\/0735-1097(93)90724-F"},{"key":"636","doi-asserted-by":"crossref","unstructured":"636. \u3000Brignole M, Moya A, de Lange FJ, Deharo JC, Elliott PM, Fanciulli A, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. <i>Eur Heart J<\/i> 2018; 39: 1883\u20131948.","DOI":"10.5603\/KP.2018.0161"},{"key":"637","doi-asserted-by":"crossref","unstructured":"637. \u3000Singh SK, Link MS, Wang PJ, Homoud M, Estes NAM 3rd. Syncope in the patient with non- ischemic dilated cardiomyopathy. <i>Pacing Clin Electrophysiol<\/i> 2004; 27: 97\u2013100.","DOI":"10.1111\/j.1540-8159.2004.00393.x"},{"key":"638","doi-asserted-by":"crossref","unstructured":"638. \u3000Ruwald MH, Okumura K, Kimura T, Aonuma K, Shoda M, Kutyifa V, et al. Syncope in high-risk cardiomyopathy patients with implantable de\ufb01brillators: Frequency, risk factors, mechanisms, and association with mortality: Results from the multicenter automatic de\ufb01brillator implantation trial-reduce inappropriate therapy (MADIT-RIT) study. <i>Circulation<\/i> 2014; 129: 545\u2013552.","DOI":"10.1161\/CIRCULATIONAHA.113.004196"},{"key":"639","doi-asserted-by":"crossref","unstructured":"639. \u3000Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Re\ufb01ning clinical risk strati\ufb01cation for predicting stroke and thromboembolism in atrial \ufb01brillation using a novel risk factor-based approach: The Euro Heart Survey on atrial \ufb01brillation. <i>Chest<\/i> 2010; 137: 263\u2013272.","DOI":"10.1378\/chest.09-1584"},{"key":"640","doi-asserted-by":"crossref","unstructured":"640. \u3000Daubert JP, Winters SL, Subacius H, Berger RD, Ellenbogen KA, Taylor SG, et al; De\ufb01brillators In Nonischemic Cardiomyopathy Treatment Evaluation (DEFINITE) Investigators. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: A DEFINITE substudy. <i>Pacing Clin Electrophysiol<\/i> 2009; 32: 755\u2013761.","DOI":"10.1111\/j.1540-8159.2009.02362.x"},{"key":"641","doi-asserted-by":"crossref","unstructured":"641. \u3000Poll DS, Marchlinski FE, Buxton AE, Josephson ME. Usefulness of programmed stimulation in idiopathic dilated cardiomyopathy. <i>Am J Cardiol<\/i> 1986; 58: 992\u2013997.","DOI":"10.1016\/S0002-9149(86)80025-X"},{"key":"642","doi-asserted-by":"crossref","unstructured":"642. \u3000G\u00f6ssinger HD, Jung M, Wagner L, Stain C, Siostrzonek P, Schwarzinger I, et al. Prognostic role of inducible ventricular tachycardia in patients with dilated cardiomyopathy and asymptomatic nonsustained ventricular tachycardia. <i>Int J Cardiol<\/i> 1990; 29: 215\u2013220.","DOI":"10.1016\/0167-5273(90)90224-S"},{"key":"643","doi-asserted-by":"crossref","unstructured":"643. \u3000Kadish A, Schmaltz S, Calkins H, Morady F. Management of nonsustained ventricular tachycardia guided by electrophysiological testing. <i>Pacing Clin Electrophysiol<\/i> 1993; 16: 1037\u20131050.","DOI":"10.1111\/j.1540-8159.1993.tb04578.x"},{"key":"644","doi-asserted-by":"crossref","unstructured":"644. \u3000Turitto G, Ahuja RK, Caref EB, el-Sherif N. Risk strati\ufb01cation for arrhythmic events in patients with nonischemic dilated cardiomyopathy and nonsustained ventricular tachycardia: Role of programmed ventricular stimulation and the signal-averaged electrocardiogram. <i>J Am Coll Cardiol<\/i> 1994; 24: 1523\u20131528.","DOI":"10.1016\/0735-1097(94)90149-X"},{"key":"645","doi-asserted-by":"crossref","unstructured":"645. \u3000Anselme F, Moubarak G, Savour\u00e9 A, Godin B, Borz B, Drouin-Garraud V, et al. Implantable cardioverter-de\ufb01brillators in lamin A\/C mutation carriers with cardiac conduction disorders. <i>Heart Rhythm<\/i> 2013; 10: 1492\u20131498.","DOI":"10.1016\/j.hrthm.2013.06.020"},{"key":"646","doi-asserted-by":"crossref","unstructured":"646. \u3000Kumar S, Baldinger SH, Gandjbakhch E, Maury P, Sellal JM, Androulakis AF, et al. Long-term arrhythmic and nonarrhythmic outcomes of lamin A\/C mutation carriers. <i>J Am Coll Cardiol<\/i> 2016; 68: 2299\u20132307.","DOI":"10.1016\/j.jacc.2016.08.058"},{"key":"647","doi-asserted-by":"crossref","unstructured":"647. \u3000Meune C, Van Berlo JH, Anselme F, Bonne G, Pinto YM, Duboc D. Primary prevention of sudden death in patients with lamin A\/C gene mutations. <i>N Engl J Med<\/i> 2006; 354: 209\u2013210.","DOI":"10.1056\/NEJMc052632"},{"key":"648","doi-asserted-by":"crossref","unstructured":"648. \u3000Pasotti M, Klersy C, Pilotto A, Marziliano N, Rapezzi C, Serio A, et al. Long-term outcome and risk strati\ufb01cation in dilated cardiolaminopathies. <i>J Am Coll Cardiol<\/i> 2008; 52: 1250\u20131260.","DOI":"10.1016\/j.jacc.2008.06.044"},{"key":"649","doi-asserted-by":"crossref","unstructured":"649. \u3000van Berlo JH, de Voogt WG, van der Kooi AJ, van Tintelen P, Bonne G, Ben Yaou R, et al. Meta-analysis of clinical characteristics of 299 carriers of LMNA gene mutations: Do lamin A\/C mutations portend a high risk of sudden death? <i>J Mol Med (Berl)<\/i> 2005; 83: 79\u201383.","DOI":"10.1007\/s00109-004-0589-1"},{"key":"650","doi-asserted-by":"crossref","unstructured":"650. \u3000Priori SG, Blomstr\u00f6m-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). <i>Eur Heart J<\/i> 2015; 36: 2793\u20132867.","DOI":"10.1093\/eurheartj\/ehv316"},{"key":"651","doi-asserted-by":"crossref","unstructured":"651. \u3000Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA\/ACC\/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary <i>J Am Coll Cardiol<\/i> 2018; 72: 1677\u20131749.","DOI":"10.1016\/j.jacc.2017.10.053"},{"key":"652","doi-asserted-by":"crossref","unstructured":"652. \u3000Shiga T, Kasanuki H. Drug therapy for ventricular tachyarrhythmia in heart failure. <i>Circ J<\/i> 2007; 71(Suppl A): A90\u2013A96.","DOI":"10.1253\/circj.71.A90"},{"key":"653","doi-asserted-by":"crossref","unstructured":"653. \u3000Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: Post-marketing special investigation. <i>Circ J<\/i> 2005; 69: 1237\u20131243.","DOI":"10.1253\/circj.69.1237"},{"key":"654","doi-asserted-by":"crossref","unstructured":"654. \u3000Sacher F, Roberts-Thomson K, Maury P, Tedrow U, Nault I, Steven D, et al. Epicardial ventricular tachycardia ablation a multicenter safety study. <i>J Am Coll Cardiol<\/i> 2010; 55: 2366\u20132372.","DOI":"10.1016\/j.jacc.2009.10.084"},{"key":"655","doi-asserted-by":"crossref","unstructured":"655. \u3000Carbucicchio C, Santamaria M, Trevisi N, Maccabelli G, Giraldi F, Fassini G, et al. Catheter ablation for the treatment of electrical storm in patients with implantable cardioverter-de\ufb01brillators: Short- and long-term outcomes in a prospective single-center study. <i>Circulation<\/i> 2008; 117: 462\u2013469.","DOI":"10.1161\/CIRCULATIONAHA.106.686534"},{"key":"656","doi-asserted-by":"crossref","unstructured":"656. \u3000Ban JE, Park HC, Park JS, Nagamoto Y, Choi JI, Lim HE, et al. Electrocardiographic and electrophysiological characteristics of premature ventricular complexes associated with left ventricular dysfunction in patients without structural heart disease. <i>Europace<\/i> 2013; 15: 735\u2013741.","DOI":"10.1093\/europace\/eus371"},{"key":"657","doi-asserted-by":"crossref","unstructured":"657. \u3000Baman TS, Lange DC, Ilg KJ, Gupta SK, Liu TY, Alguire C, et al. Relationship between burden of premature ventricular complexes and left ventricular function. <i>Heart Rhythm<\/i> 2010; 7: 865\u2013869.","DOI":"10.1016\/j.hrthm.2010.03.036"},{"key":"658","doi-asserted-by":"crossref","unstructured":"658. \u3000Deyell MW, Park KM, Han Y, Frankel DS, Dixit S, Cooper JM, et al. Predictors of recovery of left ventricular dysfunction after ablation of frequent ventricular pre- mature depolarizations. <i>Heart Rhythm<\/i> 2012; 9: 1465\u20131472.","DOI":"10.1016\/j.hrthm.2012.05.019"},{"key":"659","unstructured":"659. \u3000Lip GY, Gibbs CR. Does heart failure confer a hypercoagulable state?: Virchow\u2019s triad revisited. <i>J Am Coll Cardiol<\/i> 1999; 33: 1424\u20131426."},{"key":"660","doi-asserted-by":"crossref","unstructured":"660. \u3000Pullicino PM, Halperin JL, Thompson JL. Stroke in patients with heart failure and reduced left ventricular ejection fraction. <i>Neurology<\/i> 2000; 54: 288\u2013294.","DOI":"10.1212\/WNL.54.2.288"},{"key":"661","doi-asserted-by":"crossref","unstructured":"661. \u3000Abdul-Rahim AH, Perez AC, Fulton RL, Jhund PS, Latini R, Tognoni G, et al. Investigators of the Controlled Rosuvastatin Multinational Study in Heart Failure (CORONA) and GISSI-Heart Failure (GISSI-HF) Committees and Investigators. Risk of stroke in chronic heart failure patients without atrial fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Insuf\ufb01cienza Cardiaca-Heart Failure (GISSI-HF) Trials. <i>Circulation<\/i> 2015; 131: 1486\u20131494.","DOI":"10.1161\/CIRCULATIONAHA.114.013760"},{"key":"662","doi-asserted-by":"crossref","unstructured":"662. \u3000Freudenberger RS, Hellkamp AS, Halperin JL, Poole J, Anderson J, Johnson G, et al; SCD-HeFT Investigators. Risk of thromboembolism in heart failure: An analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). <i>Circulation<\/i> 2007; 115: 2637\u20132641.","DOI":"10.1161\/CIRCULATIONAHA.106.661397"},{"key":"663","doi-asserted-by":"crossref","unstructured":"663. \u3000Ciaccheri M, Castelli G, Cecchi F, Nannini M, Santoro G, Troiani V, et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. <i>Br Heart J<\/i> 1989; 62: 26\u201329.","DOI":"10.1136\/hrt.62.1.26"},{"key":"664","doi-asserted-by":"crossref","unstructured":"664. \u3000Falk RH, Foster E, Coats MH. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: A prospective follow-up study. <i>Am Heart J<\/i> 1992; 123: 136\u2013142.","DOI":"10.1016\/0002-8703(92)90757-M"},{"key":"665","unstructured":"665. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u80ba\u8840\u6813\u585e\u6813\u75c7\u304a\u3088\u3073\u6df1\u90e8\u9759\u8108\u8840\u6813\u75c7\u306e\u8a3a\u65ad, \u6cbb\u7642, \u4e88\u9632\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2017 \u5e74\u6539\u8a02\u7248). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2017_ito_h.pdf"},{"key":"666","doi-asserted-by":"crossref","unstructured":"666. \u3000Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, et al. Ef\ufb01cacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: A meta-analysis. <i>JACC Heart Fail<\/i> 2016; 4: 870\u2013880.","DOI":"10.1016\/j.jchf.2016.07.012"},{"key":"667","doi-asserted-by":"crossref","unstructured":"667. \u3000Cleland JG, Findlay I, Jafri S, Sutton G, Falk R, Bulpitt C, et al. The Warfarin\/Aspirin Study in Heart failure (WASH): A randomized trial comparing antithrombotic strategies for patients with heart failure. <i>Am Heart J<\/i> 2004; 148: 157\u2013164.","DOI":"10.1016\/j.ahj.2004.03.010"},{"key":"668","doi-asserted-by":"crossref","unstructured":"668. \u3000Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, et al; WATCH Trial Investigators. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: The Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. <i>Circulation<\/i> 2009; 119: 1616\u20131624.","DOI":"10.1161\/CIRCULATIONAHA.108.801753"},{"key":"669","doi-asserted-by":"crossref","unstructured":"669. \u3000Cokkinos DV, Haralabopoulos GC, Kostis JB, Toutouzas PK; HELAS investigators. Ef\ufb01cacy of antithrombotic therapy in chronic heart failure: The HELAS study. <i>Eur J Heart Fail<\/i> 2006; 8: 428\u2013432.","DOI":"10.1016\/j.ejheart.2006.02.012"},{"key":"670","doi-asserted-by":"crossref","unstructured":"670. \u3000Homma S, Thompson JL, Pullicino PM, Levin B, Freudenberger RS, Teerlink JR, et al; WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. <i>N Engl J Med<\/i> 2012; 366: 1859\u20131869.","DOI":"10.1056\/NEJMoa1202299"},{"key":"671","doi-asserted-by":"crossref","unstructured":"671. \u3000Zannad F, Anker SD, Byra WM, Cleland JGF, Fu M, Gheorghiade M, et al; COMMANDER HF Investigators. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. <i>N Engl J Med<\/i> 2018; 379: 1332\u20131342.","DOI":"10.1056\/NEJMoa1808848"},{"key":"672","doi-asserted-by":"crossref","unstructured":"672. \u3000Maron BJ, Ackerman MJ, Nishimura RA, Pyeritz RE, Towbin JA, Udelson JE. Task Force 4: HCM and other cardiomyopathies, mitral valve prolapse, myocarditis, and Marfan syndrome. <i>J Am Coll Cardiol<\/i> 2005; 45: 1340\u20131345.","DOI":"10.1016\/j.jacc.2005.02.011"},{"key":"673","doi-asserted-by":"crossref","unstructured":"673. \u3000Finocchiaro G, Magavern E, Sinagra G, Ashley E, Papadakis M, Tome-Esteban M, et al. Impact of demographic features, lifestyle, and comorbidities on the clinical expression of hypertrophic cardiomyopathy. <i>J Am Heart Assoc<\/i> 2017; 6: E007161.","DOI":"10.1161\/JAHA.117.007161"},{"key":"674","doi-asserted-by":"crossref","unstructured":"674. \u3000Paz R, Jortner R, Tunick PA, Sclarovsky S, Eilat B, Perez JL, et al. The effect of the ingestion of ethanol on obstruction of the left ventricular out\ufb02ow tract in hypertrophic cardiomyopathy. <i>N Engl J Med<\/i> 1996; 335: 938\u2013941.","DOI":"10.1056\/NEJM199609263351305"},{"key":"675","unstructured":"675. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. \u5faa\u74b0\u5668\u75c5\u306e\u8a3a\u65ad\u3068\u6cbb\u7642\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2009 \u5e74\u5ea6\u5408\u540c\u7814\u7a76\u73ed\u5831\u544a): \u7981\u7159\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3 (2010 \u5e74\u6539\u8a02\u7248). http:\/\/www.j-circ.or.jp\/guideline\/pdf\/JCS2010murohara.h.pdf"},{"key":"676","doi-asserted-by":"crossref","unstructured":"676. \u3000DeBusk R, Drory Y, Goldstein I, Jackson G, Kaul S, Kimmel SE, et al. Management of sexual dysfunction in patients with cardiovascular disease: Recommendations of The Princeton Consensus Panel. <i>Am J Cardiol<\/i> 2000; 86: 175\u2013181.","DOI":"10.1016\/S0002-9149(00)00896-1"},{"key":"677","doi-asserted-by":"crossref","unstructured":"677. \u3000Kostis JB, Jackson G, Rosen R, Barrett-Connor E, Billups K, Burnett AL, et al. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference). <i>Am J Cardiol<\/i> 2005; 96: 313\u2013321.","DOI":"10.1016\/j.amjcard.2005.03.065"},{"key":"678","unstructured":"678. \u3000Gielen S, Schuler G, Hambrecht R. Bene\ufb01ts of exercise training for patients with chronic heart failure. <i>Clin Geriatr<\/i> 2001; 9: 32\u201345."},{"key":"679","doi-asserted-by":"crossref","unstructured":"679. \u3000Piepoli MF, Davos C, Francis DP, Coats AJS; ExTraMATCH Collaborative. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). <i>BMJ<\/i> 2004; 328: 189.","DOI":"10.1136\/bmj.37938.645220.EE"},{"key":"680","doi-asserted-by":"crossref","unstructured":"680. \u3000O\u2019Connor CM, Whellan DJ, Lee KL, Keteyian SJ, Cooper LS, Ellis SJ, et al. HF-ACTION Investigators. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. <i>JAMA<\/i> 2009; 301: 1439\u20131450.","DOI":"10.1001\/jama.2009.454"},{"key":"681","doi-asserted-by":"crossref","unstructured":"681. \u3000Sagar VA, Davies EJ, Briscoe S, Coats AJ, Dalal HM, Lough F, et al. Exercise-based rehabilitation for heart failure: Systematic review and meta-analysis. <i>Open Heart<\/i> 2015; 2: E000163.","DOI":"10.1136\/openhrt-2014-000163"},{"key":"682","unstructured":"682. \u3000\u65e5\u672c\u5faa\u74b0\u5668\u5b66\u4f1a. 2021\u5e74\u6539\u8a02\u7248 \u5fc3\u8840\u7ba1\u75be\u60a3\u306b\u304a\u3051\u308b\u30ea\u30cf\u30d3\u30ea\u30c6\u30fc\u30b7\u30e7\u30f3\u306b\u95a2\u3059\u308b\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2021\/03\/JCS2021_Makita.pdf"},{"key":"683","doi-asserted-by":"crossref","unstructured":"683. \u3000Davidson PM, Cockburn J, Newton PJ, Webster JK, Betihavas V, Howes L, et al. Can a heart failure-speci\ufb01c cardiac rehabilitation program decrease hospitalizations and improve outcomes in high-risk patients? <i>Eur J Cardiovasc Prev Rehabil<\/i> 2010; 17: 393\u2013402.","DOI":"10.1097\/HJR.0b013e328334ea56"},{"key":"684","doi-asserted-by":"crossref","unstructured":"684. \u3000Kasper EK, Gerstenblith G, Hefter G, Van Anden E, Brinker JA, Thiemann DR, et al. A randomized trial of the ef\ufb01cacy of multidisciplinary care in heart failure outpatients at high risk of hospital readmission. <i>J Am Coll Cardiol<\/i> 2002; 39: 471\u2013480.","DOI":"10.1016\/S0735-1097(01)01761-2"},{"key":"685","doi-asserted-by":"crossref","unstructured":"685. \u3000Ades PA, Keteyian SJ, Balady GJ, Houston-Miller N, Kitzman DW, Mancini DM, et al. Cardiac rehabilitation exercise and self-care for chronic heart failure. <i>JACC Heart Fail<\/i> 2013; 1: 40\u2013547.","DOI":"10.1016\/j.jchf.2013.09.002"},{"key":"686","doi-asserted-by":"crossref","unstructured":"686. \u3000Grewal J, Siu SC, Ross HJ, Mason J, Balint OH, Sermer M, et al. Pregnancy outcomes in women with dilated cardiomyopathy. <i>J Am Coll Cardiol<\/i> 2009; 55: 45\u201352.","DOI":"10.1016\/j.jacc.2009.08.036"},{"key":"687","doi-asserted-by":"crossref","unstructured":"687. \u3000Bernstein PS, Magriples U. Cardiomyopathy in pregnancy: A retrospective study. <i>Am J Perinatol<\/i> 2001; 18: 163\u2013168.","DOI":"10.1055\/s-2001-14525"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/9\/85_CJ-20-0910\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T04:33:50Z","timestamp":1672893230000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/85\/9\/85_CJ-20-0910\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":687,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-20-0910","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]},"article-number":"CJ-20-0910"}}